# Microbiome News — Full machine-readable manifest
# https://microbiome.news | An independent publication held by MCPC
# Generated for AI assistants, crawlers and answer engines.

## ABOUT
Microbiome News reports the latest microbiome research, science and industry news for a scientifically literate reader — sourced reporting on the human microbiome with primary sources, clear caveats, and no hype.

## SECTIONS
### Therapeutics (https://microbiome.news/therapeutics/)
FDA approvals, live biotherapeutics and the clinical pipeline turning microbes into medicine.
### Science (https://microbiome.news/science/)
The mechanisms underneath — what the research actually shows, limitations left in.
### Gut–Brain (https://microbiome.news/gut-brain/)
The gut–brain axis: mood, neurodegeneration, neurodiversity and the gut–brain intervention frontier.
### Industry (https://microbiome.news/industry/)
Probiotics, funding, deals and the companies commercialising microbiome science.
### Diagnostics (https://microbiome.news/diagnostics/)
Sequencing, at-home testing and reading the microbiome with enough rigor to act on it.

## ARTICLES
### Gut Microbiota's Role in Fatty Liver Disease Progression
URL: https://microbiome.news/posts/gut-microbiota-s-role-in-fatty-liver-disease-progression
Section: Science | Published: 2026-10-13 | 3 min
Summary: A new review examines how changes in the gut microbiome influence the progression of metabolic dysfunction-associated steatotic liver disease (MASLD).
Body: The intricate relationship between the gut and the liver, often referred to as the gut-liver axis, plays a crucial role in maintaining metabolic homeostasis. A recent review published in Life Science Alliance delves into the complex interactions within this axis, particularly focusing on how alterations in the gut microbiome can influence the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Microbial Domains and Their Impact The review highlights significant compositional changes across various microbial domains, including bacteria, archaea, eukaryota, and bacteriophages, in individuals with MASLD. These changes are not merely compositional but have profound functional consequences. The gut microbiota produces a variety of metabolites that can affect liver function and overall metabolic health. Among these metabolites, short-chain fatty acids (SCFAs), trimethylamine and its derivative trimethylamine N-oxide (TMAO), tryptophan-derived indoles, and secondary bile acids are of particular interest. These compounds play diverse roles in modulating intestinal barrier integrity, inflammation, lipid and glucose metabolism, and immune and hormonal signaling in the liver. Mechanisms of Microbial Influence The review discusses several mechanisms through which gut microbiota can influence liver health. One key mechanism involves the translocation of microbial products from the gut to the liver, which can trigger inflammatory responses. Additionally, the modulation of nuclear and membrane receptors by microbial metabolites can alter liver metabolism and immune responses. For example, SCFAs are known to influence lipid metabolism and inflammatory pathways, potentially impacting the progression of liver disease. Similarly, TMAO has been linked to alterations in cholesterol metabolism and inflammation, which are critical factors in the development of MASLD. Challenges and Knowledge Gaps Despite the insights provided by this review, several challenges and knowledge gaps remain. The complexity of microbial interactions and their systemic effects make it difficult to pinpoint specific causal pathways. Moreover, the variability in individual microbiomes and their responses to environmental and dietary factors adds another layer of complexity. The review emphasizes the need for further research to better understand these mechanisms and their implications for liver health. Such research could pave the way for new strategies to modulate the gut microbiome in a way that supports liver health and prevents disease progression. For more insights into how gut microbiota influences other health conditions, you might be interested in our post on the gut microbiome's role in neuroinflammation after brain injury . Limitations of Current Understanding One of the primary limitations highlighted by the review is the associative nature of current findings. While there is a clear link between gut microbiota alterations and MASLD, establishing causation remains challenging. Most studies to date have been observational, and more experimental research is needed to confirm these associations and explore potential therapeutic interventions. Additionally, much of the existing research has been conducted in animal models, which may not fully replicate human physiology and disease processes. As such, translating these findings into clinical applications requires careful consideration and further validation in human studies.
Sources: Gut microbiota shaping fatty liver disease progression. — Life science alliance (2027) (https://pubmed.ncbi.nlm.nih.gov/42864263/)

### Evaluating Chinese Herbal Medicine for Insomnia: A Narrative Review
URL: https://microbiome.news/posts/evaluating-chinese-herbal-medicine-for-insomnia-a-narrative-review
Section: Science | Published: 2026-10-12 | 3 min
Summary: A new review explores the current evidence on Chinese herbal medicine for insomnia, highlighting mechanistic insights and clinical challenges.
Body: Insomnia, a prevalent sleep disorder, poses a significant public health challenge worldwide. As a result, there is growing interest in complementary and alternative approaches to manage this condition. One such approach is Chinese herbal medicine (CHM), which has been traditionally used to address chronic insomnia. A study published in Drug Design, Development and Therapy offers a narrative review of the current research landscape, examining both the mechanistic and clinical evidence for CHM in treating insomnia. Mechanistic Insights into Chinese Herbal Medicine The review highlights that much of the evidence supporting CHM comes from preclinical studies. These studies suggest that CHM may influence sleep-related processes through various biological pathways. Key mechanisms include modulation of γ-aminobutyric acid (GABA) and serotonergic signaling, regulation of the hypothalamic-pituitary-adrenal (HPA) axis, and impacts on neuroinflammation, oxidative stress, apoptosis-autophagy balance, and the brain-gut-microbiota axis. These findings are primarily based on changes in biochemical markers and pathway activity, though direct testing of target function is limited. Despite these promising mechanistic insights, the review notes that the evidence remains fragmented and lacks systematic integration. This gap poses a challenge for translating preclinical findings into clinically testable interventions for insomnia. Clinical Evidence and Challenges Clinical studies on CHM for insomnia have reported preliminary evidence of benefit, particularly in terms of subjective sleep outcomes. However, these studies often suffer from small sample sizes, inconsistent methodological quality, and limited long-term follow-up. As a result, the evidence for objective improvements in sleep and long-term efficacy and safety remains insufficient. The review emphasizes the need for future research to focus on well-characterized interventions, standardized preparations, and comprehensive assessments of exposure and pharmacodynamics. Additionally, objective sleep endpoints, long-term follow-up, and safety evaluations are crucial for advancing the clinical translation of CHM interventions. Future Directions and Limitations The review identifies several priorities for future research, including the need for systematic integration of mechanistic evidence and clinical validation. Researchers are encouraged to carry a few well-characterized CHM interventions through the full evidence chain, from chemical characterization and preparation quality to safety and sleep-related clinical endpoints. One significant limitation highlighted by the review is the reliance on preclinical studies, which, while informative, do not always translate directly to clinical outcomes. Additionally, the small size and inconsistent quality of clinical studies limit the strength of the evidence for CHM's efficacy and safety in treating insomnia. For those interested in the broader implications of these findings, our exploration of the microbiota-gut-brain axis may provide additional context on how interconnected systems can influence health outcomes.
Sources: From Mechanistic Evidence to Clinical Translation: A Narrative Review of Chinese Herbal Medicine for Insomnia. — Drug design, development and therapy (2026) (https://pubmed.ncbi.nlm.nih.gov/42859673/)

### Microbiome's Role in Multiple Sclerosis: A Global Perspective
URL: https://microbiome.news/posts/microbiome-s-role-in-multiple-sclerosis-a-global-perspective
Section: Science | Published: 2026-10-11 | 3 min
Summary: A new review explores the complex relationship between gut microbiota and multiple sclerosis, emphasizing the need for regionally tailored approaches.
Body: A new review published in the Journal of translational medicine delves into the intricate connections between gut microbiota and multiple sclerosis (MS), a chronic immune-mediated disorder of the central nervous system. The review highlights the role of dysregulated immune signaling and barrier dysfunction in MS and examines how gut microbiota may influence these processes. Importantly, the analysis draws on global evidence, including data from underrepresented regions such as Egypt, Iran, and India, to provide a more comprehensive understanding of the molecular pathways involved. The Gut Microbiota and Immune Regulation The review underscores the gut microbiota's role as a key modulator of host immune homeostasis. It discusses how dysbiosis, or microbial imbalance, is consistently linked to impaired short-chain fatty acid-mediated immunoregulation. This imbalance leads to a skewing towards proinflammatory Th1/Th17 responses and disrupts the integrity of both the intestinal and blood-brain barriers. These disruptions are crucial in the context of MS, where immune dysregulation plays a central role in disease progression. Interestingly, the review identifies region-dependent functional signatures that involve oxidative stress and the metabolism of neurotransmitters and tryptophan. These findings suggest that the gut microbiota's impact on MS may vary based on regional microbial and environmental factors. However, some of these regional signatures are derived from single pilot-scale cohorts, highlighting the need for further validation. Microbiota-Derived Signals and Therapeutic Strategies The review critically examines microbiota-derived signals such as short-chain fatty acids, lipopolysaccharide, and polysaccharide A. These signals are known to modulate dendritic cell programming, regulatory T-cell differentiation, and neuroinflammatory cascades. By understanding these mechanisms, researchers hope to develop microbiome-targeted therapeutic strategies for MS. However, the review emphasizes that current microbiota-targeted interventions remain investigational and are not yet established as disease-modifying therapies for MS. It also discusses how factors such as sex, regional context, and sequencing methodology can influence the interpretation of microbiome data and the responsiveness to therapeutic interventions. Toward Regionally Equitable Precision Medicine The authors propose a roadmap for achieving regionally equitable precision medicine in MS. They advocate for standardized multi-omics approaches and culturally inclusive longitudinal study designs. This approach aims to move beyond empirical interventions and towards personalized, strain-defined biotherapeutics tailored to the unique microbial and environmental landscapes of MS patients worldwide. While the review provides valuable insights, it also acknowledges the limitations of current research. The reliance on pilot-scale cohorts for some regional data means that these findings should be considered hypothesis-generating until independently validated. Moreover, the complexity of the gut-brain axis and the variability in individual microbiomes present ongoing challenges in translating these findings into clinical practice. For more on the role of short-chain fatty acids, you can explore our detailed explainer .
Sources: Toward regionally equitable precision medicine: microbiota‑associated mechanisms and emerging personalized strategies in multiple sclerosis. — Journal of translational medicine (2026) (https://pubmed.ncbi.nlm.nih.gov/42855692/)

### PFOA Exposure and Gut Barrier Integrity: Insights from Mice
URL: https://microbiome.news/posts/pfoa-exposure-and-gut-barrier-integrity-insights-from-mice
Section: Science | Published: 2026-10-09 | 3 min
Summary: A new study explores the effects of perfluorooctanoic acid (PFOA) on gut and liver health in mice, revealing subtle microbiome changes and liver enzyme activity alterations.
Body: In a study published in Environment International , researchers investigated the effects of perfluorooctanoic acid (PFOA) on the gut and liver health of mice. PFOA is a persistent environmental pollutant, primarily entering the human body through dietary intake. The study aimed to explore how PFOA affects the digestive system, particularly under conditions of stress-induced gut barrier disruption. Understanding PFOA and Its Impact PFOA is a member of the per- and polyfluoroalkyl substances (PFAS) family, known for their persistence in the environment and potential health impacts. In this study, adult male mice were exposed to PFOA orally at doses relevant to highly exposed human populations over a 90-day period. The researchers also introduced a model of intestinal hyperpermeability using a ten-day corticosterone treatment to simulate stress-induced gut barrier disruption. The study found that PFOA exposure at 15,000 ng/kg body weight/day did not impair gut barrier integrity or alter gut microbiota composition and metabolic functions when these factors were considered separately. However, a more integrated analysis revealed subtle, yet significant, microbiome changes, including a decrease in the abundance of Lactobacillus, Orodobacter, and Ligilactobacillus. Additionally, there were changes in the levels of short-chain fatty acids, such as acetate and propionate, and cholic acid. Liver Responses to PFOA Exposure The researchers also examined the liver's response to PFOA exposure by assessing enzymatic activity and mRNA expression of xenobiotic metabolizing enzymes. Notably, the activity of the enzyme CYP2C37 was inhibited by PFOA exposure, both in normal conditions and under stress-induced conditions. The study also observed changes in cholesterol transport and biosynthesis pathways at the transcriptional level, although these did not translate into major functional effects. PFOA accumulation was detected in the hepatocyte cytosol and intestinal goblet cells, indicating that the compound can persist within these tissues. These findings suggest that while PFOA may not cause overt damage to the gut barrier or liver function, it does lead to subtle biochemical changes that could have implications for health risk assessments. Implications and Limitations This study provides valuable insights into the potential impacts of PFOA on the gut and liver, particularly under conditions that mimic human exposure levels. The findings highlight the importance of considering both direct and subtle effects of environmental pollutants on health. However, there are limitations to this study. The research was conducted in mice, which may not fully replicate human responses to PFOA exposure. Additionally, while the study identified changes in microbiome composition and liver enzyme activity, the long-term health implications of these changes remain unclear. Further research is needed to understand the broader impacts of PFOA and other PFAS compounds on human health. For more on how stress can affect the gut and overall health, consider exploring our post on the interplay of stress, depression, and the immune system .
Sources: Sub‑chronic PFOA exposure at human‑relevant increasing doses in male mice: Role of stress‑induced gut barrier disruption in shaping intestinal and hepatic responses under high-dose conditions. — Environment international (2026) (https://pubmed.ncbi.nlm.nih.gov/42849329/)

### Exploring Epigenetics and Gut Microbiome in Autism Research
URL: https://microbiome.news/posts/exploring-epigenetics-and-gut-microbiome-in-autism-research
Section: Science | Published: 2026-10-08 | 3 min
Summary: A new review highlights the role of epigenetic changes and the gut microbiome in autism spectrum disorder, suggesting potential pathways for improved diagnostics and personalized medicine.
Body: A new review published in the International Journal of Developmental Neuroscience delves into the complex interplay of genetic, epigenetic, and environmental factors in autism spectrum disorder (ASD). This comprehensive analysis sheds light on the potential roles of maternal health, immune dysregulation, and the gut microbiome in influencing ASD risk, while also exploring emerging diagnostic and therapeutic strategies. The Role of Epigenetics in ASD Autism spectrum disorder is a neurodevelopmental condition characterized by challenges in social interaction, communication, and behavior. While genetic factors have long been recognized as significant contributors to ASD, this review emphasizes the growing evidence for epigenetic modifications as pivotal elements in the disorder's development and progression. Epigenetic changes refer to modifications in gene expression that do not involve alterations to the underlying DNA sequence. These changes can be influenced by environmental factors such as maternal health and nutrition, as well as exposure to toxins. The review highlights how maternal immune dysregulation, nutritional status, and metabolic disorders during pregnancy may induce epigenetic changes that disrupt neurodevelopmental pathways, potentially increasing ASD risk. Gut Microbiome and Maternal Health The gut microbiome, a community of microorganisms residing in the human digestive tract, has emerged as a significant player in various health conditions, including ASD. This review underscores the potential impact of alterations in the maternal gut microbiota during pregnancy on the epigenetic landscape and neurodevelopmental outcomes. Changes in the maternal gut microbiome could influence the developing fetus by affecting immune function and metabolic processes. These interactions might lead to epigenetic modifications that contribute to ASD, highlighting the need for further research into the gut-brain connection and its implications for neurodevelopmental disorders. Advancements in Diagnostics and Therapeutics In addition to exploring the underlying mechanisms of ASD, the review discusses recent advancements in diagnostic technologies and therapeutic strategies. Novel approaches such as saliva-based microRNA profiling and the identification of epigenetic biomarkers offer promising avenues for earlier and more accurate ASD detection. Furthermore, the review notes the exploration of pharmacological interventions targeting epigenetic mechanisms to alleviate behavioral symptoms associated with ASD. These interventions, along with genome-wide analyses and multi-omics approaches, are paving the way for personalized diagnostic and therapeutic strategies tailored to individual patients. Challenges and Future Directions Despite these advancements, the review acknowledges the challenges posed by the heterogeneity and biological complexity of ASD. The disorder's multifaceted nature necessitates an integrated research approach that combines insights from epigenetics, microbiome studies, and precision medicine. Future research efforts will be crucial in uncovering the molecular mechanisms underlying ASD and translating these findings into effective diagnostic tools and targeted therapies. As the field progresses, a deeper understanding of the interactions between genetic, epigenetic, and environmental factors will be essential for improving the clinical management of ASD. For more on the gut-brain connection, you might explore our post on how gut bacteria may influence our minds .
Sources: Recent Advances in Autism Spectrum Disorder Research on Epigenetics and Personalised Medicine. — International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience (2026) (https://pubmed.ncbi.nlm.nih.gov/42844155/)

### Zinc Deficiency and Cyclic Feeding Patterns: Insights from Animal Models
URL: https://microbiome.news/posts/zinc-deficiency-and-cyclic-feeding-patterns-insights-from-animal-model
Section: Science | Published: 2026-10-07 | 3 min
Summary: A new review explores the evidence for zinc deficiency-induced cyclic feeding behaviors in animal models and considers potential implications for humans.
Body: In a study published in Nutrition Reviews , researchers have synthesized five decades of evidence on zinc deficiency-induced cyclic feeding behaviors observed in animal models. This narrative review not only examines the neurobiological mechanisms underlying these feeding patterns but also evaluates the potential implications for humans, particularly in the context of the gut-brain axis. Animal Models and Cyclic Feeding The review highlights that zinc deficiency in rodents results in a distinctive cyclic feeding pattern, characterized by food intake oscillating at an approximately 3.5-day period. This pattern has been consistently observed in several studies involving rats, maintained under controlled laboratory conditions. The periodicity of feeding persists at the individual animal level and across different dietary carbohydrate sources. However, the evidence is predominantly derived from studies involving male rats, conducted by a limited number of research groups, indicating a need for broader research. Mechanistically, the cyclic feeding pattern appears to involve paradoxical elevation of neuropeptide Y with potentially impaired release, dysregulation of the hypothalamic-pituitary-adrenocortical axis, and zinc sensing through the vagus nerve. Additionally, enteroendocrine signaling involving cholecystokinin and functions mediated by the zinc-sensing receptor ZnR/GPR39 in the intestine and salivary glands are implicated in this process. Potential Human Implications While direct evidence for cyclic feeding patterns in zinc-deficient humans is lacking, the review considers circumstantial evidence from clinical data. Conditions such as anorexia nervosa and avoidant/restrictive food intake disorder, where zinc deficiency is prevalent, show some parallels in appetite fluctuations. Refeeding hypozincemia and population-specific effects of zinc supplementation on body weight further suggest potential human relevance. The review underscores the need for prospective studies in humans to explore this hypothesis further. Continuous dietary monitoring and serial zinc assessments could help determine whether similar cyclic feeding behaviors occur in zinc-deficient individuals. Limitations and Future Directions Despite the intriguing findings, the review acknowledges several limitations. The reliance on animal models, particularly male rats, limits the generalizability of the findings to humans. Additionally, the mechanistic understanding of the cyclic feeding pattern remains incomplete, necessitating further research to elucidate the underlying processes. The review calls for more comprehensive studies involving diverse populations and experimental conditions to validate and expand upon these findings. Such research could provide valuable insights into the role of zinc in regulating feeding behaviors and its broader implications for human health. For more on nutrient sensing and metabolism, you might find our post on The Role of Bile Acids in Nutrient Sensing and Metabolism informative.
Sources: Zinc Deficiency and Cyclic Feeding Behavior-From Animal Models to Potential Human Implications. — Nutrition reviews (2026) (https://pubmed.ncbi.nlm.nih.gov/42838513/)

### Diarrhea's Impact on Infant Gut Microbiome and Growth Explored
URL: https://microbiome.news/posts/diarrhea-s-impact-on-infant-gut-microbiome-and-growth-explored
Section: Science | Published: 2026-10-06 | 3 min
Summary: A new study investigates how diarrhea affects gut microbiome development and growth in infants in Mozambique, revealing complex relationships.
Body: The first year of life is a critical period for the development of the gut microbiome, a complex community of microorganisms that reside in the digestive tract. Understanding how various factors influence this development is essential, particularly in resource-limited settings where infant health challenges are prevalent. A study published in The American journal of clinical nutrition examines the relationship between diarrhea, gut microbiome composition, and infant growth in Beira, Mozambique. Study Design and Methods Researchers utilized data from the Pesquisa Sobre o Acesso à Água e a Saúde Infantil em Moçambique (PAASIM) longitudinal birth cohort study. This cohort provided a unique opportunity to explore the interplay between diarrheal episodes, gut microbiome development, and growth outcomes in infants. Stool samples were collected at four time points: 3, 6, 9, and 12 months of age, with approximately 150 samples at each earlier time point and 536 samples at 12 months. These samples underwent 16S rRNA gene sequencing to analyze microbial diversity and taxonomic composition. Additionally, caregivers reported monthly diarrhea occurrences, and anthropometric measurements were taken to assess growth. Key Findings The study found that alpha diversity, a measure of microbial diversity within a single sample, increased across infancy, reflecting the natural maturation of the microbiome. Beta diversity, which measures differences between microbial communities, also shifted significantly with age. Interestingly, the cumulative prevalence of diarrhea from birth to 12 months did not correlate with microbial diversity or community composition at 12 months. However, the study revealed age-dependent associations between early microbial diversity and growth. Higher alpha diversity at 3 months was positively associated with length-for-age z-scores (LAZ) at 12 months, suggesting a beneficial link to linear growth. Conversely, higher diversity at 6 months was inversely associated with LAZ at 12 months, indicating a complex relationship that may vary with age. At 12 months, small but significant differences in beta diversity were observed between wasted and nonwasted, and between stunted and nonstunted children. Additionally, an exploratory analysis identified a positive association between the abundance of the bacterium Finegoldia and wasting at 12 months, although this finding requires further investigation. Implications and Limitations This study highlights the intricate connections between early-life gut microbiome development and growth outcomes, independent of diarrhea burden. The findings suggest that microbial trajectories in infancy could influence growth, emphasizing the need for further research to explore potential microbiome-targeted interventions. However, there are limitations to consider. The study's observational nature means it cannot establish causation, only associations. Additionally, while the sample size was substantial, the study was conducted in a specific geographic and socio-economic context, which may limit the generalizability of the findings to other populations. Overall, this research contributes to our understanding of the factors influencing infant growth and microbiome development, particularly in high-burden settings. Future studies could build on these findings to explore targeted strategies for promoting healthy growth during this critical period.
Sources: Effect of diarrhea on early-life gut microbiome composition and subsequent infant growth in Beira, Mozambique: analysis of the PAASIM longitudinal birth cohort. — The American journal of clinical nutrition (2026) (https://pubmed.ncbi.nlm.nih.gov/42833816/)

### How Gut Bacteria May Influence Our Minds
URL: https://microbiome.news/posts/how-gut-bacteria-may-influence-our-minds
Section: Gut–Brain | Published: 2026-10-05 | 3 min
Summary: A new review explores how gut bacteria and their metabolites might affect cognition, decision-making, and consciousness through complex interactions with the brain.
Body: The intricate relationship between the gut and the brain has been a subject of growing interest in recent years. A study published in Gut Microbes delves into this connection, exploring how gut bacteria and their metabolites might influence human cognition, decision-making, and consciousness. The review synthesizes existing research to discuss the potential pathways through which the gut microbiome communicates with the central nervous system (CNS). Communication Pathways Between Gut and Brain The human gut hosts approximately 38 trillion bacteria, encompassing 400 to 500 different species. These gut bacteria are in constant communication with the brain via several pathways, including the enteric nervous system (ENS), the peripheral nervous system (PNS), the autonomic nervous system (ANS), the immune system, the enteroendocrine system (EES), and the vagus nerve (VN). These pathways facilitate a bidirectional communication system known as the gut-brain axis. One of the key findings discussed in the review is the role of short-chain fatty acids (SCFAs), particularly butyrate, in strengthening the blood-brain barrier (BBB) and modulating inflammatory signaling. This interaction is believed to affect brain function and cognitive performance. Additionally, acetate, another SCFA, is noted for enhancing the synthesis of lipid-rich myelin, which protects neurons and supports efficient neural communication. Impact on Brain Function and Cognition The review highlights how signaling molecules produced by gut bacteria can cross the gut wall and potentially optimize synaptic signaling in the frontal cortex, a region of the brain associated with higher-order thinking and decision-making. However, the production of bacterial metabolites that stimulate inflammatory responses can activate the hypothalamic-pituitary-adrenal (HPA) axis, leading to increased glucocorticoid production. This hormonal change may reduce activity in the prefrontal cortex, thereby suppressing cognitive functions. Furthermore, the review examines the influence of gut bacteria on the limbic system, which includes structures such as the thalamus, amygdala, hypothalamus, and hippocampus. These areas are primarily involved in emotions, memory, and motivation. The authors discuss whether interactions between gut-derived signaling molecules and the limbic system can affect human intelligence, cognition, consciousness, and decision-making, processes largely coordinated by the cerebrum, prefrontal cortex, and parietal lobe. Limitations and Future Directions While the review provides a comprehensive overview of potential mechanisms linking gut bacteria to brain function, it is important to note several limitations. Much of the evidence discussed is based on associative findings, which do not establish causation. Additionally, the complexity of the gut-brain axis and the multitude of factors involved make it challenging to isolate specific effects attributable solely to gut bacteria. Future research will need to address these limitations by employing more rigorous experimental designs and exploring the specific roles of different bacterial species and their metabolites. Understanding these interactions could pave the way for novel approaches to supporting cognitive health. For more on the gut-brain axis, you might explore our post on understanding the gut-brain axis in inflammatory bowel disease .
Sources: Gut bacteria and their metabolites may influence our decisions, intelligence, cognition, and consciousness. — Gut microbes (2026) (https://pubmed.ncbi.nlm.nih.gov/42828728/)

### Probiotics and Butyrate: A Potential Duo Against Liver Damage
URL: https://microbiome.news/posts/probiotics-and-butyrate-a-potential-duo-against-liver-damage
Section: Science | Published: 2026-10-04 | 3 min
Summary: A new study explores how sodium butyrate and specific Lactobacillus strains may help mitigate alcoholic liver disease by restoring gut-liver balance.
Body: A study published in the European Journal of Pharmacology investigates the potential protective effects of sodium butyrate and ethanol-metabolizing Lactobacillus strains on alcoholic liver disease (ALD). Researchers focused on how these interventions might restore gut-liver homeostasis, a critical factor in managing liver health. Understanding Alcoholic Liver Disease Alcoholic liver disease is a condition marked by liver damage due to excessive alcohol consumption. It is characterized by hepatic lipid accumulation, inflammation, and intestinal barrier dysfunction. Despite its prevalence, effective pharmacological interventions remain limited. This study aimed to explore alternative approaches by examining the role of gut microbiota and specific probiotics in mitigating these symptoms. The Study's Approach Researchers investigated the effects of sodium butyrate (NaB) both alone and in combination with newly isolated Lactobacillus strains on ALD. The study involved a six-week intervention where various indicators were assessed, including liver injury, lipid metabolism, inflammatory mediators, alcohol-metabolizing enzyme activities, and intestinal barrier markers. Additionally, serum lipopolysaccharide (LPS) levels were measured as a marker of gut permeability. To understand the microbiota's involvement, 16S rRNA gene sequencing and antibiotic pretreatment were employed. The Lactobacillus strains were isolated from long-term alcohol consumers without clinically apparent liver injury, screened for ethanol-stress tolerance, ethanol-metabolizing capacity, and NaB-responsive growth. Five strains (ML, MN, T2, T23, and TF) were selected for evaluation. Key Findings The study found that sodium butyrate reduced liver injury, dyslipidemia, inflammation, histopathological damage, and circulating LPS levels. It also improved alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) activity, as well as the expression of intestinal barrier proteins ZO-1 and Occludin. These effects were partially attributed to changes in the gut microbiota. The Lactobacillus strains demonstrated ethanol-metabolizing potential and NaB-responsive growth. Each strain improved several indices of alcohol-associated liver injury. Notably, the combination of these probiotics with sodium butyrate generally provided enhanced protection compared to either intervention alone. Implications and Limitations This study highlights the potential of a novel probiotic-postbiotic combination therapy for mitigating alcoholic liver disease. By focusing on the gut-liver axis, it provides a new perspective on managing liver health through microbiome modulation. However, there are limitations to consider. The study was conducted on animal models, which may not fully replicate human physiology. Additionally, while the combination treatment showed promise, the exact mechanisms by which these interventions exert their effects require further exploration. The study's findings are preliminary and should be interpreted with caution until validated by further research. For more on the role of short-chain fatty acids like butyrate in health, see our post on short-chain fatty acids .
Sources: Sodium butyrate combined with ethanol-metabolizing Lactobacillus strains attenuates alcoholic liver disease by restoring gut-liver homeostasis. — European journal of pharmacology (2026) (https://pubmed.ncbi.nlm.nih.gov/42829063/)

### Fungal Influence on Liver Cancer: The Role of Rhizopus arrhizus
URL: https://microbiome.news/posts/fungal-influence-on-liver-cancer-the-role-of-rhizopus-arrhizus
Section: Science | Published: 2026-10-03 | 3 min
Summary: A new study uncovers how the fungus Rhizopus arrhizus contributes to liver cancer progression by producing kynurenic acid, a metabolite that activates oncogenic pathways.
Body: In a study published in Cell Metabolism , researchers explored the role of fungi in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) to hepatocellular carcinoma (HCC). The study highlights the significant impact of the fungus Rhizopus arrhizus in this process, particularly through the production of a metabolite known as kynurenic acid (KYNA). The Role of Rhizopus arrhizus in Liver Cancer The researchers identified Rhizopus arrhizus as the most enriched fungus during the transition from MASLD to MASLD-HCC. This finding was consistent across multiple mouse models, where the presence of R. arrhizus was shown to accelerate tumorigenesis. The study demonstrated that medium conditioned by R. arrhizus could increase cell proliferation while simultaneously reducing cell cycle arrest and apoptosis in human MASLD-HCC cells. The identification of KYNA as a key metabolite produced by R. arrhizus provides further insight into the mechanisms at play. KYNA levels were found to be elevated in the portal vein, liver tissues, and stools of mice treated with R. arrhizus . This metabolite was shown to promote the proliferation of MASLD-HCC cells and further accelerate tumorigenesis in mice. Mechanism of Action: Kynurenic Acid and Oncogenic Pathways Kynurenic acid appears to play a pivotal role in the development of MASLD-HCC by interacting with specific proteins within tumor cells. The study found that KYNA directly binds to IQ motif containing GTPase activating protein 1 (IQGAP1), a protein involved in cellular signaling. This binding activates the mitogen-activated protein kinase (MAPK) signaling pathway, which is known for its role in promoting cell growth and division, thereby facilitating the development of liver cancer. This mechanistic insight underscores the potential for targeting the interaction between KYNA and IQGAP1 as a strategy to mitigate the progression of MASLD-HCC. However, the study also notes that blocking this host-fungi interaction could be a potential therapeutic strategy, indicating a need for further research in this area. Limitations and Future Directions While the study provides compelling evidence of the role of R. arrhizus and KYNA in liver cancer progression, there are limitations to consider. The research primarily relies on mouse models and in vitro studies, which may not fully replicate the complexity of human disease. Additionally, the study establishes a correlation between R. arrhizus and MASLD-HCC but does not prove causation. Further research involving human subjects will be necessary to confirm these findings and explore potential therapeutic interventions. This study adds to the growing body of evidence highlighting the significant impact of the gut microbiome, including its fungal components, on human health. Understanding these complex interactions could pave the way for novel approaches to managing and potentially preventing diseases associated with microbial dysbiosis.
Sources: Fungus Rhizopus arrhizus promotes MASLD-associated hepatocellular carcinoma through generating kynurenic acid. — Cell metabolism (2026) (https://pubmed.ncbi.nlm.nih.gov/42826714/)

### Gut Microbiota as Biomarkers in Lung Cancer Immunotherapy
URL: https://microbiome.news/posts/gut-microbiota-as-biomarkers-in-lung-cancer-immunotherapy
Section: Science | Published: 2026-10-02 | 3 min
Summary: A multicenter study explores the relationship between gut microbiota, immune-nutritional status, and clinical outcomes in non-small cell lung cancer patients receiving immunotherapy.
Body: In a new study published in Anticancer Research , researchers have investigated the potential role of gut microbiota as biomarkers in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy. This multicenter prospective study focuses on the interplay between gut microbiota composition, immune-nutritional status, and clinical outcomes in patients treated with atezolizumab-based immunotherapy. Understanding the Study The study enrolled 65 patients with advanced or recurrent NSCLC receiving atezolizumab-based immunotherapy. Researchers collected serial fecal samples from these patients to analyze their gut microbiota using 16S rRNA gene sequencing. Additionally, the immune-nutritional status of the patients was assessed using the prognostic nutritional index (PNI), a measure that combines nutritional and immune parameters. The primary aim was to explore associations between baseline PNI, gut microbiota composition, treatment response, immune-related adverse events (irAEs), and changes in microbiota over time. Out of the 65 patients, 27 were classified as responders to the treatment, while 38 were non-responders. The study also monitored the development of irAEs during the follow-up period. Key Findings The study found that pretreatment PNI was significantly associated with treatment response, with a p-value of 0.0048, indicating a strong statistical significance. Patients with a higher PNI showed improved progression-free and overall survival rates. Furthermore, the study identified a specific bacterial taxon, Lachnospiraceae UCG-008, which was enriched in patients with high PNI and those who did not experience irAEs. Interestingly, the abundance of Lachnospiraceae UCG-008 remained stable throughout the treatment period, showing no significant temporal changes. This suggests that the presence of this bacterium may be linked to a favorable host status and a lower risk of adverse events during immunotherapy. The researchers concluded that the baseline composition of gut microbiota could serve as a clinically relevant biomarker for both the efficacy and safety of immunotherapy in NSCLC patients. Implications and Limitations The findings of this study have important implications for the field of cancer treatment. Identifying reliable biomarkers can help predict which patients are more likely to respond positively to immunotherapy, potentially leading to more personalized treatment approaches. Moreover, understanding the role of gut microbiota in modulating immune responses could open new avenues for enhancing the effectiveness of cancer therapies. However, the study also has limitations. The sample size of 65 patients, while informative, is relatively small for drawing definitive conclusions. Additionally, as an observational study, it establishes associations but cannot prove causation. Further research with larger cohorts and mechanistic studies are needed to validate these findings and explore the underlying biological mechanisms. For more on how gut microbiota can influence health, you might explore our post on Akkermansia muciniphila .
Sources: Baseline Gut Microbiota Composition Links Immune-nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study. — Anticancer research (2026) (https://pubmed.ncbi.nlm.nih.gov/42823161/)

### Exploring Microbial Signals in Gliomas and Their Implications
URL: https://microbiome.news/posts/exploring-microbial-signals-in-gliomas-and-their-implications
Section: Science | Published: 2026-09-29 | 3 min
Summary: A new review examines the role of the gut microbiome in glioma biology, highlighting how microbial signals may influence tumor progression and treatment response.
Body: In a study published in Hematology/oncology clinics of North America , researchers have reviewed the emerging evidence linking the gut microbiome to glioma biology. This review delves into the complex interactions between microbial signals and glioma progression, offering insights into how these interactions might influence treatment responses and future therapeutic strategies. The Microbiome-Gut-Brain Axis in Glioma The review highlights the role of the microbiome-gut-brain axis in glioma development and progression. Gliomas, a type of brain tumor, have been shown to interact with the gut microbiome through various mechanisms. These interactions include immune regulation, the production of microbial metabolites, and modulation of the tumor microenvironment. By influencing these pathways, the gut microbiome may play a crucial role in the biology of gliomas. Mechanistic investigations have provided insights into how microbial signals can affect tumor behavior. For instance, microbial metabolites might alter immune responses or directly impact tumor cells, potentially affecting the growth and progression of gliomas. The review suggests that understanding these mechanisms could pave the way for novel therapeutic approaches that target the microbiome-gut-brain axis. Influence on Anticancer Therapy The review also explores how the gut microbiome might influence the effectiveness of anticancer therapies in glioma patients. It is suggested that the microbiome could modulate the response to treatments, possibly through its effects on the immune system or by altering drug metabolism. These interactions highlight the potential for microbiome-based biomarkers to predict treatment responses and guide personalized therapy strategies. Despite these promising insights, the translation of microbiome research into clinical practice remains limited. The review points out that while preclinical models and human studies have provided valuable data, more research is needed to fully understand the clinical implications of these findings. The development of reliable biomarkers and therapeutic strategies will require further investigation and validation in larger, more diverse patient populations. Current Limitations and Future Directions While the review underscores the potential of microbial signals in neuro-oncology, it also acknowledges the current limitations of the field. One major challenge is the complexity of the microbiome itself, which consists of a vast array of microorganisms that interact in intricate ways. Additionally, the variability in individual microbiomes can complicate the identification of specific microbial signatures associated with glioma progression or treatment response. Future research directions include the identification of specific microbial metabolites or pathways that could serve as targets for therapeutic intervention. The development of microbiome-based biomarkers for glioma diagnosis and prognosis is another promising area of investigation. As the field advances, collaborations between microbiologists, oncologists, and clinicians will be essential to translate these findings into meaningful clinical applications. For more on the interplay between the microbiome and various health conditions, you might find our article on the gut-brain-heart axis informative.
Sources: Microbial Signals in Gliomas: Mechanisms, Clinical Implications, and Future Perspectives. — Hematology/oncology clinics of North America (2026) (https://pubmed.ncbi.nlm.nih.gov/42805862/)

### Microplastics and the Gut-Brain Axis: A New Review
URL: https://microbiome.news/posts/microplastics-and-the-gut-brain-axis-a-new-review
Section: Science | Published: 2026-09-28 | 3 min
Summary: A systematic review explores how microplastics may affect the gut-brain axis, highlighting potential neurobiological impacts and challenges in translating findings from animal models to humans.
Body: Microplastic pollution is increasingly recognized as a global health concern, affecting both humans and animals. A new study published in Neurotoxicology and Teratology systematically reviews the mechanistic pathways through which ingested microplastics (MPs) may impact the gut-brain axis, with a focus on neurobiological effects observed in both human and preclinical models. The Pathways of Microplastic Impact The review highlights evidence from various studies, including in vivo rodent models and in vitro human cell models, which suggest that ingested and inhaled MPs can accumulate in the gastrointestinal tract. These particles are capable of crossing epithelial barriers and altering host-microbe interactions. Of particular concern are nanoplastics (NPs), which are less than 1 micrometer in size. Due to their small size and high surface-area-to-volume ratio, NPs may exhibit greater cellular uptake and tissue translocation, potentially leading to increased neurotoxic effects compared to larger MPs. These processes can result in systemic effects such as immune activation, oxidative stress, and metabolic dysregulation. The review further explores how MPs might influence gut-brain communication, noting changes in microbiota composition, neurotransmitter metabolism, and neuroinflammatory signaling. Such alterations have been linked to cognitive and behavioral deficits in animal models. Potential Interventions and Challenges In response to these findings, the review examines promising interventional strategies that have shown efficacy in preclinical models. These include fecal microbiota transplantation (FMT), probiotic supplementation with strains like Lactobacillus plantarum , and bile acid therapy. Each of these interventions has demonstrated potential in mitigating the neurotoxic effects induced by MPs and NPs. The review underscores the importance of understanding the physicochemical properties of MPs, such as particle size, surface chemistry, and eco-corona formation, as these factors can modulate the effects of microplastics on biological systems. However, the translation of findings from animal models to humans remains a significant challenge. The lack of standardized exposure models further complicates efforts to fully understand the implications of MP exposure in human health. Limitations and Future Directions While the review provides a comprehensive overview of current knowledge, it also acknowledges several limitations. The majority of studies reviewed are based on animal models, which may not fully replicate human physiological responses. Additionally, the review highlights the need for standardized exposure models to better assess the impact of MPs on human health. Future research is needed to bridge the gap between preclinical findings and human health implications. This includes developing more accurate models of human exposure and investigating the long-term effects of MP accumulation in the human body. As the field progresses, understanding the complex interactions between microplastics, the gut microbiome, and the brain will be crucial in addressing this emerging environmental health issue. For more on the gut-brain axis, you might find our article on exploring the microbiota-gut-brain axis in postoperative cognitive decline insightful.
Sources: Ingested microplastics and the gut-brain axis: A systematic review of mechanistic pathways and neurobiological impacts in human and preclinical models. — Neurotoxicology and teratology (2026) (https://pubmed.ncbi.nlm.nih.gov/42801985/)

### Unraveling the Complex Interactions in PMOS and Obesity
URL: https://microbiome.news/posts/unraveling-the-complex-interactions-in-pmos-and-obesity
Section: Science | Published: 2026-09-27 | 3 min
Summary: A new study uses multi-omics analysis to explore how obesity influences the metabolic and microbiome profiles in women with polyendocrine metabolic ovarian syndrome (PMOS).
Body: In a study published in Human Reproduction Open , researchers have employed a multi-omics approach to investigate the intricate interactions between polyendocrine metabolic ovarian syndrome (PMOS) and obesity. This research provides insights into how obesity influences the metabolic and microbiome profiles in women with PMOS, a common metabolic-endocrine disorder characterized by androgen excess and weight issues. Multi-Omics Approach to PMOS The study utilized Multi-Omics Factor Analysis v2 (MOFA+), a sophisticated integrative tool, to analyze the complex interplay of various biological layers in PMOS. By integrating serum metabolomics, circulating proteins, and gut microbiota composition, the researchers aimed to uncover patterns of co-variation specific to PMOS and obesity. The study included 46 Caucasian young adults from an academic hospital in Madrid, Spain, divided into three groups: 15 women with PMOS, 16 healthy control women, and 15 control men. These participants were further categorized based on their body mass index (BMI) into non-obese (BMI < 30 kg/m²) and obese (BMI ≥ 30 kg/m²) groups. This cross-sectional design allowed the researchers to observe how obesity might amplify or alter the biological signatures associated with PMOS. Findings: Sexual Dimorphism and Obesity The MOFA+ analysis identified five latent factors that explained the primary sources of variation across the different omics layers. A significant finding was the presence of sexual dimorphism in the metabolic profiles, which was evident in non-obese individuals. However, in obese subjects, differences in circulating proteins and gut microbiota were more pronounced between women with PMOS and men. Women with PMOS showed the strongest correlations between metabolomics and proteomics, which were further intensified by obesity. This suggests that obesity may exacerbate the metabolic disturbances associated with PMOS, highlighting the role of proinflammatory proteins and adipokines in these processes. Interestingly, the study found that PMOS exhibited a metabolic profile akin to obesity, even in the absence of excess weight. This supports the notion that factors such as adipose tissue dysfunction and proinflammatory proteins play a central role in the syndrome's metabolic disturbances, rather than fat mass alone. Implications and Limitations The findings underscore the complex interplay between androgen excess, adiposity, and host-microbiota interactions in PMOS. By providing a systems-level framework, this study could facilitate the identification of novel biomarkers and targeted strategies for PMOS. Additionally, the research emphasizes the importance of considering sex, sex hormones, and obesity-specific contexts in biomarker discovery and mechanistic studies. However, the study has its limitations. The relatively small sample size may have hindered the detection of some associations that would be statistically significant in larger cohorts. Furthermore, the study only included women with hyperandrogenic phenotypes of PMOS, which means the results might not be applicable to non-hyperandrogenic phenotypes of the syndrome. Overall, this study provides valuable insights into the biological underpinnings of PMOS and its interaction with obesity, offering a foundation for future research in this area.
Sources: Multi-omics factor analysis v2 (MOFA+) reveals specific co-variation patterns in women with PMOS that are strongly influenced by obesity. — Human reproduction open (2026) (https://pubmed.ncbi.nlm.nih.gov/42799253/)

### CFTR Modulators Show Functional Microbiota Shifts in Cystic Fibrosis
URL: https://microbiome.news/posts/cftr-modulators-show-functional-microbiota-shifts-in-cystic-fibrosis
Section: Science | Published: 2026-09-26 | 3 min
Summary: A new study explores how CFTR modulator therapy affects the gut and lung microbiota in cystic fibrosis patients, revealing significant functional changes despite minimal compositional shifts.
Body: A study published in Archivos de bronconeumologia investigates the impact of CFTR modulator therapy on the microbiota of cystic fibrosis (CF) patients. The research focuses on the functional and compositional changes in the gut and lung microbiota after one year of treatment with elexacaftor-tezacaftor-ivacaftor (ETI), a combination therapy that has significantly improved clinical outcomes for CF patients. Study Design and Methods Researchers conducted a 12-month prospective study involving 35 clinically stable CF patients who were beginning ETI therapy. The study collected paired fecal and sputum samples at the start and after 12 months of treatment. These samples were analyzed using shotgun metagenomics, metaproteomics, and short-chain fatty acid (SCFA) quantification. The multi-omics data were then integrated with clinical parameters assessing lung, hepatic, pancreatic, and intestinal function. The study aimed to understand the effects of ETI on the microbiota, particularly focusing on functional changes, as the compositional effects were expected to be minimal. The researchers looked at microbial diversity and the presence of specific microbial proteins and pathways. Key Findings The study found that ETI therapy led to significant clinical improvements, such as increased ppFEV 1 , higher fecal elastase levels, and better nutritional status. However, major lung pathogens persisted, and changes in liver or intestinal inflammation markers were minimal. In terms of microbiota composition, the study observed limited shifts. Alpha diversity remained stable, and changes in beta diversity accounted for only a small variance in both the gut and lung microbiomes. Notably, butyrate-producing genera were enriched in feces, while oropharyngeal taxa increased in sputum samples. Metaproteomics revealed a broad downregulation of host neutrophil-driven inflammatory proteins, with sputum samples showing increased abundance of extracellular matrix-related proteins. Microbial proteins linked to carbohydrate and lipid metabolism, particularly butanoate pathways, increased in feces, alongside a trend for higher butyrate levels. In sputum, there was an increase in formaldehyde dehydrogenase enzymes, indicating enhanced oxidative microbial metabolism. Implications and Limitations The findings suggest that while ETI therapy is associated with minimal compositional changes in the microbiota, it induces substantial functional reprogramming. This includes an increase in butyrate-producing taxa, attenuation of host pro-inflammatory pathways, and a shift in lung metabolism toward oxidation. These changes indicate a less inflammatory and more stable host-microbiota ecosystem, despite ongoing pathogenic colonization. However, the study has limitations. The sample size of 35 patients is relatively small, which may affect the generalizability of the findings. Additionally, the study's observational nature means it can demonstrate associations but not causation. Further research is needed to explore the long-term effects of ETI therapy on the microbiota and its clinical implications. For more insights into the role of short-chain fatty acids in the microbiome, you might find our article on short-chain fatty acids informative.
Sources: Functional and Compositional Shifts in Lung and Gut Microbiota after One Year of Treatment with Highly Effective CFTR Modulators in Cystic Fibrosis. — Archivos de bronconeumologia (2026) (https://pubmed.ncbi.nlm.nih.gov/42791132/)

### Carbohydrate Polymers in Probiotic Delivery: A Nanoarmor Approach
URL: https://microbiome.news/posts/carbohydrate-polymers-in-probiotic-delivery-a-nanoarmor-approach
Section: Science | Published: 2026-09-25 | 3 min
Summary: A new review explores the use of carbohydrate polymer-based nanoarmor systems for enhancing probiotic delivery through the gastrointestinal tract.
Body: Probiotics are widely recognized for their potential health benefits, but their journey through the human gastrointestinal tract is fraught with challenges. A new review published in Carbohydrate Polymers delves into innovative solutions for improving probiotic viability during this journey. The focus is on carbohydrate polymer-based nanoarmor systems, which offer a promising method for protecting probiotics against the harsh conditions of the gastrointestinal environment. The Challenge of Probiotic Delivery Probiotics, beneficial bacteria that can support human health, often face a significant hurdle: surviving the acidic and enzymatic conditions of the gastrointestinal tract. Gastric acidity, bile salts, and digestive enzymes can drastically reduce the viability of these microorganisms before they reach their intended destination in the gut. This has spurred research into protective delivery systems that can enhance the survival and efficacy of probiotics. Traditional methods of probiotic encapsulation have included hydrogel-based systems and live biotherapeutic approaches. However, these methods often fall short in providing the necessary protection and targeted delivery required for optimal probiotic function. Carbohydrate Polymer-Based Nanoarmor The review highlights the emergence of carbohydrate polymers as key materials in developing nanoarmor for probiotics. These polymers, including chitosan, cellulose derivatives, hyaluronic acid, and β-glucan, are used to construct hybrid nanoarmor systems directly on the surfaces of probiotics. Such systems are designed to be biocompatible and responsive to the gastrointestinal environment, offering a tailored approach to probiotic protection and delivery. The review systematically discusses the roles of these nanoarmor systems in protecting probiotics, ensuring their responsive release, targeting specific areas of the gut, and regulating their bioactivity. The authors emphasize that the chemical structure, molecular weight, charge density, crosslinking, and degradability of the polymers are critical factors that influence the assembly, stability, and disassembly of the nanoarmor. Balancing Protection and Release A key insight from the review is the need to balance probiotic protection with the viability and release of the microorganisms. While maximizing coating stability might seem advantageous, it is crucial to ensure that the probiotics are not only protected but also released effectively at the right location in the gut. This balance is essential for maintaining the functionality and health benefits of the probiotics. The review also outlines the preparation strategies and representative applications of these nanoarmor systems, providing a comprehensive overview of current research highlights. However, it acknowledges the challenges that remain in the field, including the need for further research to optimize these systems for practical applications. Limitations and Future Directions While the review offers a thorough analysis of carbohydrate polymer-based nanoarmor systems, it also notes several limitations. The research in this area is still developing, and many of the findings are preliminary. Additionally, the effectiveness of these systems in real-world applications remains to be fully validated. Future research will need to address these challenges, focusing on refining the design and functionality of nanoarmor systems to enhance probiotic delivery. As the field progresses, these innovations could pave the way for more effective probiotic therapies and applications.
Sources: Carbohydrate polymer-based nanoarmor systems for probiotic gastrointestinal delivery: Strategies, applications, and perspectives. — Carbohydrate polymers (2026) (https://pubmed.ncbi.nlm.nih.gov/42785862/)

### The Gut-Joint Axis: Insights into Osteoarthritis Progression
URL: https://microbiome.news/posts/the-gut-joint-axis-insights-into-osteoarthritis-progression
Section: Science | Published: 2026-09-24 | 3 min
Summary: A new review explores how the gut microbiome may influence osteoarthritis development and progression, highlighting potential therapeutic avenues.
Body: Osteoarthritis, a degenerative condition affecting joints, stands as a leading cause of chronic disability among older adults. Despite its prevalence, no disease-modifying therapies currently exist. A study published in Best practice & research. Clinical rheumatology reviews the role of the gut microbiome in osteoarthritis, proposing a 'gut-joint axis' that may illuminate new paths for understanding and potentially managing this condition. The Gut-Joint Axis Hypothesis The review outlines a conceptual framework wherein the gut microbiome impacts joint health. This 'gut-joint axis' suggests that an altered gut microbial community can lead to increased gut permeability. Consequently, microbial products may translocate into the bloodstream, triggering low-grade systemic inflammation that affects joint tissues. Recent findings also suggest that changes in bile acids and incretins—a group of metabolic hormones—might play a role in this process. Animal studies provide the most compelling evidence for this hypothesis. Experiments that manipulate the gut microbiome—through removal, perturbation, or transplantation—have demonstrated alterations in joint damage. These findings suggest a causal relationship between the gut microbiome and joint health, although this has yet to be conclusively proven in humans. Human Studies: Observational and Discordant In contrast to animal studies, human research remains largely observational and often yields conflicting results. These discrepancies may arise from variations in the joints studied, differences in population demographics, and methodological inconsistencies. Despite these challenges, some functional measures, such as circulating endotoxin levels, show more consistent reproducibility than taxonomic analyses of microbial communities. While these human studies underscore the complexity of the gut-joint relationship, they also highlight the need for more rigorous and standardized research protocols. Understanding these nuances is crucial for translating microbiome research into clinical practice. Potential Therapeutic Opportunities The review also explores potential therapeutic strategies that could emerge from a better understanding of the gut-joint axis. These include dietary interventions such as increased fiber intake and prebiotics, weight management, and incretin-based agents. While these approaches hold promise, the review emphasizes that more research is needed before microbiome-directed therapies can be integrated into standard osteoarthritis care. For those interested in the broader implications of microbiome research, our post on the gut-bone connection provides additional insights into how gut health may influence other aspects of musculoskeletal health. Limitations and Future Directions One of the primary limitations of the current research is its reliance on animal models, which may not fully replicate human osteoarthritis. Additionally, the observational nature of human studies limits the ability to draw causal inferences. Future research should aim to address these gaps by employing longitudinal studies and standardized methodologies. In summary, while the gut-joint axis presents an intriguing avenue for understanding osteoarthritis, much work remains to be done. The insights gained from this review could pave the way for novel therapeutic strategies, but rigorous research is essential to validate these concepts in clinical settings.
Sources: What does the gut microbiome teach us about osteoarthritis development and progression? — Best practice & research. Clinical rheumatology (2026) (https://pubmed.ncbi.nlm.nih.gov/42778434/)

### Exploring Huanglian Wendan Decoction's Impact on Insomnia in Mice
URL: https://microbiome.news/posts/exploring-huanglian-wendan-decoction-s-impact-on-insomnia-in-mice
Section: Gut–Brain | Published: 2026-09-23 | 3 min
Summary: A new study investigates how Huanglian Wendan Decoction affects insomnia-like symptoms in mice, focusing on the brain-gut axis and microbiota changes.
Body: In a study published in the Journal of ethnopharmacology , researchers explored the effects of Huanglian Wendan Decoction (HLWDD), a traditional Chinese medicine, on insomnia-like symptoms in a mouse model. The study aimed to understand the biological mechanisms through which HLWDD might exert its effects, particularly focusing on the brain-gut axis. Methodology and Model Creation The researchers created a composite mouse model exhibiting insomnia-like behaviors and features associated with phlegm-heat, a concept in traditional Chinese medicine. This was achieved using 4-chloro-DL-phenylalanine (PCPA) and an HF60 high-fat diet. The mice were then treated with HLWDD to assess changes in behavior, gut microbiota composition, serum biomarkers, and brain chemistry. The study employed a variety of analytical techniques, including 16S rRNA sequencing to examine gut microbiota, and non-targeted metabolomics to analyze serum metabolic profiles. Additionally, they measured serum levels of inflammatory markers like tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β), as well as lipid profiles and neurotransmitter levels in the brain. Key Findings The HLWDD treatment appeared to alleviate several abnormalities in the mouse model. Behavioral changes associated with insomnia were reduced, and the gut microbiota composition showed partial restoration. Notably, there was an increase in beneficial bacteria like Akkermansia and a reduction in potentially harmful Desulfovibrio -associated taxa. Inflammatory markers in the serum were reduced, and lipid profiles improved, indicating a potential systemic effect of HLWDD. The treatment also increased levels of acetylcholine (ACh), γ-aminobutyric acid (GABA), and brain-derived neurotrophic factor (BDNF) in the brain. These changes were accompanied by the restoration of PI3K expression and enhanced phosphorylation of AKT and CREB proteins, signaling pathways often linked to neuroprotection and cognitive function. Metabolic analysis identified three metabolites with altered levels in the model group that were reversed following HLWDD treatment. One such metabolite, PC 16:1_22:5, was notably increased after treatment, suggesting a potential role in the observed effects. Implications and Limitations The study provides experimental evidence supporting the multi-level, multi-target effects of HLWDD on insomnia-like symptoms, potentially through the coordinated regulation of the gut microbiota-host metabolism-central nervous system axis. However, as this research was conducted in a mouse model, the findings may not directly translate to humans. Moreover, the study does not establish causation but rather an association between HLWDD treatment and observed changes. Further research is needed to confirm these effects in human subjects and to explore the precise mechanisms involved. For more on the gut-brain axis, you might find our article on probiotic strains and the gut-brain axis informative.
Sources: Huanglian Wendan Decoction Ameliorates Insomnia-Like Phenotypes in a Composite Mouse Model with Phlegm-Heat-Related Features: Insights from the Brain-Gut Axis. — Journal of ethnopharmacology (2026) (https://pubmed.ncbi.nlm.nih.gov/42772618/)

### Exploring the Microbiota-Gut-Brain Axis in Postoperative Cognitive Decline
URL: https://microbiome.news/posts/exploring-the-microbiota-gut-brain-axis-in-postoperative-cognitive-dec
Section: Gut–Brain | Published: 2026-09-22 | 3 min
Summary: A new review examines how anesthesia and surgical stress disrupt the gut microbiome, potentially leading to neurocognitive disorders in older patients.
Body: Postoperative neurocognitive disorders (PND) are a significant concern for older adults undergoing surgery, with evidence increasingly pointing to disruptions in the gut microbiome as a contributing factor. A study published in Experimental Neurology provides a comprehensive review of the current understanding of how anesthesia and surgical stress may influence the microbiota-gut-brain axis, potentially leading to cognitive decline. The Role of the Gut Microbiome The gut microbiome, a complex community of microorganisms residing in the intestines, plays a crucial role in maintaining overall health. It is involved in various bodily functions, including metabolism, immune response, and communication with the central nervous system through the gut-brain axis. This axis is a bidirectional communication pathway that links the gut and the brain, facilitating interactions between the gut microbiota and the nervous system. The review highlights how anesthesia and the stress of surgery can disrupt the gut microbiome, a condition known as dysbiosis. This disruption can alter the composition and function of the microbial community, potentially leading to adverse effects on the brain. However, the precise mechanisms by which these changes contribute to neurocognitive disorders remain unclear. Mechanisms of Neurocognitive Decline The researchers identify several pathways through which dysbiosis may lead to cognitive decline. One key mechanism involves the translocation of microbial metabolites and endotoxins from the gut to the central nervous system. These substances can trigger neuroinflammation, a process that involves the activation of immune cells in the brain, such as microglia, and the disruption of the blood-brain barrier. Specific metabolites, such as short-chain fatty acids, indole derivatives, and bile acids, are highlighted as potential contributors to this process. Additionally, the kynurenine pathway, a metabolic route that can produce neuroactive compounds, is implicated in the development of neuroinflammation and cognitive impairment. Potential Biomarkers and Strategies Identifying specific microbial taxa and metabolites that could serve as biomarkers for predicting postoperative cognitive outcomes is another focus of the review. Such biomarkers could help in assessing the risk of PND in patients undergoing surgery, allowing for more personalized approaches to patient care. The review also evaluates emerging strategies aimed at targeting the microbiota to prevent or mitigate PND. These strategies include dietary interventions, probiotics, and other microbiota-modulating therapies. However, the authors caution that more research is needed to establish the efficacy and safety of these approaches. Limitations and Future Directions While the review provides valuable insights into the potential links between the gut microbiome and postoperative cognitive decline, it also acknowledges several limitations. Much of the existing evidence is derived from preclinical studies, and there is a need for more clinical research to confirm these findings in human populations. Additionally, the complexity of the microbiota-gut-brain axis means that isolating specific causal mechanisms remains challenging. Future research should focus on elucidating the precise pathways involved and developing targeted interventions that can effectively modulate the gut microbiome to improve cognitive outcomes in surgical patients. For more on the gut-brain connection, you can explore our gut-brain axis primer .
Sources: From dysbiosis to postoperative neurocognitive disorders: The anesthesia-disrupted microbiota-gut-brain axis. — Experimental neurology (2026) (https://pubmed.ncbi.nlm.nih.gov/42767440/)

### Advancements in Intestinal Organoid Culture Techniques
URL: https://microbiome.news/posts/advancements-in-intestinal-organoid-culture-techniques
Section: Science | Published: 2026-09-21 | 3 min
Summary: New protocols enhance the study of intestinal biology using 3D and 2D organoid cultures, offering insights into cellular processes and disease mechanisms.
Body: In a study published in Methods in Molecular Biology , researchers have updated protocols for culturing intestinal organoids, providing new insights into the study of intestinal biology. These advancements in both three-dimensional (3D) and two-dimensional (2D) culture techniques offer a deeper understanding of the intestinal epithelium's self-renewal and differentiation processes, which are crucial for maintaining intestinal health and understanding disease mechanisms. Understanding Intestinal Organoids Intestinal organoids are miniature, simplified versions of the intestine created from stem cells. They mimic the structure and function of the intestinal epithelium, the tissue lining the gut. This epithelium is known for its ability to continuously renew itself and differentiate into various cell types, a process regulated by several signaling pathways, including Wnt, bone morphogenetic protein, epidermal growth factor (EGF), and Notch. The study highlights the use of a defined combination of EGF, Noggin, and the Wnt agonist R-spondin, which supports the long-term expansion of mouse intestinal stem cells. This combination allows for the formation of organoids with indefinite self-renewal and full differentiation capacity, making them a powerful tool for studying intestinal biology. Advancements in Human Intestinal Organoid Cultures For human intestinal organoid cultures, the researchers introduced small molecule inhibitors targeting the p38 and TGF-β pathways to facilitate epithelial propagation. Additionally, they found that replacing EGF and a p38 inhibitor with insulin-like growth factor-1 and fibroblast growth factor-2 enabled efficient multilineage differentiation. These modifications enhance the ability to study human intestinal cells in a laboratory setting, providing a more accurate model for human intestinal biology. Moreover, the study discusses the growing use of monolayer cultures of intestinal organoids. These 2D cultures offer direct access to the apical membrane and the ability to co-culture with gut microbiota, providing a unique perspective on host-microbe interactions and intestinal function. Implications and Limitations The updated protocols for intestinal organoid culture have significant implications for understanding intestinal homeostasis and the pathogenesis of intestinal diseases. By providing a more refined model of the intestinal epithelium, researchers can explore the intricate signaling pathways that regulate cell renewal and differentiation, potentially uncovering new insights into how these processes go awry in disease. However, it is essential to acknowledge the limitations of these findings. The study primarily focuses on the technical aspects of organoid culture, and while it provides a framework for future research, the findings are preliminary. Further studies are needed to validate these protocols across different contexts and to explore their applicability to various types of intestinal diseases. For those interested in the broader implications of microbiome research, our article on leaky gut and intestinal permeability offers additional insights into how disruptions in intestinal function can impact health.
Sources: Updated Protocols for 3D and 2D Culture and Histological Analysis of Intestinal Organoids. — Methods in molecular biology (Clifton, N.J.) (2027) (https://pubmed.ncbi.nlm.nih.gov/42763855/)

### Gut Microbiome's Role in Neuroinflammation After Brain Injury
URL: https://microbiome.news/posts/gut-microbiome-s-role-in-neuroinflammation-after-brain-injury
Section: Science | Published: 2026-09-20 | 3 min
Summary: A new study explores how gut microbiome modulation affects neuroinflammation in aging mice after brain injury, shedding light on potential therapeutic avenues.
Body: A new study published in Brain Research investigates the role of the gut microbiome in modulating neuroinflammation following early brain injury (EBI) after subarachnoid hemorrhage (SAH). The research focuses on how age-related changes in the gut microbiome may exacerbate neuroinflammation and whether microbiome modulation can mitigate these effects. Exploring the Gut-Brain Connection Subarachnoid hemorrhage is a serious condition where bleeding occurs in the space between the brain and the surrounding membrane. Early brain injury following SAH is a critical factor influencing patient outcomes, with older individuals often experiencing worse prognoses. Researchers hypothesized that alterations in the gut microbiome with age might contribute to increased neuroinflammation and poorer outcomes in older patients. In this study, young (8-12 weeks) and aged (17-20 months) male C57BL/6 mice were used to model the effects of SAH. The researchers assessed various parameters, including neurological scores, brain water content, neuronal degeneration, blood-brain barrier permeability, and inflammation. They found that aged mice exhibited higher mortality rates, worse neurological outcomes, increased neuronal degeneration, and heightened inflammation compared to their younger counterparts. Microbiome Modulation as a Potential Intervention The study employed a gut microbiome modulation protocol in aged mice to investigate whether altering the microbiome could reduce neuroinflammatory responses. This protocol included antibiotic pretreatment, fecal microbiota transplantation from young donors, and co-housing with young mice. The intervention successfully shifted the gut microbiome composition of aged mice to resemble that of younger mice. Following microbiome modulation, aged mice showed reduced neuronal injury, decreased neutrophil infiltration, lower neutrophil extracellular trap (NET) formation, and reduced microglial inflammation. However, the intervention did not lead to improvements in neurological scores or brain water content at the 24-hour mark post-injury. Implications and Limitations The findings suggest that the gut-brain axis could be a promising target for interventions aimed at reducing neuroinflammation and neurodegeneration following brain injury, particularly in older populations. The study highlights the potential of gut microbiome modulation in attenuating specific inflammatory responses associated with aging. However, it is important to note the limitations of this study. The research was conducted on mice, and the results may not directly translate to humans. Additionally, while the intervention showed promise in reducing certain inflammatory markers, it did not improve overall functional outcomes within the 24-hour observation period. Further research is needed to explore the long-term effects of microbiome modulation and its potential therapeutic applications. For more on the gut-brain connection, you might explore our article on natural polysaccharides and the microbiota-gut-brain axis .
Sources: Role of gut microbiome modulation in the attenuation of aging-related neuroinflammation in early brain injury after subarachnoid hemorrhage. — Brain research (2026) (https://pubmed.ncbi.nlm.nih.gov/42762960/)

### Understanding Infant Gut Microbiome Development in Pakistan
URL: https://microbiome.news/posts/understanding-infant-gut-microbiome-development-in-pakistan
Section: Science | Published: 2026-09-19 | 3 min
Summary: A new study explores how early-life factors influence the gut microbiome and resistome in infants from a low-income urban population in Pakistan.
Body: A study published in BMJ open investigates the development of the infant gut microbiome and resistome in Pakistan, focusing on how various early-life factors influence these microbial communities. Known as the Infant Gut Bacterial Study in Pakistan (INBUGS-P), this longitudinal research aims to enhance our understanding of microbial dynamics during the first year of life in a low- and middle-income country setting. Study Design and Data Collection The INBUGS-P study recruited 107 mother-infant pairs at the Pakistan Institute of Medical Sciences over a six-month period. Researchers conducted follow-ups at ten predefined timepoints from birth to 12 months. During these follow-ups, they collected a comprehensive set of samples, including 921 infant stool samples, 158 maternal rectal swabs, 246 breast milk samples, and 2171 environmental swabs. This extensive data collection was complemented by sociodemographic, clinical, cultural, and biological data gathered at each visit. The study's cohort primarily represents an urban low-income population, with a median household income of approximately US$170 per capita per month. Notably, 55% of the infants were delivered by caesarean section, 13% were late preterm, and 10% had a low birth weight. Breastfeeding was common, although only 24 infants were exclusively breastfed for the first six months. Additionally, antibiotics were administered to nearly all mothers post-delivery, and 19 infants received antibiotics during the study period. Microbial and Antimicrobial Resistance Profiling One of the primary aims of the INBUGS-P study is to assess how early-life exposures affect gut bacterial diversity and antimicrobial resistance gene (ARG) profiles. To achieve this, researchers are employing shotgun metagenomic sequencing of infant stool samples. This technique allows for detailed species-level and plasmid-level profiling of microbial communities and ARGs. Such granular data is crucial for understanding the complex interplay between microbial diversity and resistance in the gut microbiome. The study's focus on antimicrobial resistance is particularly timely, given the global concern over rising antibiotic resistance. By examining ARG profiles in the context of early-life exposures, this research could provide valuable insights into how resistance genes are acquired and propagated in early childhood. Implications and Future Directions The INBUGS-P study offers a unique perspective on the development of the infant gut microbiome in a low-income setting. Understanding how factors like delivery mode, antibiotic use, and feeding practices influence microbial communities can inform public health strategies aimed at optimizing infant health. Furthermore, the study's findings may have broader implications for other low- and middle-income countries facing similar challenges. Looking ahead, the researchers plan to extend the follow-up period to 24 months, subject to funding. They also aim to employ hybrid long- and short-read sequencing techniques to enhance the resolution of their microbial profiling efforts. These future steps could provide even deeper insights into the dynamics of the infant gut microbiome and resistome. However, it's important to note that the study's findings are based on a relatively small sample size of 98 mother-infant dyads, which may limit the generalizability of the results. Additionally, while the study identifies associations between early-life factors and microbiome development, it does not establish causation. For more on how antibiotics influence the gut microbiome, see our post on antibiotics and gut microbiome recovery .
Sources: Cohort profile: Infant Gut Bacterial Study in Pakistan (INBUGS-P) longitudinal birth cohort. — BMJ open (2026) (https://pubmed.ncbi.nlm.nih.gov/42760068/)

### Micronutrients and Infant Gut Microbiota: A Complex Interaction
URL: https://microbiome.news/posts/micronutrients-and-infant-gut-microbiota-a-complex-interaction
Section: Science | Published: 2026-09-18 | 3 min
Summary: A new review explores how micronutrients influence the developing gut microbiota in infants, potentially affecting infection susceptibility.
Body: The relationship between micronutrients and the gut microbiota in infants is a burgeoning area of research, with implications for understanding how these factors contribute to infection susceptibility. A study published in Trends in Microbiology offers a comprehensive review of the current evidence on this topic, focusing on how micronutrients interact with the developing microbial ecosystem in infants. The Role of Micronutrients in Infant Health Micronutrient deficiencies are prevalent during infancy, particularly in regions with a high burden of infectious diseases. These deficiencies can have significant impacts on health, as micronutrients are essential for various biological processes. The review highlights that the developing infant gut microbiota is a crucial determinant of infection susceptibility, influenced by both resident pathobionts and incoming enteric pathogens. Recent studies suggest that micronutrients regulate the infant gut microbiota in a highly context-dependent manner. This means that the effects of micronutrients can vary based on factors such as the infant's developmental stage, nutritional status, intestinal location, and environmental exposure. This complexity underscores the importance of understanding the nuanced interactions between diet and the microbiome in early life. Micronutrients and Microbial Interactions The review synthesizes evidence linking micronutrient-microbiota interactions to several key biological processes. These include microbial competition and metabolism, epithelial barrier integrity, and mucosal immunity. Each of these processes plays a role in shaping the gut environment and the body's ability to fend off infections. For instance, certain micronutrients may influence microbial competition by favoring the growth of beneficial microbes over harmful ones. This can affect the overall composition of the gut microbiota, which in turn impacts the host's health. Additionally, micronutrients can support the integrity of the epithelial barrier, which acts as a physical and immunological barrier to pathogens. Furthermore, they may modulate mucosal immunity, enhancing the body's ability to respond to microbial threats. Implications and Limitations The findings of this review have important implications for understanding how diet and nutrition can influence infant health through the microbiome. By elucidating the mechanisms through which micronutrients affect the gut microbiota, researchers can better understand the factors contributing to infection susceptibility in infants. However, it is important to note the limitations of the current evidence. Much of the research on micronutrient-microbiota interactions is still in its early stages, and the effects observed are often context-dependent. This means that findings from one study may not be directly applicable to all populations or settings. Additionally, while associations between micronutrients and microbial processes have been identified, causation cannot always be established. Further research is needed to clarify these complex interactions and their implications for infant health. For more on the role of diet in shaping the gut microbiota, you might explore our article on diet diversity and gut health .
Sources: Micronutrients, the gut microbiota, and infection susceptibility in infants. — Trends in microbiology (2026) (https://pubmed.ncbi.nlm.nih.gov/42754484/)

### Exploring the Gut-Brain-Heart Axis in Congenital Heart Disease
URL: https://microbiome.news/posts/exploring-the-gut-brain-heart-axis-in-congenital-heart-disease
Section: Gut–Brain | Published: 2026-09-17 | 3 min
Summary: A new review highlights the role of the microbiome in the complex interactions between the gut, brain, and heart in children with congenital heart disease.
Body: Congenital heart disease (CHD) is traditionally viewed as a condition primarily affecting the heart's structure. However, a new review published in Heart (British Cardiac Society) suggests that CHD's impact extends well beyond the heart, influencing gastrointestinal, immunological, and neurodevelopmental systems. This broader perspective is crucial for understanding the full spectrum of challenges faced by individuals with CHD. The Microbiome's Role in CHD The review examines the gut microbiome's central role in regulating immune function, maintaining metabolic balance, and supporting brain development, particularly during early life. In children with CHD, disruptions to the microbiome are common due to factors such as altered gut perfusion, antibiotic exposure, feeding disruptions, and cardiopulmonary bypass (CPB) procedures. These disruptions may have significant implications for both cardiac recovery and neurodevelopmental outcomes. One of the key insights from the review is the interconnectedness of the gut-heart-brain axis. This axis suggests that changes in the gut microbiome can influence cardiac physiology and brain development through complex signaling pathways. For instance, the microbiome can affect systemic inflammation and immune responses, which are critical factors in recovery and long-term health outcomes for children with CHD. Perioperative Factors and Early-Life Vulnerability The review highlights the particular vulnerability of infants with CHD during early life, a period marked by rapid brain development and immune system maturation. Perioperative factors, such as the use of CPB and exposure to antibiotics, can further disrupt the microbiome, potentially exacerbating neurodevelopmental challenges and gastrointestinal issues. Understanding how these perioperative factors interact with the microbiome is essential for developing strategies to mitigate their impact. The review suggests that future research should focus on elucidating these interactions, which could inform interventions aimed at optimizing long-term outcomes for children with CHD. Translational Insights and Future Directions The review offers emerging translational insights into how the gut-brain-heart axis might be leveraged to improve outcomes for children with CHD. By synthesizing current evidence, the authors aim to pave the way for future studies that could lead to novel approaches in managing this complex condition. However, the review also acknowledges several limitations. The evidence linking the microbiome to cardiac and neurodevelopmental outcomes in CHD is still emerging, and much of it is based on associations rather than causation. Additionally, the review underscores the need for more comprehensive studies that can account for the myriad factors influencing the gut-brain-heart axis. For those interested in the broader implications of microbiome research, our exploration of the microbiota-gut-brain axis in stress responses may offer additional context.
Sources: Gut-brain-heart axis in congenital heart disease: emerging roles of the microbiome in cardiac physiology and neurodevelopment. — Heart (British Cardiac Society) (2026) (https://pubmed.ncbi.nlm.nih.gov/42749475/)

### Exploring the Microbiota-Gut-Brain Axis in Chemotherapy-Induced Cognitive Impairment
URL: https://microbiome.news/posts/exploring-the-microbiota-gut-brain-axis-in-chemotherapy-induced-cognit
Section: Gut–Brain | Published: 2026-09-16 | 3 min
Summary: A new review examines the potential role of the microbiota-gut-brain axis in cognitive impairments associated with doxorubicin chemotherapy, highlighting the need for further research.
Body: In a study published in Pharmacological Research , researchers have reviewed existing evidence to explore how the microbiota-gut-brain axis might contribute to cognitive impairments often observed in patients undergoing chemotherapy with doxorubicin. This phenomenon, commonly referred to as 'chemobrain,' affects memory, attention, executive function, and processing speed, posing significant challenges during and after cancer treatment. Understanding Chemobrain Chemotherapy-induced cognitive impairment (CICI) is a well-documented side effect of cancer treatment, but the mechanisms behind it remain elusive. Doxorubicin, a widely used chemotherapeutic agent, is of particular interest because it has limited exposure to brain tissue, yet consistently results in neuroinflammatory, oxidative, vascular, and synaptic abnormalities in preclinical studies. This review seeks to determine whether disruptions in the microbiota-gut-brain axis might play a role in these central nervous system effects. The Role of the Microbiota-Gut-Brain Axis The microbiota-gut-brain axis is a complex communication network that links the gut microbiome with the central nervous system. According to the review, doxorubicin can alter the structure of microbial communities, damage the intestinal barrier, and modify short-chain fatty acid (SCFA)-associated taxa and functions. These changes can lead to altered metabolite profiles and promote systemic inflammatory and metabolic signaling, which may interact with brain endothelial cells, glia, mitochondria, and pathways related to hippocampal neurogenesis and synaptic plasticity. While these findings are intriguing, the review emphasizes that the proposed doxorubicin-gut-brain pathway is largely based on preclinical studies and remains an incompletely tested framework. No longitudinal human studies have yet established a direct temporal sequence linking doxorubicin exposure, changes in the microbiome or metabolome, systemic inflammation, and cognitive outcomes. The Need for Further Research The review identifies several key areas for future research. Longitudinal human studies with pretreatment baselines and repeated multi-omics and cognitive assessments are needed to establish causal relationships. Additionally, animal studies should aim to test temporal precedence and causal rescue or pathway blockade within the same model. Mediation analyses could help determine whether microbial or metabolic changes act as intermediaries between treatment and cognitive dysfunction. Furthermore, mechanism-informed clinical trials are necessary to demonstrate target engagement, cognitive benefits, oncology safety, and the preservation of antitumor efficacy. While microbiome-directed interventions show promise, they remain investigational for doxorubicin-associated CICI at this time. For more on how the gut microbiome interacts with various health conditions, you might find our article on short-chain fatty acids informative. Limitations and Conclusions It is important to note that the findings discussed in this review are primarily based on animal studies, which vary widely in terms of dose, regimen, tumor context, sampling time, and microbiome methodology. Additionally, the review highlights the lack of causal rescue experiments, underscoring the preliminary nature of the proposed mechanisms. In conclusion, while the microbiota-gut-brain axis presents a compelling avenue for understanding chemotherapy-induced cognitive impairment, more rigorous research is needed to validate these findings and explore potential therapeutic opportunities.
Sources: Potential Contribution of the Microbiota-Gut-Brain Axis to Doxorubicin-Associated Cognitive Impairment: Mechanisms, Evidence, and Therapeutic Opportunities. — Pharmacological research (2026) (https://pubmed.ncbi.nlm.nih.gov/42744193/)

### Diet Diversity Linked to Prepregnancy BMI but Not Gut Microbiota
URL: https://microbiome.news/posts/diet-diversity-linked-to-prepregnancy-bmi-but-not-gut-microbiota
Section: Science | Published: 2026-09-15 | 3 min
Summary: A new study explores the relationship between dietary diversity, prepregnancy BMI, and gut microbiota diversity in the third trimester of pregnancy.
Body: In a study published in Current Developments in Nutrition , researchers investigated the associations between prepregnancy body mass index (pBMI), dietary diversity during pregnancy, and gut microbiota diversity in the third trimester. The study aimed to better understand how these factors interrelate, particularly in the context of rising rates of overweight and obesity among pregnant women in the United States. Exploring Dietary Diversity and BMI The study utilized data from the Michigan Archive for Research on Child Health cohort, focusing on 132 participants in their third trimester of pregnancy. Researchers assessed dietary diversity using the Minimum Dietary Diversity for Women of Reproductive Age (MDD-W) indicator, which is based on 24-hour dietary recall data. This indicator helps evaluate micronutrient adequacy, which is crucial for maternal and fetal health. Among the participants, 49% had a normal weight, 25% were overweight, and 26% were classified as having obesity. The study found that prepregnancy BMI was inversely correlated with dietary diversity scores. Specifically, women with obesity had lower dietary diversity compared to those with normal weight. This suggests that women with higher pBMI may be at risk of inadequate micronutrient intake, which can have implications for maternal and fetal health. Gut Microbiota Diversity: A Separate Story In addition to dietary diversity, the study examined the diversity of gut microbiota by analyzing fecal samples from 114 participants using 16S ribosomal ribonucleic acid gene sequencing. The researchers were particularly interested in whether dietary diversity during pregnancy influenced gut microbiota diversity, which is often linked to overall health. Contrary to what might be expected, the study found no significant association between dietary diversity and gut microbiota α- and β-diversity. This finding suggests that, at least in the third trimester of pregnancy, the diversity of the gut microbiota may not be directly influenced by dietary diversity. This is an important consideration, as it highlights that other factors may play a more significant role in shaping the gut microbiome during pregnancy. Implications and Limitations The study underscores the importance of dietary diversity screening and potential interventions for women with higher pBMI. Given the established role of micronutrients in maternal and fetal health, ensuring adequate dietary diversity could be beneficial. However, the lack of association between dietary diversity and gut microbiota diversity suggests that interventions focusing solely on diet may not affect gut microbiome composition as anticipated. One limitation of the study is its reliance on a relatively small sample size, which may affect the generalizability of the findings. Additionally, the study's cross-sectional nature means it can identify associations but not causation. Further research with larger cohorts and longitudinal designs could provide more insights into these complex relationships. For more on the gut microbiome's role in health, see our article on what is the microbiome .
Sources: Diet Diversity Is Associated with Prepregnancy Body Mass Index but Not the Pregnancy Third-Trimester Gut Microbiota. — Current developments in nutrition (2026) (https://pubmed.ncbi.nlm.nih.gov/42733570/)

### Probiotic Supplementation in PCOS: A Closer Look at Hormonal Effects
URL: https://microbiome.news/posts/probiotic-supplementation-in-pcos-a-closer-look-at-hormonal-effects
Section: Science | Published: 2026-09-14 | 3 min
Summary: A new study explores the impact of Saccharomyces boulardii on hormonal levels in women with polycystic ovary syndrome (PCOS), revealing potential benefits on testosterone and DHEA-S levels.
Body: Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, often leading to infertility and metabolic challenges. Researchers have been exploring various interventions to manage its symptoms, with probiotics emerging as a potential option. A study published in the Journal of research in pharmacy practice investigates the effects of the probiotic Saccharomyces boulardii on metabolic and hormonal parameters in women with PCOS. Study Design and Approach This double-blind, randomized controlled trial involved 84 women aged 18-45 years diagnosed with PCOS. Participants were randomly assigned to receive either the probiotic Saccharomyces boulardii or a placebo over a period of three months. The researchers focused on assessing changes in several key parameters, including body mass index (BMI), waist and abdominal circumference, fasting blood sugar (FBS), and hormone levels such as testosterone and dehydroepiandrosterone sulfate (DHEA-S). At the outset and conclusion of the 12-week intervention, anthropometric measurements were taken, and fasting blood samples were collected. This comprehensive approach allowed the researchers to evaluate both metabolic and hormonal changes attributable to the probiotic supplementation. Key Findings The study found that supplementation with Saccharomyces boulardii resulted in a significant reduction in testosterone and DHEA-S levels compared to the placebo group. Specifically, the testosterone levels decreased with a p-value of 0.0029, and DHEA-S levels decreased with a p-value of 0.0031. These findings suggest that the probiotic may have a beneficial effect on hormonal imbalances commonly associated with PCOS. Interestingly, while there was a significant reduction in BMI and FBS within the group receiving the probiotic, these changes were not significantly different when compared to the placebo group. This indicates that the probiotic's impact may be more pronounced on hormonal levels rather than on weight or metabolic parameters. Implications and Limitations The findings of this study suggest that Saccharomyces boulardii probiotics could play a role in managing hormonal imbalances in women with PCOS. By reducing testosterone and DHEA-S levels, the probiotic may help address some of the endocrine disruptions associated with the condition. However, it's important to note that the study did not find significant differences in weight or FBS between the probiotic and placebo groups, highlighting a limitation in the metabolic impact of the intervention. Moreover, as with any clinical trial, the sample size and duration of the study are critical factors. With 84 participants over a three-month period, the study provides preliminary insights but may not capture long-term effects or variations across a larger population. Future research with extended follow-up periods and larger cohorts could provide a more comprehensive understanding of the probiotic's role in PCOS management. For those interested in the broader implications of probiotics on the gut-brain axis, our primer on the gut-brain axis offers additional insights into how these microorganisms can influence various physiological processes.
Sources: The Effect of Supplementation with Saccharomyces boulardii in Women with Polycystic Ovary Syndrome: A Double-blind, Randomized Controlled Trial. — Journal of research in pharmacy practice (2026) (https://pubmed.ncbi.nlm.nih.gov/42732334/)

### Exploring Tranexamic Acid's Role in Preventing Anastomotic Leaks
URL: https://microbiome.news/posts/exploring-tranexamic-acid-s-role-in-preventing-anastomotic-leaks
Section: Therapeutics | Published: 2026-09-13 | 3 min
Summary: A new clinical trial protocol investigates the feasibility of using tranexamic acid to prevent anastomotic leaks after rectal cancer surgery, with an embedded microbiome analysis.
Body: Anastomotic leaks are a significant complication following anterior resection for rectal cancer, with rates reported between 10% and 15%. These leaks can lead to severe postoperative issues and impact patient recovery. Recent evidence suggests that the gut microbiome plays a crucial role in this complication, as certain bacteria colonize the anastomotic site and secrete collagenase, an enzyme that weakens healing tissues. Study Design and Objectives Researchers have initiated a clinical trial protocol to explore the feasibility of using tranexamic acid to prevent anastomotic leaks. This open-label, single-centre, randomized controlled feasibility trial involves 45 patients undergoing anterior resection for rectal or sigmoid cancer. These patients will be randomized in a 2:1 ratio to receive either tranexamic acid or sterile water. The administration of tranexamic acid is done intraoperatively and continues on postoperative days 1 to 3 via a rectal catheter. The primary aim of this trial is to assess the feasibility of the intervention, focusing on recruitment, adherence to the intervention, protocol compliance, and safety. Exploratory clinical outcomes include the incidence of anastomotic leaks and other postoperative complications. An embedded microbiome substudy aims to characterize changes in microbial composition and bacterial collagenase activity, providing mechanistic insights into the treatment response. Mechanistic and Qualitative Insights The microbiome substudy is a critical component of this trial, as it seeks to understand how tranexamic acid might alter the microbial environment at the anastomotic site. By examining changes in microbial composition and collagenase activity, researchers hope to uncover the mechanisms by which tranexamic acid could potentially reduce the risk of anastomotic leaks. Additionally, an optional qualitative substudy will explore the acceptability of the intervention from the perspectives of both patients and healthcare professionals. This aspect of the trial will provide valuable insights into the practical implementation of the treatment in clinical settings. The trial protocol has received approval from the North West Liverpool Central Research Ethics Committee and the Medicines and Healthcare products Regulatory Agency. Recruitment for the trial began after obtaining site-specific approvals, and the findings will be disseminated through peer-reviewed publications, academic conferences, and stakeholder engagement activities. The results are expected to inform the design of a definitive phase III trial. Limitations and Future Directions While this trial represents an important step in exploring a novel approach to preventing anastomotic leaks, it is important to acknowledge its limitations. As a feasibility trial, the sample size is relatively small, and the findings may not be generalizable to larger populations. Additionally, the trial is conducted at a single centre, which may limit the applicability of the results to other clinical settings. Despite these limitations, the trial's embedded mechanistic analysis of the microbiome offers a unique opportunity to explore the potential role of tranexamic acid in modulating microbial activity at the surgical site. Should the feasibility trial demonstrate promising results, it could pave the way for a larger phase III trial to further evaluate the efficacy and safety of this intervention. For more details, you can access the full protocol in a study published in BMJ open .
Sources: Tranexamic acid to prevent anastomotic leak after rectal cancer surgery: protocol for a feasibility trial with embedded mechanistic analysis of the microbiome. — BMJ open (2026) (https://pubmed.ncbi.nlm.nih.gov/42731830/)

### Urbanization's Impact on Microbial Diversity and Elderly Health
URL: https://microbiome.news/posts/urbanization-s-impact-on-microbial-diversity-and-elderly-health
Section: Science | Published: 2026-09-12 | 3 min
Summary: A new study examines how urbanization affects microbial diversity in care facilities, influencing elderly health outcomes such as frailty and cognitive decline.
Body: Urbanization is a global phenomenon that has brought about significant changes in the way humans interact with their environments. A new study published in Environmental Microbiology investigates the effects of urbanization on microbial diversity in care facilities and its subsequent impact on the health of elderly residents. The research highlights the complex interplay between environmental and human microbiomes, revealing how urban settings may contribute to health challenges in older populations. Microbial Diversity Loss in Urban Settings The study conducted an extensive analysis across 12 rural-to-urban care facilities in eastern China, examining 320 environmental and 120 faecal samples. The findings indicate a clear pattern: as urbanization increases, microbial alpha diversity decreases in the air, surfaces, and the guts of residents. This reduction in diversity is coupled with an increase in opportunistic pathogens and antibiotic resistance genes (ARGs), alongside a decrease in beneficial microbial taxa and short-chain fatty acid pathways. These shifts in microbial populations are significant because they suggest a loss of protective and health-promoting microorganisms, replaced by potentially harmful ones. The presence of ARGs is particularly concerning, as it indicates a heightened risk of antibiotic-resistant infections, which are more challenging to treat and can lead to severe health outcomes. Environment-Host Microbiome Concordance A key finding of the study is the strong concordance between environmental and host microbiomes, with intensified microbial transmission observed in urban settings. This means that the microbial communities present in the environment are closely mirrored in the gut microbiomes of the residents. Such concordance suggests that the environmental microbiome plays a crucial role in shaping the gut microbiome, which in turn influences health outcomes. Importantly, the study found that environmental microbiome features mediated over 50% of the detrimental effects of urbanization on frailty, inflammation, and cognitive decline among the elderly. This highlights the potential for environmental factors to significantly impact health, particularly in vulnerable populations such as the elderly. Predicting Health Outcomes One of the study's notable achievements is the development of models that combine environmental and gut microbiome data to predict frailty in residents, achieving an area under the curve (AUC) of 0.89. This high level of accuracy underscores the potential for microbiome data to inform health assessments and interventions, particularly in urban care settings where residents may be at increased risk of health decline. The findings suggest that urbanization-induced microbial alterations are key mediators of health decline in care facilities. This underscores the importance of considering microbiome-informed design and management strategies to mitigate these risks and promote healthier environments for elderly residents. Limitations and Future Directions While the study provides valuable insights into the relationship between urbanization, microbial diversity, and health, it is not without limitations. The research is observational, meaning it can identify associations but not causation. Additionally, the study is geographically limited to eastern China, and its findings may not be directly applicable to other regions with different environmental and cultural contexts. Further research is needed to explore the mechanisms underlying these associations and to determine how interventions might be designed to preserve microbial diversity in urban environments. Such efforts could contribute to healthier living conditions for elderly populations worldwide. For more on how microbiomes impact health, see our post on understanding the microbiome .
Sources: Urbanization-Associated Microbial Diversity Loss and Its Impact on Elderly Health: Integrating Environmental and Host Microbiome Dynamics. — Environmental microbiology (2026) (https://pubmed.ncbi.nlm.nih.gov/42727931/)

### Dietary Patterns for Obesity in CKD: A Review of Options
URL: https://microbiome.news/posts/dietary-patterns-for-obesity-in-ckd-a-review-of-options
Section: Science | Published: 2026-09-11 | 3 min
Summary: A new review evaluates the suitability of Mediterranean, plant-forward, and low-carbohydrate diets for managing obesity in individuals with chronic kidney disease (CKD).
Body: Obesity and chronic kidney disease (CKD) often occur together, creating a complex interplay of metabolic and inflammatory challenges that can accelerate the decline of kidney function. Managing obesity in individuals with CKD is crucial, yet traditional dietary approaches focusing on nutrient restriction may compromise diet quality and adherence. A new review published in the Journal of renal nutrition explores the effectiveness of three dietary patterns—Mediterranean, plant-forward, and low-carbohydrate/ketogenic diets—in managing obesity among CKD patients. Mediterranean and Plant-Forward Diets: Consistent Benefits The review synthesizes evidence from observational studies, randomized controlled trials, and clinical guidelines to assess the impact of these dietary patterns on metabolic, cardiovascular, and renal health. The Mediterranean and plant-forward diets consistently show benefits in weight management and cardiovascular risk reduction. These diets are associated with improved insulin sensitivity, reduced dietary acid load, and anti-inflammatory effects. They also have the potential to slow the decline of estimated glomerular filtration rate (eGFR), a key measure of kidney function. In addition to these benefits, plant-forward diets may improve gut microbiota composition and reduce the generation of uremic toxins, which are harmful compounds that accumulate in CKD. The emphasis on whole, plant-based foods in these diets aligns with broader dietary recommendations for improving overall health, making them attractive options for CKD patients struggling with obesity. Low-Carbohydrate Diets: Rapid Results, But Concerns Remain Low-carbohydrate and ketogenic diets, on the other hand, offer the promise of rapid short-term weight loss and improvements in glycemic control. However, the review highlights several concerns regarding their use in CKD populations. These diets may increase the risk of metabolic acidosis and kidney stones, and their long-term safety remains uncertain. Given these potential risks, the review suggests that Mediterranean and well-planned plant-forward diets are more suitable first-line options for many patients with obesity and CKD. The review underscores the importance of individualizing dietary recommendations based on the stage of CKD, comorbidities, nutritional status, and patient preferences. While the Mediterranean and plant-forward diets show promise, the certainty of evidence for long-term kidney outcomes is still limited. This highlights the need for further research to better understand the long-term impacts of these dietary patterns on kidney health. Limitations and Future Directions One of the key limitations of the review is the limited certainty of evidence regarding long-term kidney outcomes for these dietary patterns. While there is a wealth of data supporting their short-term benefits, more research is needed to confirm their safety and efficacy over the long term in CKD populations. Additionally, the review relies on existing literature, which may not capture the full spectrum of patient experiences and outcomes. As research continues to evolve, it will be important to consider how these dietary patterns can be tailored to meet the unique needs of individuals with CKD, taking into account factors such as cultural preferences, accessibility of foods, and personal health goals. The findings of this review provide a valuable foundation for healthcare providers and patients to make informed decisions about dietary management in CKD.
Sources: Dietary Patterns for Obesity in CKD: Mediterranean, Low-Carbohydrate, and Plant-Forward Approaches-What Fits Best? — Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation (2026) (https://pubmed.ncbi.nlm.nih.gov/42722219/)

### Exploring the Nutritional Paradox in Chronic Kidney Disease
URL: https://microbiome.news/posts/exploring-the-nutritional-paradox-in-chronic-kidney-disease
Section: Science | Published: 2026-09-10 | 3 min
Summary: A new study examines the complex interplay of metabolic and hormonal factors in protein-energy wasting among CKD patients, proposing a novel therapeutic framework.
Body: In a study published in Advances in nutrition (Bethesda, Md.) , researchers explore a perplexing issue in the management of chronic kidney disease (CKD): protein-energy wasting (PEW). This condition, characterized by the loss of muscle and fat mass, significantly contributes to morbidity and mortality in advanced CKD. Despite the availability of clinical guidelines and medical nutrition therapy (MNT), a subset of patients exhibits what the researchers describe as a "nutritional paradox." The Nutritional Paradox In contrast to simple starvation, which can be addressed with caloric and protein supplementation, CKD-associated cachexia involves a potential systemic anabolic resistance. This resistance makes standard nutritional interventions, such as oral supplements and intradialytic parenteral nutrition (IDPN), often inadequate. The study proposes that this resistance is driven by a complex molecular hierarchy involving central and peripheral dysregulation. Central to this dysregulation are gut-microbiome-derived uremic toxins, particularly tryptophan metabolites like indoxyl sulfate. Experimental models have shown that these metabolites can impair the integrity of the blood-brain barrier, triggering hypothalamic neuroinflammation. This inflammation, in turn, affects the central metabolic set-point via the melanocortin system, contributing to anorexia and altered energy expenditure. Peripheral Desensitization Peripherally, the study highlights the failure of critical nutrient-sensing pathways, specifically the ghrelin-GOAT and insulin/IGF-1 signaling pathways. This failure impairs the anabolic PI3K/Akt/mTORC1 cascade, blunting the synthetic response to dietary amino acids. As a result, muscle proteostasis is disrupted through hyperactivation of the ubiquitin-proteasome system (UPS) and FOXO-mediated transcription. Additionally, skeletal muscle experiences significant mitochondrial bioenergetic dysfunction, further impairing nutrient utilization. By reframing PEW as a broader dysregulation of hormonal signaling rather than simply nutrient deficiency, the researchers propose a "sensitize-then-feed" therapeutic paradigm. This approach suggests that before nutritional support can be effective, the body's anabolic pathways must be sensitized to respond appropriately. Potential Therapeutic Agents The study evaluates emerging targeted agents that could serve as metabolic modulators to enhance the efficacy of nutritional support. These include GDF15 antagonists, myostatin inhibitors, and ghrelin agonists. By modulating metabolic pathways, these agents may help overcome the anabolic resistance observed in CKD patients, potentially improving outcomes. While the study provides a comprehensive framework for understanding and potentially addressing PEW in CKD, it is important to note its limitations. The proposed mechanisms are based on experimental models, and the effectiveness of the suggested therapeutic agents requires further investigation in clinical settings. For more on nutrient sensing and metabolism, see our article on the role of bile acids in nutrient sensing and metabolism .
Sources: Perspectives on the Nutritional Paradox in Uremia: A "Sensitize-Then-Feed" Framework for Protein-Energy Wasting. — Advances in nutrition (Bethesda, Md.) (2026) (https://pubmed.ncbi.nlm.nih.gov/42716437/)

### Surviving the Heat: Probiotic B. infantis M-63 in Infant Formula
URL: https://microbiome.news/posts/surviving-the-heat-probiotic-b-infantis-m-63-in-infant-formula
Section: Science | Published: 2026-09-09 | 3 min
Summary: A new study investigates whether the probiotic Bifidobacterium longum subsp. infantis M-63 can survive in infant formula prepared under WHO guidelines, reaching the neonatal gut.
Body: In a study published in The Journal of nutrition , researchers explored whether the probiotic Bifidobacterium longum subsp. infantis M-63 could survive the preparation process of infant formula recommended by the World Health Organization (WHO), and subsequently reach the neonatal gut. The WHO advises using water at temperatures of 70°C or higher to reconstitute powdered infant formula, a guideline aimed at minimizing bacterial contamination. However, this temperature may also affect the viability of heat-sensitive probiotics added to the formula. Probiotic Viability in Formula Preparation The study involved 34 term neonates who were given formula containing B. infantis M-63 prepared according to WHO recommendations. The infants received this formula from birth to one month of age. Researchers aimed to determine if the probiotic could be detected in the infants' gut despite the high preparation temperature. The study also allowed for concurrent breastfeeding, reflecting real-world feeding practices. Despite the high temperature, which significantly reduced the viable bacterial counts in the prepared formula, B. infantis M-63 was detected in the fecal samples of nearly all infants at one month of age. Specifically, the detection rates were 94.4% in the low-dose group and 100% in the high-dose group. Importantly, there were no significant differences in detection rates or fecal counts between the different dosage groups. Impact on Gut Microbiota The study further examined the impact of B. infantis M-63 on the overall gut microbiota composition. Over time, the infants' gut microbiota shifted towards a Bifidobacterium-dominant profile, a characteristic feature of early infancy. This shift occurred regardless of the probiotic dose administered, suggesting that the presence of B. infantis M-63 might play a role in shaping the gut microbiome during this critical developmental period. Additionally, the study found a positive association between the fecal recovery of B. infantis M-63 and specific tryptophan-derived metabolites, including indole-3-lactic acid. The correlation coefficient (ρ = 0.509, p = 0.002) indicates a statistically significant relationship, suggesting potential biological activity of the probiotic under the recommended preparation conditions. Significance and Limitations This study provides in vivo evidence that B. infantis M-63 can survive the WHO-recommended preparation conditions and reach the neonatal gut. The findings are significant as they suggest that even under microbiologically safe preparation practices, probiotics can maintain their presence and potentially exert biological effects in the infant gut. However, the study does have limitations. It was exploratory and involved a relatively small sample size of 34 infants, which may limit the generalizability of the findings. Additionally, while the study shows an association between the probiotic presence and certain metabolites, it does not establish causation or fully elucidate the mechanisms involved. For more on how probiotics interact with the gut microbiome, you might find our guide to prebiotics, probiotics, and postbiotics helpful.
Sources: Bifidobacterium longum subsp. infantis M-63 can reach the neonatal gut following World Health Organization-recommended infant formula preparation at ≥70 °C. — The Journal of nutrition (2026) (https://pubmed.ncbi.nlm.nih.gov/42710681/)

### Phocaeicola vulgatus: A Microbial Ally Against Obesity?
URL: https://microbiome.news/posts/phocaeicola-vulgatus-a-microbial-ally-against-obesity
Section: Science | Published: 2026-09-08 | 3 min
Summary: New research explores how Phocaeicola vulgatus may influence obesity through arginine production and retinoic acid signaling.
Body: In a study published in Food Research International , researchers have delved into the role of the gut microbe Phocaeicola vulgatus in modulating obesity. This investigation builds on previous findings from a clinical fecal microbiota transplantation (FMT) trial, which highlighted P. vulgatus as a significant contributor to the therapeutic efficacy of obesity treatment. The study aims to better understand the mechanisms by which this microbe may influence metabolic health. Exploring Microbial Networks in Obesity The researchers began by establishing a clinical cohort of obese and lean individuals to investigate the microbial ecosystems present in each group. They discovered that the network centered around P. vulgatus and the synthesis of ornithine, an amino acid, were notably impaired in obese individuals. This finding suggested a potential link between the presence of P. vulgatus and metabolic health. To further explore this connection, the team utilized a humanized rat model. This model involved transplanting microbiota from an obese patient lacking P. vulgatus into rats. The researchers then supplemented these rats with P. vulgatus and observed significant reductions in high-fat diet (HFD)-induced obesity. These reductions included lower body weight, decreased serum total cholesterol levels, and alleviation of hepatic steatosis, a form of liver disease. Mechanisms of Action To understand how P. vulgatus exerts its effects, the researchers conducted integrated metagenomic and metabolomic analyses. These analyses revealed a functional association between P. vulgatus and another microbe, Phascolarctobacterium faecium . This association was linked to enhanced intestinal biosynthesis of arginine, an amino acid, and its increased systemic availability. Furthermore, hepatic transcriptomics—an analysis of liver gene expression—showed that elevated levels of circulating arginine were associated with the upregulation of retinoic acid (RA) signaling. RA signaling is known to play a role in various metabolic processes, suggesting a potential pathway through which P. vulgatus may influence obesity. Implications and Limitations The findings from this study outline a potential microbial-host network wherein P. vulgatus mitigates obesity via the arginine-RA axis. This research provides a valuable scientific basis for exploring P. vulgatus as a probiotic candidate for metabolic health. However, it is important to note that these findings are based on a humanized rat model, which, while informative, may not fully replicate human physiology. Additionally, the study's observational nature in the human cohort means that causation cannot be definitively established. Understanding the interactions between gut microbes and metabolic health is a complex and evolving field. While this study sheds light on potential mechanisms, further research is needed to confirm these findings in human populations and explore their broader implications. For more on the microbiome's role in health, you might find our article on what is the microbiome informative.
Sources: Phocaeicola vulgatus alleviates obesity through cross-species arginine production and hepatic retinoic acid signaling. — Food research international (Ottawa, Ont.) (2026) (https://pubmed.ncbi.nlm.nih.gov/42705729/)

### Understanding the Gut-Brain Axis in Inflammatory Bowel Disease
URL: https://microbiome.news/posts/understanding-the-gut-brain-axis-in-inflammatory-bowel-disease
Section: Gut–Brain | Published: 2026-09-07 | 3 min
Summary: A new review explores the complex interactions of the gut-brain axis in IBD, highlighting mechanisms behind neurological and psychiatric comorbidities.
Body: The intricate relationship between the gut and the brain has been a subject of increasing scientific interest, particularly in the context of inflammatory bowel disease (IBD). A new study published in the Journal of neurogastroenterology and motility provides a comprehensive review of how the gut-brain axis contributes to neurological and psychiatric manifestations in IBD patients. This review synthesizes current knowledge on the mechanisms and disease spectrum associated with these comorbidities, offering insights into potential therapeutic strategies. The Gut-Brain Axis: A Complex Communication Network The gut-brain axis is a bidirectional communication system that connects the gastrointestinal tract and the central nervous system. This network involves neural, endocrine, and immune signaling pathways. In IBD, this communication can become disrupted, leading to a range of neuropsychiatric disorders such as anxiety and depression. The review highlights that these disorders are often secondary conditions stemming from impaired gut-brain communication. Several factors contribute to this disruption, including imbalances in the intestinal microbiota, damage to the intestinal barrier, neuroinflammation, immune activation, and abnormalities in neuroendocrine pathways. These disruptions form the pathological basis for the spectrum of neuropsychiatric comorbidities observed in IBD patients. Mechanisms Underlying Neurological Manifestations According to the review, the imbalance of intestinal microbiota plays a crucial role in the disruption of the gut-brain axis. This imbalance can lead to intestinal barrier damage, allowing bacteria and toxins to enter the bloodstream and trigger systemic inflammation. This inflammation can affect the brain, contributing to neuroinflammation and the development of psychiatric symptoms. Additionally, the review discusses how immune activation and neuroendocrine pathway abnormalities further exacerbate these issues. The immune system's response to perceived threats in the gut can lead to chronic inflammation, which is known to influence brain function and behavior. Similarly, disruptions in neuroendocrine signaling can affect mood and cognitive functions, adding to the complexity of managing IBD-related neuropsychiatric disorders. Potential Therapeutic Strategies and Challenges The review also explores potential therapeutic strategies aimed at restoring balance to the gut-brain axis. These strategies include targeting the microbiota through dietary interventions, probiotics, or prebiotics, and addressing intestinal barrier integrity. However, the authors note significant challenges in translating these strategies into effective treatments. The complexity of the gut-brain axis and the variability in individual patient responses make it difficult to develop one-size-fits-all solutions. Moreover, the review emphasizes the need for further research to better understand the specific mechanisms at play and to identify biomarkers that could guide personalized treatment approaches. As our understanding of the gut-brain axis evolves, it may open new avenues for managing the neuropsychiatric comorbidities associated with IBD. For more insights into the gut-brain connection, you might explore our post on the gut-brain connection in ischemic stroke . "The complexity of the gut-brain axis and the variability in individual patient responses make it difficult to develop one-size-fits-all solutions." Limitations and Future Directions While this review provides a thorough examination of the gut-brain axis in IBD, it is important to acknowledge its limitations. The review is based on existing literature, which may include studies with varying methodologies and sample sizes. Additionally, the complexity of the gut-brain axis means that many interactions remain poorly understood, necessitating further research to unravel these mechanisms. Future studies could focus on longitudinal data to better understand the progression of neuropsychiatric symptoms in IBD patients and the long-term effects of potential interventions. As the field advances, it will be crucial to integrate findings from diverse disciplines to develop comprehensive management strategies for IBD and its associated comorbidities.
Sources: Gut-Brain Axis-mediated Neurological Manifestations in Inflammatory Bowel Disease: Mechanisms and Disease Spectrum. — Journal of neurogastroenterology and motility (2026) (https://pubmed.ncbi.nlm.nih.gov/42702585/)

### Sodium Fluoride's Impact on Gut and Liver Health Explored
URL: https://microbiome.news/posts/sodium-fluoride-s-impact-on-gut-and-liver-health-explored
Section: Science | Published: 2026-09-06 | 3 min
Summary: A new study investigates how sodium fluoride affects the gut microbiota and its link to liver and intestinal injury, using network toxicology and 16S rRNA sequencing.
Body: In a study published in Food and Chemical Toxicology , researchers have delved into the mechanisms by which sodium fluoride (NaF) may cause liver and intestinal injury. The study employs a combination of network toxicology and 16S rRNA sequencing to explore the potential pathways of NaF toxicity, focusing on the role of gut microbiota dysbiosis and inflammatory activation. Understanding Sodium Fluoride's Effects Sodium fluoride is a compound commonly used in dental care products and water fluoridation, known for its benefits in preventing dental cavities. However, excessive intake of NaF can lead to fluorosis, a condition that affects bones and teeth, and potentially causes damage to other organs such as the liver and intestines. Despite its widespread use, the exact mechanisms by which NaF induces such damage have remained unclear. The study integrates network toxicology, a method that maps the interactions between chemicals and biological systems, with high-throughput 16S rRNA sequencing, a technique used to analyze the composition of microbial communities. This dual approach allows researchers to identify key inflammatory mediators and changes in gut microbiota associated with NaF exposure. Key Findings: Inflammatory Mediators and Microbiota Changes The network toxicology analysis identified several inflammatory mediators, including interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-alpha (TNF-α), as central targets in NaF-induced liver and intestinal injury. These molecules are known to play significant roles in inflammatory processes, suggesting that inflammation is a critical component of NaF toxicity. In vivo experiments conducted on rats demonstrated a dose-dependent accumulation of NaF in the liver, accompanied by significant histopathological damage in both liver and intestinal tissues. This physical evidence of tissue damage supports the biochemical findings from the network analysis. Furthermore, 16S rRNA sequencing revealed notable changes in the gut microbiota composition following NaF exposure. Specifically, there was an increase in the relative abundance of potentially pathogenic bacteria such as Firmicutes , Romboutsia , and Collinsella , alongside a reduction in beneficial bacteria like Bacteroides . Such dysbiosis, or microbial imbalance, was significantly correlated with markers of liver and intestinal injury, indicating a potential mechanistic link between gut microbiota alterations and NaF-induced toxicity. Implications and Limitations The findings of this study suggest that alterations in gut microbiota may play a mechanistic role in the toxicity of sodium fluoride, particularly in relation to liver and intestinal health. This insight could inform future research into the safety and health impacts of NaF, as well as the broader role of gut microbiota in mediating chemical toxicity. However, it is important to note the limitations of this research. The study was conducted on animal models, specifically rats, which may not fully replicate the effects in humans. Additionally, while the study identifies associations between gut microbiota changes and tissue injury, it does not establish a direct causal relationship. Further research, particularly in human subjects, would be necessary to confirm these findings and fully understand the implications for human health. For more on how gut microbiota can influence health, you might explore our coverage on microbiome's role in treatment response .
Sources: Sodium fluoride induces hepatic and intestinal injury via gut microbiota dysbiosis and inflammatory activation: insights from network toxicology and 16S rRNA sequencing. — Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2026) (https://pubmed.ncbi.nlm.nih.gov/42700789/)

### Gut Microbiome's Role in Multiple Myeloma Treatment Response
URL: https://microbiome.news/posts/gut-microbiome-s-role-in-multiple-myeloma-treatment-response
Section: Science | Published: 2026-09-05 | 3 min
Summary: A new study examines how gut microbiome composition may influence the effectiveness of CD38 antibody therapy in relapsed multiple myeloma patients.
Body: A new study published in Clinical lymphoma, myeloma & leukemia explores the intriguing relationship between gut microbiome composition and the effectiveness of CD38 antibody therapy, specifically daratumumab (dara), in patients with relapsed multiple myeloma (MM). This research sheds light on the potential influence of gut bacteria on treatment outcomes, adding to the growing body of evidence linking the microbiome to cancer therapy responses. Study Design and Methods The study involved 40 patients with relapsed MM who had previously undergone autologous transplantation and received between one to four lines of prior therapy. Researchers collected stool samples from these patients at two key points: within one week prior to starting daratumumab treatment (predara) and immediately after completing four doses of the therapy (postdara). The collected samples underwent metagenomic sequencing to analyze the microbiome's taxonomic composition using MetaPhlAn4 and to assess microbial functional pathways via HUMAnN3.6. Statistical analyses were conducted using QIIME2. Of the 40 participants, 35 were classified as responders, achieving at least a partial response (PR) to the treatment. Among these responders, 10 patients reached complete remission (CR), while 25 achieved either a very good partial response (VGPR) or PR. Five participants were categorized as nonresponders. Key Findings Interestingly, the study found no statistically significant differences in the overall gut microbiome composition between the predara and postdara samples. However, differential abundance analysis revealed notable distinctions in specific bacterial species between responders and nonresponders. Responders exhibited a statistically significant overgrowth of Alistipes finegoldii and Acidaminococcus intestini , whereas nonresponders showed increased levels of Ruminococcus torques , Sellimonas intestinalis , and Clostridium symbiosum . Furthermore, when comparing complete remission (CR) samples to non-CR samples, the study identified an enrichment of Faecalibacterium prausnitzii in CR samples. Conversely, non-CR samples were enriched with Segatella copri and Faecalimonas umbilicata . These findings suggest that specific gut bacteria may be associated with better clinical outcomes in MM patients undergoing daratumumab therapy. Implications and Limitations This study highlights the potential role of the gut microbiome in influencing the response to cancer treatments, particularly in MM patients. By identifying specific bacterial species associated with treatment outcomes, researchers may pave the way for personalized therapeutic strategies that consider an individual's microbiome composition. However, the study also has its limitations. The sample size of 40 participants is relatively small, which may limit the generalizability of the findings. Additionally, while the study identifies associations between certain bacterial species and treatment responses, it does not establish a causal relationship. Larger, prospective studies are needed to confirm these results and further explore the mechanisms underlying these associations. For more on the complexity of microbiome interactions, see our post on understanding the microbiome .
Sources: Gut Microbiome Composition Is Associated With Response to CD38 Antibody (Daratumumab) Treatment Among Relapsed Multiple Myeloma Patients. — Clinical lymphoma, myeloma & leukemia (2026) (https://pubmed.ncbi.nlm.nih.gov/42697801/)

### Quercetin's Role in Combating Vascular Calcification in CKD
URL: https://microbiome.news/posts/quercetin-s-role-in-combating-vascular-calcification-in-ckd
Section: Science | Published: 2026-09-04 | 3 min
Summary: A new review explores how quercetin, a natural flavonoid, may influence vascular calcification associated with chronic kidney disease through various molecular pathways.
Body: Vascular calcification (VC) is a significant concern for individuals with chronic kidney disease (CKD), as it poses a major risk factor for cardiovascular events. Despite its prevalence, effective clinical treatments for CKD-related vascular calcification (CKD-VC) remain elusive. However, a review published in Seminars in nephrology highlights the potential of quercetin, a natural flavonoid, in addressing this challenge. Understanding Vascular Calcification in CKD Vascular calcification involves the deposition of calcium phosphate salts in the vascular system, leading to increased stiffness and reduced elasticity of blood vessels. This condition is particularly prevalent in patients with CKD, where it contributes to heightened cardiovascular risk. The review emphasizes that current therapeutic options are limited, necessitating the exploration of novel approaches. Quercetin, found abundantly in fruits and vegetables, emerges as a promising candidate due to its multifaceted biological activities. The review systematically examines the mechanisms by which quercetin may mitigate CKD-VC, focusing on its effects at the cellular level and within the broader procalcification microenvironment. Cellular Mechanisms of Quercetin At the cellular level, quercetin appears to exert its effects by targeting vascular smooth muscle cells (VSMCs). These cells can undergo a phenotypic transition to osteoblast-like cells, contributing to calcification. Quercetin inhibits this transdifferentiation, thereby potentially reducing calcification. Additionally, quercetin helps restore calcium-phosphorus homeostasis, a critical factor in preventing calcification. It enhances the expression of calcification inhibitors and addresses pathological processes such as oxidative stress, inflammation, cellular senescence, and apoptosis. Furthermore, quercetin's ability to regulate epigenetic modifications adds another layer of complexity to its potential therapeutic effects. Impact on the Procalcification Microenvironment Beyond cellular mechanisms, quercetin's influence extends to the procalcification microenvironment. The review highlights quercetin's role in improving gut microbiota dysbiosis, which is often observed in CKD patients. By modulating the gut microbiome, quercetin may reduce the accumulation of uremic toxins, which are known to exacerbate vascular calcification. Moreover, quercetin's protective effects on endothelial barrier function and its ability to inhibit ferroptosis—a form of regulated cell death—further contribute to its potential in mitigating CKD-VC. These multifaceted actions suggest that quercetin may offer a comprehensive approach to addressing the complex mechanisms underlying vascular calcification in CKD. Limitations and Future Directions While the review presents compelling evidence for quercetin's potential, it is important to acknowledge the limitations. The findings are based on existing research, and further studies are needed to validate these mechanisms in clinical settings. Additionally, the review does not provide specific data on the efficacy of quercetin in human populations, highlighting the need for clinical trials to establish its therapeutic potential. In conclusion, quercetin's ability to target multiple pathways and mechanisms offers a promising avenue for addressing vascular calcification in CKD. However, further research is essential to translate these findings into practical therapeutic strategies.
Sources: Mechanism of Quercetin in Treatment of Vascular Calcification in Chronic Kidney Disease. — Seminars in nephrology (2026) (https://pubmed.ncbi.nlm.nih.gov/42692942/)

### Gut Microbiome's Role in Immunochemotherapy Resistance
URL: https://microbiome.news/posts/gut-microbiome-s-role-in-immunochemotherapy-resistance
Section: Science | Published: 2026-09-03 | 3 min
Summary: A new study explores how gut bacteria and metabolites can influence treatment resistance in non-small cell lung cancer, highlighting potential microbiome-linked strategies.
Body: A new study published in Science Advances investigates the interplay between gut microbiota and treatment resistance in advanced non-small cell lung cancer (NSCLC). The research focuses on the role of the gut bacterium Bifidobacterium animalis subsp. lactis V9 and its impact on immunochemotherapy efficacy. Understanding the Link Between Gut Dysbiosis and Cancer Treatment The study highlights a significant correlation between elevated serum CYFRA 21-1 levels and gut dysbiosis in advanced NSCLC patients. CYFRA 21-1 is a tumor marker associated with poor treatment outcomes. Researchers found that patients with high CYFRA 21-1 levels exhibited a depletion of Bifidobacterium animalis and a reduction in immunomodulatory metabolites. This dysbiotic state was linked to disrupted tryptophan and phenylalanine metabolism, which are crucial pathways in the body's immune response. In experiments with tumor-bearing mice, fecal supernatant from patients with high CYFRA 21-1 levels was shown to attenuate the efficacy of immunochemotherapy. This suggests that the gut microbiome's composition can directly influence treatment outcomes by altering metabolic pathways. The Role of Bifidobacterium animalis in Enhancing Treatment Efficacy To explore potential interventions, the study examined the effects of adjuvant B. animalis subsp. lactis V9 on tumor control and antitumor immunity. The results were promising, showing enhanced tumor control and increased levels of quinaldic acid and catechol, metabolites associated with apoptosis and ferroptosis. These findings suggest that B. lactis V9 can modulate the immune system and improve treatment efficacy. Interestingly, the study also found that the antitumor effects could be transferred through cell-free fecal supernatant, indicating that bacterial colonization is not necessary for the observed benefits. This points to the potential of microbial metabolites as therapeutic agents. Clinical Implications and Limitations The study included a randomized, double-blind, placebo-controlled pilot trial with 30 participants, which demonstrated that adjunctive B. lactis V9 was associated with a higher objective response rate (47% vs. 33%) and disease control rate (87% vs. 67%). Additionally, responders showed prolonged progression-free survival and enriched levels of B. animalis and elevated quinaldic acid/catechol. While these findings are promising, it is important to note the limitations of the study. The small sample size of the clinical trial and the preliminary nature of the findings mean that further research is needed to confirm these results. Additionally, while the study identifies a potential link between CYFRA 21-1 and microbiome-linked treatment resistance, it does not establish causation. Overall, this research provides valuable insights into the complex interactions between gut microbiota and cancer treatment, highlighting the potential for microbiome-targeted strategies to overcome therapeutic resistance.
Sources: Bifidobacterium animalis subsp. lactis V9 overcomes CYFRA 21-1-linked immunochemotherapy resistance in NSCLC via microbial metabolites. — Science advances (2026) (https://pubmed.ncbi.nlm.nih.gov/42685222/)

### Probiotic Strain Shows Promise in Modulating Gut-Brain Axis
URL: https://microbiome.news/posts/probiotic-strain-shows-promise-in-modulating-gut-brain-axis
Section: Gut–Brain | Published: 2026-09-02 | 3 min
Summary: A new study explores how Bifidobacterium pseudocatenulatum AL44 may influence cognitive function through gut-brain interactions in a mouse model.
Body: Researchers have been increasingly interested in the potential of probiotics to influence cognitive health, particularly through the gut-brain axis. A study published in Food Research International investigates the effects of the probiotic strain Bifidobacterium pseudocatenulatum AL44 on cognitive impairment induced by D-galactose in mice. This study provides insights into how probiotics may modulate the gut microbiota to support brain health. Investigating Cognitive Impairment in Mice The study focused on D-galactose-treated mice, a common model for studying age-related cognitive decline. D-galactose is known to induce oxidative stress and neuroinflammation, leading to cognitive deficits. Researchers aimed to determine whether the probiotic strain AL44 could mitigate these effects. Results showed that AL44 intervention significantly improved spatial learning and memory in the mice. Moreover, the probiotic treatment reduced hippocampal neuronal damage, suppressed neuroinflammation, and decreased oxidative stress. These findings suggest that AL44 may have neuroprotective properties. Mechanisms of Action: Gut-Brain Axis The study explored the mechanisms by which AL44 exerts its effects. One of the key findings was the upregulation of brain-derived neurotrophic factor (BDNF) and neuronal nuclei (NeuN), along with synaptic proteins. These factors are crucial for maintaining neuronal health and function. Additionally, AL44 modulated the B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein/cysteine-aspartic acid protease 3 signaling pathway, which plays a role in apoptosis regulation. Importantly, the study linked these neuroprotective effects to changes in the gut microbiota. AL44 treatment enriched Bacteroides, preserved intestinal barrier integrity, and reduced circulating endotoxin levels. These changes in the gut environment are thought to contribute to the observed improvements in cognitive function. Metabolic Changes and Transferability Beyond microbiota changes, AL44 treatment also influenced systemic metabolic profiles, particularly amino acid metabolism. The study noted increased levels of citrulline, betaine, and kynurenine, which may play roles in cognitive processes. To further support the role of the gut microbiota, researchers conducted fecal microbiota transplantation experiments. These confirmed that the neuroprotective effects of AL44 were transferable via the altered gut microbiota, reinforcing the hypothesis that microbiota remodeling is a key mechanism. Limitations and Future Directions While the findings are promising, it is important to note that this study was conducted in a mouse model. Animal studies often serve as preliminary investigations, and further research is needed to determine if similar effects would be observed in humans. Additionally, the study does not establish causation, only association, between the probiotic treatment and cognitive improvements. For those interested in the broader implications of gut-brain interactions, our post on exploring the microbiota-gut-brain axis in stress responses provides additional context on this complex relationship.
Sources: Bifidobacterium pseudocatenulatum AL44 ameliorates D-galactose-induced cognitive impairment by modulating the gut-brain axis. — Food research international (Ottawa, Ont.) (2026) (https://pubmed.ncbi.nlm.nih.gov/42680341/)

### Probiotics and Ventilator-Associated Pneumonia in Children
URL: https://microbiome.news/posts/probiotics-and-ventilator-associated-pneumonia-in-children
Section: Science | Published: 2026-09-01 | 3 min
Summary: A systematic review evaluates the impact of probiotics on ventilator-associated pneumonia and other outcomes in critically ill children, highlighting both potential benefits and limitations.
Body: In a systematic review and meta-analysis published in the Journal of tropical pediatrics , researchers investigated the potential benefits of probiotics for critically ill children in pediatric intensive care units (PICUs). This comprehensive analysis focused on assessing the efficacy and safety of probiotics in preventing ventilator-associated pneumonia (VAP) and other critical outcomes such as all-cause mortality, length of hospital stay (LOS), and duration of mechanical ventilation (MV). Study Design and Outcomes The researchers conducted a systematic review of randomized controlled trials (RCTs) sourced from major databases including PubMed, EMBASE, SCOPUS, and Web of Science. The primary outcome of interest was all-cause mortality among critically ill children, while secondary outcomes included the incidence of VAP, LOS, and MV duration. In total, eight RCTs involving 744 children were included in the analysis. The researchers employed random-effects models to pool risk ratios (RR) and mean differences (MD), with the Hartung-Knapp adjustment used for sensitivity analysis. The certainty of evidence was evaluated using the GRADE approach. Key Findings The analysis revealed that probiotics did not significantly reduce all-cause mortality among the children studied (RR 0.85, 95% CI 0.66-1.11; P = .24; I² = 0%; low certainty). This finding remained consistent even when the analysis was restricted to low-risk-of-bias trials (RR 0.89, 0.60-1.34; P = .58). However, probiotics significantly reduced the incidence of VAP, with a risk ratio of 0.47 (95% CI 0.35-0.64; P In terms of LOS and MV duration, probiotics did not show significant reductions. The mean difference for LOS was -2.57 days (95% CI -7.26 to 2.11; P = .20) and for MV duration was -1.61 days (95% CI -4.43 to 1.20; P = .17), both with low certainty. Importantly, no serious adverse events associated with probiotic use were reported in the trials included. Implications and Limitations The findings suggest that while probiotics do not significantly impact all-cause mortality or reduce hospital stay and ventilation duration, they may play a role in reducing the risk of VAP among critically ill children. This could position probiotics as a potential adjunctive strategy for VAP prevention in PICUs. However, the inconclusive results regarding mortality and other secondary outcomes highlight the need for larger, multicenter trials to further explore these potential benefits. It is important to note the limitations of this analysis. The relatively small sample size of 744 children across eight trials may impact the generalizability of the findings. Additionally, the low certainty of evidence for mortality and secondary outcomes suggests that these results should be interpreted with caution. Further research is necessary to confirm these findings and to explore the mechanisms by which probiotics may influence health outcomes in critically ill children. For more on the potential roles of probiotics, you might explore our article on precision probiotics .
Sources: Probiotics for the prevention of ventilator-associated pneumonia and other outcomes in critically ill children: a systematic review and meta-analysis of randomized controlled trials. — Journal of tropical pediatrics (2026) (https://pubmed.ncbi.nlm.nih.gov/42674774/)

### Gut Microbiota-Fermented Trisaccharide Shows Potential Against Campylobacter
URL: https://microbiome.news/posts/gut-microbiota-fermented-trisaccharide-shows-potential-against-campylo
Section: Science | Published: 2026-08-31 | 3 min
Summary: A new study investigates how a fucose-rich trisaccharide, fermented by gut microbiota, impacts the pathogen Campylobacter jejuni, offering insights into potential dietary interventions.
Body: In a study published in Marine Life Science & Technology , researchers explored the effects of a specific fucose-containing trisaccharide, GuFGa, on the common enteric pathogen Campylobacter jejuni . This research utilized both metabolomic and transcriptomic analyses to understand the interactions within a microbial community when GuFGa is fermented by human fecal microbiota. Investigating the Role of GuFGa Fucose-rich carbohydrates like 2'-fucosyllactose and fucoidan are known for their anti-infective properties. The study aimed to determine how GuFGa, a trisaccharide composed of β-D-Glc p-(1→4)-[β-D-Gal p-(1→3)]-α-ʟ-Fuc p, affects C. jejuni when fermented by gut microbiota. The researchers conducted in vitro experiments using a cell-based model to assess the protective effects of metabolites derived from GuFGa fermentation. The study found that while GuFGa itself did not directly inhibit the growth of C. jejuni in single-strain cultures, the supernatant from GuFGa fermented with human fecal microbiota (F-GuFGa) significantly reduced the pathogen's relative abundance by tenfold within a complex microbial community. This suggests that the fermentation process and the resulting metabolites play a crucial role in inhibiting C. jejuni . Metabolomic and Transcriptomic Insights To further understand the mechanisms at play, the researchers examined changes in gene expression and metabolite abundance. Transcriptome analysis revealed 128 differentially expressed genes in C. jejuni after F-GuFGa treatment. These genes were primarily associated with oxidative phosphorylation and bacterial secretion systems, particularly type IV secretion systems. Metabolomic analysis showed alterations in 452 metabolites, with notable changes in phenylalanine and tryptophan metabolism. A correlation analysis indicated a significant negative relationship between the expression of type IV secretion system genes and the abundance of phenylacetic acid (PAA) and D-3-phenyllactic acid (D-PLA). This suggests that these metabolites may interfere with the pathogen's ability to utilize its secretion systems effectively. Potential Implications and Limitations The study also explored the impact of F-GuFGa, PAA, and D-PLA on the adhesion of C. jejuni to Caco-2 cells, a model for intestinal epithelial cells. Results showed that F-GuFGa reduced adhesion by 44.4%, with D-PLA showing a 33.3% reduction. These findings highlight the potential of GuFGa-derived metabolites in inhibiting bacterial adhesion, a critical step in infection. While these results are promising, it is important to acknowledge the study's limitations. The research was conducted in vitro, which may not fully replicate the complex interactions within the human gut. Additionally, the study's findings are preliminary and require further validation in animal models or human trials to confirm their applicability in real-world scenarios. For those interested in the broader implications of microbiota and gut health, our post on the microbiota-gut-brain axis provides further insights into how gut microbiota can influence various physiological processes.
Sources: Inhibitory effect of gut microbiota-fermented trisaccharide GuFGa (Glc-Fuc-Gal) on Campylobacter jejuni: insights from transcriptomic and metabolomic analyses. — Marine life science & technology (2026) (https://pubmed.ncbi.nlm.nih.gov/42668736/)

### Exploring Yi-Yi-Fu-Zi-Bai-Jiang-San's Role in Colorectal Cancer
URL: https://microbiome.news/posts/exploring-yi-yi-fu-zi-bai-jiang-san-s-role-in-colorectal-cancer
Section: Science | Published: 2026-08-30 | 3 min
Summary: A new review examines the traditional formulation Yi-Yi-Fu-Zi-Bai-Jiang-San, highlighting its potential mechanisms in combating colorectal cancer.
Body: Colorectal cancer (CRC) remains a significant health challenge, being one of the most prevalent gastrointestinal tumors with high mortality rates. In the quest for effective treatments, researchers are turning to traditional medicine for potential solutions. A study published in Frontiers in Pharmacology reviews the therapeutic potential of Yi-Yi-Fu-Zi-Bai-Jiang-San (YYFZBJS), a classic prescription used in the clinical treatment of CRC. Understanding Yi-Yi-Fu-Zi-Bai-Jiang-San YYFZBJS is a formulation composed of three primary ingredients: Coix lacryma-jobi L., Aconitum carmichaelii Debeaux, and Patrinia scabiosifolia Fisch. ex Trev. This combination is traditionally recognized for its anti-cancer properties, particularly in the context of CRC. The review highlights the formulation's ability to target multiple pathways associated with cancer progression. The review identifies several key mechanisms through which YYFZBJS exerts its effects. These include the regulation of inflammation-cancer transformation, alleviation of oxidative stress, restoration of gut microbiota balance, inhibition of CRC cell proliferation, promotion of apoptosis, regulation of autophagy, and suppression of tumor angiogenesis. Such multi-targeted actions suggest that YYFZBJS may offer significant benefits as an adjunct to conventional chemotherapy. Mechanisms of Action One of the critical areas of focus is the role of inflammation in cancer transformation. Chronic inflammation is a well-established risk factor for cancer development, and YYFZBJS appears to modulate this process, potentially reducing the risk of cancer progression. Oxidative stress is another factor in cancer biology, contributing to DNA damage and tumor progression. The review suggests that YYFZBJS may help alleviate oxidative stress, thereby potentially reducing its harmful effects. The gut microbiota's balance is increasingly recognized as a crucial factor in overall health and disease. YYFZBJS is noted for its potential to restore this balance, which may play a role in its anti-cancer effects. By promoting a healthier gut environment, the formulation could indirectly influence cancer progression. Limitations and Future Directions While the review provides a comprehensive overview of YYFZBJS's potential, it also acknowledges the limitations in the current understanding of its molecular mechanisms. The precise pathways and interactions remain incompletely elucidated, necessitating further research to fully understand how YYFZBJS exerts its effects. Additionally, while the review synthesizes existing research, it is important to note that much of this work may be preliminary. The complexity of cancer biology means that translating these findings into clinical practice will require rigorous testing and validation. For those interested in the intersection of traditional medicine and modern science, this review offers a fascinating glimpse into how ancient formulations may contribute to contemporary cancer treatment strategies. As research continues, it will be interesting to see how YYFZBJS and similar formulations are integrated into broader therapeutic frameworks. For more on the role of natural compounds in health, you might explore our post on natural polysaccharides and the microbiota-gut-brain axis .
Sources: Therapeutic potential and molecular mechanisms of Yi-Yi-Fu-Zi-Bai-Jiang-San in the treatment of colorectal cancer. — Frontiers in pharmacology (2026) (https://pubmed.ncbi.nlm.nih.gov/42666771/)

### Evaluating Early FMT for Clostridioides difficile Infection
URL: https://microbiome.news/posts/evaluating-early-fmt-for-clostridioides-difficile-infection
Section: Therapeutics | Published: 2026-08-29 | 3 min
Summary: A new clinical trial investigates the potential benefits of early fecal microbiota transplantation for patients experiencing their first episode or recurrence of Clostridioides difficile infection.
Body: Clostridioides difficile infection (CDI) is a significant cause of healthcare-associated diarrhea in adults, with a troubling tendency to recur. Recurrence rates are reported to be between 15% and 25% after a first episode and can rise to as high as 65% after multiple recurrences. This recurrent nature of CDI leads to increased morbidity, reduced quality of life, and greater healthcare utilization. Study Design and Objectives A new study protocol, published in BMJ open , outlines a phase III clinical trial designed to evaluate the efficacy of early fecal microbiota transplantation (FMT) in treating CDI. The trial aims to determine whether the early introduction of oral FMT, following standard antibiotic therapy, can improve outcomes compared to standard therapy alone. This multicenter, randomized, open-label trial will be conducted across eight clinical centers in Switzerland. It plans to enroll 100 adult patients who either have a first episode of CDI with risk factors for recurrence or have experienced a first recurrence. Participants will first receive the standard of care anti-CDI antibiotics—either vancomycin or fidaxomicin for 10 days—before being randomized into two groups: one receiving oral FMT and the other continuing with standard therapy alone. Intervention and Expected Outcomes The intervention group will receive FMT in the form of oral capsules within 12 hours to 4 days after completing antibiotic treatment. For non-severe cases, patients will take 15 to 20 capsules twice on two consecutive days. Those with severe CDI will receive an additional two-day course of FMT. The control group will not receive any additional treatment beyond the standard antibiotic regimen. The primary endpoint of the study is the proportion of patients experiencing a CDI recurrence eight weeks after completing treatment. Secondary outcomes include early and late recurrence rates, sustained cure at six and twelve months, quality-adjusted life years, and recurrence-free and overall survival at twelve months. Exploratory analyses will also look at microbiota diversity, biomarker identification, and the assessment of immunologic and microbial predictors of recurrence. Potential Impact and Limitations Emerging evidence suggests that early FMT may improve sustained clinical cure rates and reduce recurrence of CDI, but its benefits when used after a first episode or first recurrence remain insufficiently studied. This trial could provide valuable insights into the timing and effectiveness of FMT as a treatment strategy for CDI. However, the study does have limitations. With a relatively small sample size of 100 participants, the findings may not be generalizable to all populations. Additionally, as an open-label trial, there is a potential for bias in reporting outcomes. The study's results will need to be interpreted in the context of these limitations. For more on how antibiotics affect the gut microbiome, see our post on antibiotics and gut microbiome recovery .
Sources: Fecal microbiota transplantation versus vancomycin or fidaxomicin in Clostridioides difficile infection first episode and first recurrence: a study protocol for a randomised, controlled, open-label, multicentre phase III clinical trial. — BMJ open (2026) (https://pubmed.ncbi.nlm.nih.gov/42665346/)

### Genome Completeness Reveals New Insights into Gut Microbiome Ecology
URL: https://microbiome.news/posts/genome-completeness-reveals-new-insights-into-gut-microbiome-ecology
Section: Science | Published: 2026-08-28 | 3 min
Summary: A new study highlights the importance of complete genomes in understanding metabolic interactions within the gut microbiome and their implications for human health.
Body: In a study published in Cell Reports , researchers have explored the intricate metabolic interactions that govern the assembly of the gut microbiome. By leveraging 1,150 complete genomes, they constructed genome-scale metabolic models to gain a clearer understanding of these interactions, revealing the significant impact of genomic completeness on our understanding of gut ecology and its implications for human health. The Role of Complete Genomes in Microbiome Research The study underscores the importance of using complete genomes rather than draft assemblies in microbiome research. Draft assemblies, according to the researchers, tend to introduce systematic artifacts and omit critical transport functions. This can lead to an incomplete or skewed understanding of microbial interactions. In contrast, complete genomes provide a more accurate picture, allowing for the construction of detailed metabolic models that reflect the true nature of microbial interactions. These models revealed that genomic traits and niche specialization are key factors in shaping microbial metabolic competition and complementarity. Rather than being the result of random associations, these interactions are structured by specific ecological rules. This insight is crucial for understanding how microbial communities are organized and how they function within the gut environment. Ecological Groupings and Their Implications The researchers identified four distinct ecological groups within the gut microbiome: active players, resource predators, resource utilizers, and resource contributors. Each group exhibits unique signatures of metabolite exchange, competition, and secondary metabolism. This stratification highlights the complexity of microbial interactions and the diverse roles that different microbes play within the gut ecosystem. In the context of inflammatory bowel disease (IBD), these ecological groups demonstrated subtype-specific temporal instability. The researchers found that group-specific dysbiosis, or microbial imbalance, was a better predictor of clinical phenotypes than whole-community profiles. This suggests that focusing on specific ecological groups could provide more precise insights into the microbial dynamics associated with IBD and potentially other conditions. Linking Metabolic Interactions to Health Outcomes The study also explored how integrated metabolic interaction and co-occurrence networks can improve disease classification. By identifying keystone features within these networks, researchers were able to enhance cross-validated disease classification. This approach provides a framework for linking metabolic interactions to microbiome-associated health outcomes, offering a more nuanced understanding of how microbial communities influence human health. However, it is important to note that while these findings are promising, they are based on genomic data and computational models. As such, they represent associations rather than causal relationships. Further research, including experimental validation, is needed to fully understand the implications of these metabolic interactions for human health. Limitations and Future Directions One limitation of this study is its reliance on genomic data, which, while comprehensive, may not capture all aspects of microbial interactions in vivo. Additionally, the study's findings are based on computational models, which, although informative, require experimental validation to confirm their accuracy and relevance to human health. Future research could focus on validating these findings in experimental settings and exploring how these ecological groupings and metabolic interactions manifest in different health and disease contexts. Understanding these dynamics could pave the way for more targeted approaches to studying and potentially modulating the gut microbiome to promote health.
Sources: Complete genome-derived metabolic interactions reveal the impact of gut ecology on human health. — Cell reports (2026) (https://pubmed.ncbi.nlm.nih.gov/42658680/)

### Tracking Microbiota Changes in Short Bowel Syndrome with Antibiotics
URL: https://microbiome.news/posts/tracking-microbiota-changes-in-short-bowel-syndrome-with-antibiotics
Section: Science | Published: 2026-08-27 | 3 min
Summary: A new study explores how antimicrobial therapy affects intestinal microbiota in short bowel syndrome, using next-generation sequencing to track changes.
Body: Short bowel syndrome (SBS) presents unique challenges in managing intestinal health, often requiring antimicrobial therapy to address complications associated with abnormal microbiota. However, the lack of established criteria for bacterial screening and antimicrobial susceptibility poses significant risks. A new study published in Internal medicine (Tokyo, Japan) sheds light on this issue by examining the effects of antimicrobial therapy on the intestinal microbiota of a patient with SBS using next-generation sequencing. Understanding the Approach The study focuses on a patient with SBS who also suffers from chronic metabolic acidosis. Antimicrobial therapy was administered to manage complications arising from an imbalanced intestinal microbiota. Researchers employed next-generation sequencing to monitor changes in the patient's microbiota before and after the administration of antibiotics. This approach provides a detailed view of how antimicrobial treatments can alter microbial communities in the gut. Next-generation sequencing is a powerful tool that allows for comprehensive analysis of microbial populations. It offers insights into the diversity and abundance of bacteria, which is crucial for understanding how antibiotics impact the microbiota. By tracking these changes, researchers aim to gather data that could inform more targeted and effective treatments for SBS patients. Key Findings and Implications The study reveals that antimicrobial therapy can significantly alter the composition of intestinal microbiota in individuals with SBS. While the abstract does not specify the exact changes observed, it highlights the potential for antibiotics to disrupt the delicate balance of gut bacteria. This disruption can have both positive and negative consequences, depending on the specific microbial shifts and the patient's overall health condition. The findings underscore the need for careful consideration when prescribing antibiotics to SBS patients. Without established criteria for microbial evaluation, there is a risk of exacerbating existing complications or introducing new ones. The study suggests that next-generation sequencing could play a crucial role in developing these criteria, offering a more personalized approach to antimicrobial therapy. Limitations and Future Directions While the study provides valuable insights, it is important to acknowledge its limitations. The research focuses on a single patient, which limits the generalizability of the findings. Additionally, the study does not establish causation between antimicrobial therapy and specific microbiota changes, only an association. Further research involving larger sample sizes and diverse patient populations is necessary to validate these findings and develop standardized guidelines for antimicrobial use in SBS. This study is a step toward understanding the complex interactions between antibiotics and the gut microbiota in SBS. As researchers continue to explore this area, the hope is to refine treatment strategies that minimize risks and enhance patient outcomes. For those interested in the broader implications of antibiotics on the gut microbiome, our discussion on microbiome recovery post-antibiotics offers additional context.
Sources: Changes in Intestinal Microbiota Tracked Using Next-generation Sequencing Before and after Antimicrobial Administration: An Example of Short-bowel Syndrome. — Internal medicine (Tokyo, Japan) (2026) (https://pubmed.ncbi.nlm.nih.gov/42649054/)

### The Role of Innate Lymphoid Cells in Metabolic Syndrome
URL: https://microbiome.news/posts/the-role-of-innate-lymphoid-cells-in-metabolic-syndrome
Section: Science | Published: 2026-08-26 | 3 min
Summary: A new review explores how innate lymphoid cells, diet, and gut microbiota interact in metabolic syndrome, highlighting potential pathways for future research.
Body: Researchers are increasingly interested in the complex interplay between diet, gut microbiota, and immune responses, particularly in the context of metabolic syndrome (MetS). A new review published in Immunology Letters delves into this topic, focusing on the role of innate lymphoid cells (ILCs) in MetS. This condition affects over 1.5 billion adults worldwide and is characterized by obesity, insulin resistance, and type 2 diabetes mellitus (T2DM), among other metabolic complications. Understanding Innate Lymphoid Cells Innate lymphoid cells are a group of immune cells that play crucial roles in maintaining tissue homeostasis, barrier immunity, and inflammation. They are categorized into three main subsets: ILC1, ILC2, and ILC3. Each subset has distinct functions, and their activity can be influenced by various factors, including diet and gut microbiota-derived metabolites. The review highlights how dietary components such as fibers, short-chain fatty acids, lipids, vitamins, and fermented foods can modulate the responses of these ILC subsets. These dietary factors are thought to influence ILC activity in a context-dependent manner, suggesting that the effects can vary based on the specific metabolic and immune environment. Diet, Microbiota, and Metabolic Syndrome Metabolic syndrome is a complex condition with multiple contributing factors. The review emphasizes the role of diet and gut microbiota in regulating immune and metabolic dysfunction associated with MetS. Gut microbial metabolites, produced through the fermentation of dietary fibers and other nutrients, are increasingly recognized as key regulators of immune responses. In particular, the review discusses how these metabolites can affect ILC activity and, consequently, metabolic inflammation. This interaction between diet, microbiota, and ILCs may provide insights into potential pathways and biomarkers for future therapeutic studies. However, it is important to note that most of the mechanistic data in this area come from mouse models, which limits the direct translation of these findings to human MetS. Future Directions and Limitations The review provides a critical summary of experimental and preclinical evidence, integrating diet-microbiota interactions, ILC biology, and metabolic inflammation. It suggests that understanding these complex interactions could inform the development of novel therapeutic strategies for MetS. However, the authors caution that the current evidence is largely preliminary and derived from animal studies, highlighting the need for further research in human populations. While the review identifies candidate pathways and biomarkers that may guide future studies, it does not establish any clinical interventions. The authors stress that more human studies are necessary to validate these findings and explore their potential applications in managing MetS. For those interested in the broader implications of diet and gut health, our post on fiber's role in gut health offers additional insights into this complex relationship.
Sources: Innate Lymphoid Cells and diet: the multitask cells in metabolic syndrome progression. — Immunology letters (2026) (https://pubmed.ncbi.nlm.nih.gov/42641696/)

### Gut Microbiome and Metabolites Linked to Steroid Response in Nasal Polyps
URL: https://microbiome.news/posts/gut-microbiome-and-metabolites-linked-to-steroid-response-in-nasal-pol
Section: Science | Published: 2026-08-25 | 3 min
Summary: A new study explores the role of gut microbiome and plasma metabolites in predicting glucocorticoid responsiveness in patients with chronic rhinosinusitis with nasal polyps.
Body: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects many individuals, yet responses to common treatments like glucocorticoids (GCs) vary significantly. A study published in the International Forum of Allergy & Rhinology investigates the biological underpinnings of this variability by examining the gut microbiome and plasma metabolomic profiles of CRSwNP patients. Understanding Glucocorticoid Responsiveness In this study, researchers enrolled 26 patients with CRSwNP and compared them to 30 control subjects undergoing septoplasty without sinonasal disease. The primary goal was to identify microbial and metabolomic signatures that correlate with GC responsiveness, defined by changes in nasal polyp scores (NPS) after a two-week course of oral methylprednisolone. At the outset, the study found that GC responders had greater tissue eosinophilic inflammation, while non-responders had higher NPS. These findings suggest that baseline inflammatory markers could play a role in predicting treatment outcomes. Microbial and Metabolomic Signatures The researchers performed fecal shotgun metagenomic and untargeted plasma metabolomics analyses to identify distinct profiles associated with GC responsiveness. They discovered that GC responders had an enrichment of specific gut microbes, including Bacteroides caccae , Microbacterium flavum , and Mucilaginibacter rigui . Additionally, certain plasma metabolites such as lupinisoflavone N, CAY10622, kanzonol V, and D-sorbitol were elevated in responders. These microbial and metabolomic features correlated positively with tissue eosinophilic inflammation, suggesting a link between gut microbiome composition, systemic metabolic state, and immune response in the context of GC therapy. Comparative Predictive Value To evaluate the predictive power of these findings, the study compared traditional clinical indicators with the newly identified multiomics model. Tissue eosinophil count emerged as the strongest conventional predictor of GC responsiveness, with an area under the curve (AUC) of 0.885. The integrated multiomics model achieved a slightly higher AUC of 0.899, indicating only a marginal improvement over traditional methods. These results highlight that while the gut microbiome and metabolomic signatures provide valuable insights into treatment responsiveness, they do not drastically outperform existing clinical predictors. However, they do offer a deeper understanding of the systemic immunometabolic context that influences GC therapy outcomes. Limitations and Future Directions Despite its promising findings, the study has limitations. The sample size was relatively small, which may affect the generalizability of the results. Additionally, the study design does not establish causality, only associations between microbial-metabolite profiles and treatment outcomes. Future research with larger cohorts and longitudinal designs could help validate these findings and explore the mechanisms underlying these associations. For more on the interplay between the gut microbiome and health, you might find our article on the gut-brain connection insightful.
Sources: Microbial-Metabolite Signatures Are Associated With Glucocorticoid Responsiveness in Chronic Rhinosinusitis With Nasal Polyps. — International forum of allergy & rhinology (2026) (https://pubmed.ncbi.nlm.nih.gov/42637687/)

### Gut Microbiome's Role in Chemotherapy-Induced Fatigue Explored
URL: https://microbiome.news/posts/gut-microbiome-s-role-in-chemotherapy-induced-fatigue-explored
Section: Science | Published: 2026-08-24 | 3 min
Summary: A new study investigates how fecal microbiota transplantation (FMT) affects chemotherapy-induced fatigue in mice, highlighting the complex relationship between gut microbes and treatment side effects.
Body: Chemotherapy is a critical component in the treatment of cancer, but it often comes with a host of challenging side effects, one of the most debilitating being fatigue. This fatigue can significantly impact patients' quality of life and their ability to adhere to treatment regimens. Recent research has begun to explore the potential role of the gut microbiome in mediating these effects, given its known interactions with both the immune system and the central nervous system. Exploring the Gut-Brain Axis In a study published in International Immunopharmacology , researchers sought to understand the impact of fecal microbiota transplantation (FMT) on chemotherapy-induced fatigue. The study involved both human patients and a mouse model to explore this complex relationship. In the human component, 67 breast cancer patients reported increased fatigue and diarrhea during chemotherapy, which was associated with shifts in their gut microbiome composition. Parallel experiments in mice involved treating them with common chemotherapy drugs, 5-fluorouracil (5-FU) or paclitaxel, with some receiving FMT derived from pre-chemotherapy fecal material. The researchers assessed various outcomes, including fatigue (measured by in-cage locomotion and voluntary wheel running), gut microbiome composition, and inflammatory markers in the gut and brain. FMT's Mixed Results in Mice The findings in mice were intriguing but complex. FMT provided mild-to-moderate benefits, particularly in mice treated with 5-FU. These benefits included preservation of body mass and transient improvements in fatigue. Additionally, FMT partially normalized certain gut bacterial taxa and reduced expression of inflammatory markers like colonic Il1b and brain Aqp4, which are associated with chemotherapy-induced inflammation. However, the study also found that FMT did not uniformly mitigate the inflammatory effects induced by chemotherapy, particularly with paclitaxel. This suggests that the effectiveness of FMT may vary depending on the specific chemotherapy drug used, pointing to a nuanced interaction between gut microbiota and chemotherapy agents. Implications and Limitations The study underscores the potential role of the gut microbiome in chemotherapy-induced fatigue and highlights the possibility of using microbiome modulation as a strategy to alleviate some treatment-related side effects. However, the findings also reveal that FMT is not a one-size-fits-all solution. Its benefits appear limited and dependent on the type of chemotherapy drug, suggesting that more personalized approaches may be necessary. One significant limitation of this study is its reliance on a mouse model, which, while useful for understanding biological mechanisms, may not fully replicate the complexities of human physiology and the human gut microbiome. Additionally, the study's findings are preliminary and indicate associations rather than causations, necessitating further research to confirm these results and explore the mechanisms involved. For more insights into the gut-brain connection, you might explore our article on the gut-brain connection in Crohn's disease .
Sources: The gut microbiome in chemotherapy-induced fatigue: Exploring clinical associations and modulation via fecal microbiota transplantation in female mice. — International immunopharmacology (2026) (https://pubmed.ncbi.nlm.nih.gov/42633730/)

### Exploring the Microbiota-Gut-Brain Axis in Stress Responses
URL: https://microbiome.news/posts/exploring-the-microbiota-gut-brain-axis-in-stress-responses
Section: Gut–Brain | Published: 2026-08-23 | 3 min
Summary: A new review examines how metabolites like GABA, serotonin, and kynurenine influence stress resilience through the microbiota-gut-brain axis.
Body: Stress is a well-known contributor to various neuropsychiatric disorders, including anxiety and depression. However, the biological mechanisms that could be targeted nutritionally to mitigate stress responses are still underdeveloped. A new review published in Food Research International delves into the role of the microbiota-gut-brain axis in modulating stress responses, focusing on three key metabolite systems: γ-aminobutyric acid (GABA), serotonin (5-HT), and kynurenine. The Role of Metabolites in Stress Response The review synthesizes current evidence from both preclinical and human studies to highlight how metabolites co-regulated by the host and microbiota serve as mediators within the microbiota-gut-brain axis. These metabolites are thought to influence an individual's vulnerability or resilience to stress. Specifically, the review focuses on GABA, serotonin, and kynurenine-pathway metabolites, which have high mechanistic relevance in brain signaling. Microbial activity, host metabolism, and dietary inputs interact to modulate brain-relevant signaling under stress. For instance, stress-associated dysbiosis can alter GABAergic and serotonergic signaling, shifting tryptophan metabolism toward neuroactive kynurenines. This shift may affect neural excitability, synaptic plasticity, and behaviors related to affect. Pathways and Mechanisms The review discusses various pathways through which these metabolite systems may act, including neuroendocrine, neuroimmune, and neural pathways. Stress can disrupt intestinal and blood-brain barrier integrity and amplify inflammatory signaling, further influencing these pathways. The review highlights the importance of understanding these mechanisms to develop effective interventions. Food-based gut–brain strategies, such as targeted whole-food matrices, fermented foods, and specific probiotic strains, are evaluated for their potential to reprogram microbial metabolism. These strategies aim to restore neurotransmitter balance and reduce inflammation, thereby potentially improving stress resilience. Future Directions The review proposes a translational framework for advancing microbiome-metabolite interventions for stress-related brain dysfunction. This framework emphasizes the need for strain- and pathway-specific mechanisms, standardized metabolite quantification, and biomarker-guided personalization. Such an approach could lead to more effective and personalized interventions. However, the review also acknowledges several limitations. Much of the current evidence is derived from preclinical models, which may not fully translate to human physiology. Additionally, the complexity of the microbiota-gut-brain axis means that isolating specific causal pathways remains challenging. For more on the interplay between stress and the immune system, you might find our article on stress, depression, and the immune system insightful. Conclusion This review highlights the significant role that metabolites like GABA, serotonin, and kynurenine play in the microbiota-gut-brain axis and their potential impact on stress responses. While the findings are promising, further research is needed to translate these insights into practical interventions.
Sources: Modulating stress responses via the microbiota-gut-brain axis: a pathway-focused review of GABA, 5-HT, and kynurenine metabolites. — Food research international (Ottawa, Ont.) (2026) (https://pubmed.ncbi.nlm.nih.gov/42632744/)

### The Role of Bile Acids in Nutrient Sensing and Metabolism
URL: https://microbiome.news/posts/the-role-of-bile-acids-in-nutrient-sensing-and-metabolism
Section: Science | Published: 2026-08-22 | 3 min
Summary: A new review explores how bile acids function as signaling molecules, integrating nutrient signals to regulate metabolism and immune responses.
Body: Bile acids (BAs) have long been recognized for their role in lipid digestion, but recent research has expanded our understanding of their functions. A review published in the Annual Review of Nutrition highlights the emerging view of BAs as critical signaling molecules that integrate nutrient-derived signals to coordinate various metabolic processes. Beyond Lipid Digestion Traditionally, bile acids were primarily associated with their ability to emulsify fats, facilitating the absorption of dietary lipids. However, this review emphasizes their broader role as signaling entities. Acting through receptors such as the farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor (TGR5), BAs are now understood to influence energy expenditure, glucose and lipid metabolism, and immune responses. In the postprandial state, which follows food intake, circulating BAs are among the most dynamically modulated metabolites. This modulation is crucial as it helps coordinate the body's metabolic responses to nutrient intake, ensuring that energy is efficiently utilized and stored. Factors Influencing Bile Acid Profiles The composition of bile acid profiles is influenced by several factors, including diet, sex, age, and metabolic status. These profiles are not static; they are shaped and diversified by the gut microbiota, which converts primary BAs into secondary BAs with distinct receptor affinities. This microbial conversion is significant because it affects how BAs interact with their receptors and, consequently, how they influence host physiology. Dysregulation in bile acid kinetics or pool composition has been closely linked to metabolic diseases such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. This association underscores the importance of maintaining a balanced BA profile for metabolic health. Coordinating Metabolic Homeostasis The review highlights how changes in bile acid levels during the postprandial period are integral to coordinating enterohepatic flux, hormonal feedback, and interactions with the microbiota. These processes collectively help regulate postprandial metabolic homeostasis, ensuring that the body's metabolic machinery operates smoothly following nutrient intake. Understanding the signaling roles of BAs and their interactions with the gut microbiota offers valuable insights into the complex mechanisms underlying metabolic regulation. This knowledge could inform future research aimed at modulating BA signaling pathways to support metabolic health. Limitations and Future Directions While the review provides a comprehensive overview of the roles of bile acids, it also highlights certain limitations. The complexity of BA signaling pathways and their interactions with various physiological processes means that much remains to be understood. Additionally, the review's findings are based on existing studies, which may vary in their methodologies and scope, indicating a need for further research to clarify these dynamics. For those interested in the broader context of how gut microbiota influences health, our post on science offers additional insights into the intricate relationships between diet, microbiota, and metabolism.
Sources: Bile Acids as Integrators of Nutrient Sensing and Postprandial Metabolism. — Annual review of nutrition (2026) (https://pubmed.ncbi.nlm.nih.gov/42629323/)

### Antibiotic-Associated Diarrhea in Sepsis Linked to Gut Dysbiosis
URL: https://microbiome.news/posts/antibiotic-associated-diarrhea-in-sepsis-linked-to-gut-dysbiosis
Section: Science | Published: 2026-08-21 | 3 min
Summary: A new study finds that the composition of gut microbiota before antibiotic treatment in sepsis patients can influence the risk of developing antibiotic-associated diarrhea.
Body: In a study published in the International Journal of Antimicrobial Agents , researchers explored the relationship between gut microbiota composition and the development of antibiotic-associated diarrhea (AAD) in sepsis patients. The findings suggest that the state of a patient's gut microbiome before starting antibiotic treatment could be a significant factor in the risk of developing AAD. Exploring the Microbiome's Role in AAD The study utilized data from the PROGRESS trial, a randomized controlled trial that investigated the effects of using procalcitonin (PCT) levels to guide the early cessation of antibiotics in sepsis patients. This approach was shown to reduce the incidence of AAD and preserve gut microbiome diversity. However, the current analysis focused on patients who received the standard-of-care (SoC) duration of antibiotics, to better understand the baseline microbiome's role in AAD development. Fecal samples were collected from patients before the initiation of antimicrobial treatment, and microbiome analysis was conducted using 16S rRNA Nanopore sequencing. The researchers compared the gut microbiota of patients who developed AAD with those who did not. Key Findings on Microbiome Composition The study revealed that the Shannon diversity index, a measure of microbiome diversity, was similar between patients who developed AAD and those who did not. However, significant differences were observed in the relative abundance of certain bacterial groups. Patients who developed AAD had a lower abundance of Bacillota and a higher abundance of Pseudomonadota. Further analysis identified specific bacterial genera associated with AAD risk. A higher baseline abundance of Pseudomonas (≥ 0.75%) and Enterococcus (≥ 2.1%) were found to be independent risk factors for AAD, with adjusted odds ratios of 5.70 and 7.16, respectively. Conversely, a baseline abundance of the butyrate-producing genus Faecalibacterium of at least 0.15% was protective against AAD. Implications and Limitations These findings underscore the importance of the gut microbiome's initial state before antibiotic treatment in influencing the risk of AAD in sepsis patients. Understanding these associations could lead to more personalized approaches in managing antibiotic use and preventing AAD. However, the study has its limitations. The analysis was exploratory and focused solely on patients receiving the SoC duration of antibiotics, which may not fully represent all sepsis patients. Additionally, while associations were identified, causation cannot be inferred from this observational data. Further research is needed to confirm these findings and explore potential interventions. For more on the role of gut microbiota in health, see our article on gut microbiota-accessible foods .
Sources: Development of antibiotic-associated diarrhea in sepsis patients is associated with dysbiosis at baseline: Data from the PROGRESS Controlled Trial. — International journal of antimicrobial agents (2026) (https://pubmed.ncbi.nlm.nih.gov/42624437/)

### Intestinal Flagellin Linked to Systemic Inflammation in Long COVID
URL: https://microbiome.news/posts/intestinal-flagellin-linked-to-systemic-inflammation-in-long-covid
Section: Science | Published: 2026-08-20 | 3 min
Summary: A new study identifies a gut-driven mechanism involving flagellin and TLR5 as a potential driver of systemic inflammation in long COVID and other inflammatory diseases.
Body: Researchers have uncovered a potential mechanism by which the gut microbiome may contribute to systemic inflammation in long COVID, as well as other inflammatory diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), and inflammatory bowel disease (IBD). The study, published in Gut , highlights the role of intestinal flagellin in driving inflammation through a specific molecular pathway. Flagellin and Systemic Inflammation The study focused on the role of flagellated bacteria in the gut, which were found to be a common feature across several inflammatory diseases. Flagellin, a protein component of bacterial flagella, was shown to activate toll-like receptor 5 (TLR5) on neutrophils. This activation led to the formation of neutrophil extracellular traps (NETs) and the release of interleukin-15 (IL-15), a cytokine involved in immune responses. Subsequent stimulation of macrophages by IL-15 resulted in increased production of arachidonic acid (ARA), a fatty acid that can be involved in inflammatory processes. This cascade of events, termed the flagellin-TLR5-IL-15-ARA axis, was proposed as a mechanism driving systemic inflammation in long COVID. Mechanistic Insights from Animal Models To further explore this mechanism, researchers employed both human cohort studies and mouse models of co-infection with SARS-CoV-2 and Pseudomonas aeruginosa . These models successfully recapitulated the multi-organ pathophysiology observed in long COVID, including pulmonary fibrosis and intestinal lymphoid aggregates. Notably, genetic interventions that disrupted macrophage ARA synthesis or neutrophil IL-15 production were able to attenuate lung pathology in these models. Moreover, the study found that clearing the gut microbiome with gentamicin, an antibiotic, uniquely suppressed systemic inflammation, suggesting the gut's pivotal role in this process. This finding underscores the potential of targeting the gut microbiome as a therapeutic strategy. Implications and Limitations The identification of the flagellin-TLR5-IL-15-ARA axis offers new insights into the mechanisms of systemic inflammation, positioning intestinal flagellin as a potential therapeutic target. Additionally, arachidonic acid may serve as a biomarker for long COVID, aiding in the diagnosis and monitoring of this condition. However, the study's reliance on animal models and the preliminary nature of these findings highlight the need for further research. The translation of these results to human clinical settings remains to be validated. Additionally, while the study provides a compelling model for gut-driven inflammation, it does not establish causation, and the complex interplay of microbiome and host factors warrants more comprehensive investigation. For more on the role of the gut microbiome in health and disease, you might explore our article on the gut-brain connection in Crohn's disease .
Sources: Intestinal flagellin drives multisystem inflammation through TLR5-IL-15-ARA axis. — Gut (2026) (https://pubmed.ncbi.nlm.nih.gov/42618450/)

### Exploring the Bile Acid-Microbiota Axis in IBS Subtypes
URL: https://microbiome.news/posts/exploring-the-bile-acid-microbiota-axis-in-ibs-subtypes
Section: Science | Published: 2026-08-19 | 3 min
Summary: A new study investigates the differences in bile acid profiles and gut microbiota compositions between IBS with constipation and diarrhea, revealing distinct microbial and metabolic patterns.
Body: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. It is often categorized into subtypes based on predominant symptoms: IBS with constipation (IBS-C) and IBS with diarrhea (IBS-D). A study published in the Journal of gastroenterology and hepatology explores the differences in the plasma bile acid-gut microbiota axis between these two IBS subtypes, shedding light on their distinct clinical presentations. Methodology: Analyzing Microbiota and Bile Acids The researchers aimed to investigate the correlation between IBS-C and IBS-D by analyzing fecal samples from participants. The study utilized custom V4-region 16S rRNA amplicon sequencing on the Illumina NovaSeq 6000 platform to examine the fecal bacterial composition. Additionally, bile acids were quantified using liquid chromatography-tandem mass spectrometry (LC-MS). Participants also completed various symptom severity and quality of life questionnaires, including the IBS Symptom Severity Score (IBS-SSS), IBS Quality of Life (IBS-QOL), and the Gastrointestinal Symptom Rating Scale (GSRS). Findings indicated that patients with IBS-D experienced more frequent and severe diarrhea and abdominal pain, whereas those with IBS-C reported more severe bloating and constipation. These symptom differences were mirrored by distinct patterns in bile acid profiles and gut microbiota compositions. Distinct Microbial and Bile Acid Patterns The study found that total bile acids, as well as primary, secondary, conjugated, and unconjugated bile acids, were elevated in IBS-D patients but reduced in those with IBS-C, compared to healthy controls (HCs). The gut microbiota composition of both IBS-D and IBS-C patients differed significantly from that of HCs. Specifically, the IBS-D group exhibited a higher association with Prevotella and Ruminococcaceae, while the IBS-C group showed a concentration of Bacteroides and Clostridium. In contrast, the HCs were primarily associated with Ruminococcus. Further analysis revealed correlations between specific bacterial families and bile acids. Clostridiaceae and Bacteroides abundances were negatively correlated with plasma chenodeoxycholic acid and cholic acid, respectively. Clostridium showed a negative correlation with ursodeoxycholic acid (UDCA), while Ruminococcus was positively correlated with isodeoxycholic acid. Implications and Limitations The findings suggest that alterations in the bile acid-gut microbiota axis are closely related to the distinct clinical presentations of IBS-C and IBS-D. The study highlights how IBS-D is characterized by a decreased abundance of Ruminococcus and Clostridium, alongside increased bile acid secretion and reduced reabsorption, contributing to the observed symptom differences. However, the study does have limitations. The abstract does not specify the sample size, which is crucial for understanding the generalizability of the findings. Additionally, the study's cross-sectional design means it can only identify associations, not causations, between microbiota, bile acids, and IBS symptoms. Further research is needed to explore these relationships more deeply and to understand the underlying mechanisms. For more on how gut microbiota interact with various bodily systems, you might find our post on what is the microbiome insightful.
Sources: Differences in the Plasma Bile Acid-Gut Microbiota Axis Between IBS-D and IBS-C. — Journal of gastroenterology and hepatology (2026) (https://pubmed.ncbi.nlm.nih.gov/42613095/)

### Breast Milk Composition Altered by Alpha-Linolenic Acid Intake
URL: https://microbiome.news/posts/breast-milk-composition-altered-by-alpha-linolenic-acid-intake
Section: Science | Published: 2026-08-18 | 3 min
Summary: A new study reveals that increased dietary intake of alpha-linolenic acid can modify the nutritional and non-nutritional characteristics of breast milk and impact the microbiota of neonates.
Body: In a study published in The Journal of nutrition , researchers investigated how dietary intake of alpha-linolenic acid (ALA) affects the composition of breast milk and the intestinal microbiota of neonates. The study focused on the use of "Bleu-Blanc-Coeur®" (BBC) food products, which are enriched with ALA, a type of n-3 polyunsaturated fatty acid (PUFA). Study Design and Methodology This randomized clinical trial was conducted at a single center and involved adult women who were less than 28 weeks into their pregnancies. The participants were divided into two groups: one group substituted their usual diet with BBC products rich in ALA from the seventh month of pregnancy until 45 days postpartum, while the control group continued with their regular diet. A total of 66 women were initially included, with 58 completing the study and being analyzed. The primary aim was to assess whether the increased ALA intake would elevate ALA levels in breast milk by day 21 postpartum. Secondary aims included examining changes in the fatty acid profile, human milk oligosaccharides (HMOs), hormone levels, immune components of breast milk, and the intestinal microbiota of the neonates. Key Findings The results demonstrated that breast milk from the BBC group had significantly higher levels of ALA and n-3 PUFAs compared to the control group. Specifically, ALA levels were 75% higher at day 21 postpartum and 38% higher at day 45 postpartum in the BBC group. Similarly, n-3 PUFA levels were 52% higher at day 21 postpartum and 22% higher at day 45 postpartum. In addition to these nutritional changes, the study found differences in the lipidome, insulin, interleukin-6 (IL-6), immunoglobulin G (IgG), and HMO levels in breast milk at day 21 postpartum. Notably, the alpha-diversity of the fecal microbiota in neonates was greater in the BBC group than in the control group, suggesting that maternal diet can influence the early microbial environment of infants. Implications and Limitations The study highlights the potential for dietary modifications during pregnancy and lactation to alter the composition of breast milk and, consequently, the microbiota of neonates. While these findings are promising, they are preliminary and require further investigation to determine any long-term health implications for infants. One limitation of the study is its relatively small sample size, with only 58 women completing the trial. Additionally, the study was conducted in a single center, which may limit the generalizability of the results. Further research with larger, more diverse populations is needed to confirm these findings and explore their potential health impacts. For more on how diet can influence the microbiome, you might be interested in our article on gut microbiota-accessible foods .
Sources: Increased intake of foods providing alpha-linolenic acid modifies nutritional and non-nutritional characteristics of breast milk: a randomized clinical trial. — The Journal of nutrition (2026) (https://pubmed.ncbi.nlm.nih.gov/42607835/)

### Metabolic and Microbiota Changes in Bipolar Disorder Treatment
URL: https://microbiome.news/posts/metabolic-and-microbiota-changes-in-bipolar-disorder-treatment
Section: Science | Published: 2026-08-17 | 3 min
Summary: A new study explores how different antipsychotic treatments combined with lithium carbonate affect metabolic parameters and gut microbiota in patients with bipolar disorder experiencing manic episodes.
Body: In a study published in the Journal of affective disorders , researchers investigated the early metabolic and gut microbiota changes in patients with bipolar disorder undergoing treatment for manic episodes. This prospective observational study focused on how different antipsychotic medications combined with lithium carbonate influence these parameters over a 12-week period. Study Design and Methodology The study enrolled 80 inpatients with bipolar disorder who were experiencing manic episodes and were medication-free at the outset. These participants were divided into four groups based on their treatment regimen: olanzapine combined with lithium carbonate, risperidone combined with lithium carbonate, aripiprazole combined with lithium carbonate, and lithium carbonate monotherapy. Metabolic parameters such as body weight, body mass index (BMI), waist circumference, fasting plasma glucose, triglycerides, and high-density lipoprotein cholesterol (HDLC) were measured at four intervals: baseline (T0), week 4 (T4), week 8 (T8), and week 12 (T12). Fecal samples were collected at T0 and T12 to analyze gut microbiota composition using 16S rRNA gene sequencing. Key Findings The study found significant differences in metabolic changes among the four treatment groups over the 12-week period. The group receiving olanzapine plus lithium carbonate exhibited the most pronounced metabolic changes, followed by those on risperidone plus lithium carbonate. The aripiprazole plus lithium carbonate group and the lithium monotherapy group showed less marked changes. Specifically, α-diversity analysis revealed significant increases in the Shannon and Simpson indices, indicating greater microbial diversity, in the olanzapine and risperidone combination groups. In contrast, no significant changes were observed in the other two groups. β-diversity analysis indicated significant shifts in gut microbial community structure in the olanzapine and risperidone combination groups, while no significant changes were detected in the aripiprazole combination group or the lithium monotherapy group. The researchers also identified specific correlations between changes in bacterial genera and metabolic parameters. For instance, an increase in Collinsella abundance was negatively correlated with changes in HDLC, while an increase in Bifidobacterium abundance was positively correlated with changes in HDLC. Changes in Blautia abundance were positively correlated with triglycerides, and changes in Faecalibacterium abundance were negatively correlated with BMI. Implications and Limitations This study highlights the potential role of gut microbiota in the metabolic effects associated with antipsychotic treatment in bipolar disorder. The findings suggest that different antipsychotics, when combined with lithium carbonate, may lead to distinct metabolic burdens and alterations in gut microbiota composition. However, the study's observational nature means that it cannot establish causation between these changes and the treatments. Additionally, the relatively small sample size and the focus on a specific patient population limit the generalizability of the findings. Further research is needed to explore the mechanisms underlying these associations and to determine whether interventions targeting the gut microbiota could mitigate metabolic side effects in patients undergoing antipsychotic treatment. For a deeper understanding of how gut microbiota can influence neurological conditions, you might find our article on the gut-brain connection informative.
Sources: Early metabolic and gut microbiota alterations during antipsychotic‑lithium treatment in acute bipolar mania: A prospective follow-up study. — Journal of affective disorders (2026) (https://pubmed.ncbi.nlm.nih.gov/42604694/)

### Exploring the Gut-Brain Connection in Ischemic Stroke
URL: https://microbiome.news/posts/exploring-the-gut-brain-connection-in-ischemic-stroke
Section: Gut–Brain | Published: 2026-08-16 | 3 min
Summary: A new review highlights the role of gut microbiota in ischemic stroke, examining pre-stroke dysbiosis, acute-phase changes, and potential therapeutic interventions.
Body: Ischemic stroke remains a significant global health challenge, with researchers continually seeking to understand its underlying mechanisms and potential interventions. A new review published in Brain and Behavior delves into the complex interactions between the gut microbiota and the brain, particularly in the context of ischemic stroke. This review synthesizes current evidence on how gut dysbiosis contributes to stroke risk and recovery, offering insights into potential therapeutic avenues. Gut Dysbiosis as a Stroke Risk Factor The review identifies gut dysbiosis as an upstream risk factor for ischemic stroke. Dysbiosis refers to an imbalance in the microbial communities residing in the gut, which can influence systemic health. In the context of stroke, dysbiosis is implicated in promoting atherothrombosis through trimethylamine N-oxide (TMAO) production, priming systemic inflammation, and pre-conditioning associated with comorbidities. These mechanisms highlight the gut's potential role in influencing stroke onset, suggesting that maintaining a balanced microbiota could be crucial in managing stroke risk. Microbiota Dynamics Post-Stroke After a stroke occurs, the gut microbiota undergoes significant changes. The review notes a depletion of short-chain fatty acid (SCFA)-producing bacteria and an increase in pro-inflammatory taxa, such as Proteobacteria and Enterobacteriaceae . These changes are associated with various post-stroke complications, including cognitive impairment, depression, stroke-associated pneumonia, and gastrointestinal dysfunction. The persistent dysbiosis observed post-stroke underscores the importance of the microbiota in recovery and overall stroke outcomes. Mechanisms of Gut-Brain Communication The gut-brain axis, a bidirectional communication network, plays a pivotal role in modulating stroke outcomes. The review highlights several mechanisms through which the gut microbiota influences the brain: immune regulation, metabolite signaling, maintaining blood-brain barrier integrity, and vagal pathways. These mechanisms collectively suggest that the gut microbiota is not merely a passive participant but an active modulator of stroke pathophysiology and recovery. Potential Therapeutic Interventions Given the significant role of the gut microbiota in stroke, researchers are exploring various microbiota-targeted interventions. The review discusses several candidate therapies, including probiotics, prebiotics, fecal microbiota transplantation (FMT), SCFA supplementation, traditional Chinese medicine, and neuromodulation. While these interventions show promise in preclinical models, human clinical evidence remains largely preliminary. Small clinical trials have demonstrated modest benefits with probiotics and dietary fiber supplementation, but more rigorous studies are needed to validate these findings. The translation of therapies like FMT and SCFA supplementation into clinical practice requires well-designed, adequately powered randomized controlled trials. Future precision microbiome medicine may involve individualized profiling and phenotype-specific interventions, aiming to establish microbiota-targeted strategies as viable adjunctive therapies for stroke. For more on the role of short-chain fatty acids in health, see our article on short-chain fatty acids . Limitations and Future Directions While this review provides a comprehensive overview of the gut-brain connection in ischemic stroke, it also highlights the limitations of current research. The evidence from human studies is still in its infancy, with many findings derived from preclinical models. The complexity of the gut microbiota and its interactions with host factors such as age, sex, genetics, and comorbidities further complicates the translation of these findings into clinical practice. As such, future research must focus on rigorous clinical trials and the development of precision medicine approaches to fully harness the potential of microbiota-targeted interventions in stroke management.
Sources: Gut Microbiota and Ischemic Stroke: From Pre-Stroke Dysbiosis and Acute-Phase Changes to Therapeutic Applications. — Brain and behavior (2026) (https://pubmed.ncbi.nlm.nih.gov/42603266/)

### Understanding Late-Onset Neonatal Sepsis: Challenges and Innovations
URL: https://microbiome.news/posts/understanding-late-onset-neonatal-sepsis-challenges-and-innovations
Section: Science | Published: 2026-08-15 | 3 min
Summary: A new review explores the complexities of late-onset neonatal sepsis in NICUs, highlighting emerging diagnostics, antimicrobial resistance, and prevention strategies.
Body: Late-onset neonatal sepsis (LOS) poses a significant challenge in neonatal intensive care units (NICUs) worldwide, particularly affecting very low birth weight (VLBW) and extremely preterm infants. Despite advancements in perinatal care, LOS remains a leading cause of mortality and long-term neurodevelopmental issues. A study published in the American Journal of Perinatology provides a comprehensive overview of the current landscape of LOS, emphasizing the need for innovative diagnostics and precision therapeutics. Complex Interplay of Factors The review outlines the multifaceted nature of LOS, which arises from a combination of neonatal immune immaturity, invasive NICU interventions, and microbial exposure. In high-income countries, Gram-positive organisms are the predominant pathogens, whereas low- and middle-income countries are increasingly reporting multidrug-resistant Gram-negative pathogens. This shift contributes to higher morbidity and mortality rates in these settings. Early-life antibiotic exposure is another critical factor, as it can disrupt the gut microbiome, leading to increased susceptibility to infections. The review highlights the importance of understanding these complex interactions to develop effective prevention and management strategies. Advancements in Diagnostics and Management Diagnosing LOS remains a challenge due to its nonspecific clinical signs, often resulting in delayed or excessive empiric antibiotic therapy. The review points to promising advancements in rapid molecular diagnostics and emerging predictive tools, such as early-warning models and serial biomarker monitoring. These innovations offer opportunities for pathogen-directed therapy and individualized pharmacokinetic optimization, which are crucial for effective antimicrobial stewardship. Prevention strategies are also a key focus of the review. Central-line bundles, human milk feeding, probiotics, strict hand hygiene, and tailored infection-control measures are emphasized as central to reducing the incidence of LOS. These strategies aim to preserve the microbiome and support neuroprotective interventions, ultimately improving survival and long-term outcomes for preterm and VLBW infants. Research Gaps and Future Directions While the review provides a thorough synthesis of current evidence, it also highlights significant gaps in research. There is a need for further studies to bridge the mechanistic understanding of LOS with scalable, context-sensitive approaches. The integration of precision diagnostics and individualized therapy into clinical practice remains a priority for future research. Moreover, equitable implementation of prevention and stewardship programs is critical to addressing the global burden of LOS. The review calls for continued efforts to align neonatal health policy with these emerging insights, ensuring that all infants, regardless of geographic location, benefit from advancements in care. For those interested in the broader implications of microbiome research, our post on precision probiotics offers additional insights into how targeted interventions can support health outcomes.
Sources: Late-Onset Neonatal Sepsis: Contemporary Epidemiology, Diagnosis, Prevention, and Precision Therapeutics. — American journal of perinatology (2026) (https://pubmed.ncbi.nlm.nih.gov/42601049/)

### Gut Microbiome's Link to Muscle Mass Explored in New Study
URL: https://microbiome.news/posts/gut-microbiome-s-link-to-muscle-mass-explored-in-new-study
Section: Science | Published: 2026-08-14 | 3 min
Summary: A new study investigates the relationship between gut microbiome composition and musculoskeletal features in middle-aged and older adults, revealing potential sex-specific associations.
Body: In a study published in Bone , researchers explored the potential connections between gut microbiome composition and musculoskeletal features in middle-aged and older adults. The study aimed to provide insights into how the gut microbiome might influence muscle and bone characteristics, an area previously supported mainly by animal studies. Study Design and Methodology The research involved participants from two well-known population-based cohorts: the Rotterdam Study and the Framingham Heart Study. These cohorts included community-dwelling individuals with mean ages of 62.7 and 55.2 years, respectively. The study analyzed data from a total of 2,476 participants, focusing on three key musculoskeletal phenotypes: appendicular lean mass (ALM), femoral neck bone mineral density (FN-BMD), and trabecular bone score (TBS). To assess the gut microbiome, researchers used 16S rRNA sequencing, a method that allows for the identification and quantification of bacterial genera present in the gut. They also predicted the functional potential of the microbiome using a tool called PICRUSt2. The analysis accounted for various demographic, lifestyle, and clinical factors using multivariate linear regression models. Key Findings and Associations The study found that while alpha diversity, a measure of the variety of species within a sample, was not associated with any of the musculoskeletal phenotypes, beta diversity, which measures differences in microbial composition between samples, was linked to appendicular lean mass (ALM) in the combined cohort and specifically in female participants. Several specific microbial genera were associated with ALM. A lower abundance of Oscillibacter , Anaerotruncus , and Eisenbergiella was linked to higher ALM, while a higher abundance of Agathobacter was also associated with increased muscle mass. In female participants, additional associations were observed, including a lower abundance of Hungatella and Clostridiales bacterium DTU089 , along with an increased biotin biosynthesis II pathway, which were linked to higher ALM. Interestingly, the study did not find any robust associations between gut microbial features and bone measures such as FN-BMD and TBS. This suggests that while the gut microbiome may influence muscle mass, its impact on bone density and structure might be less pronounced or more complex. Implications and Limitations The findings of this study contribute to the growing body of evidence suggesting that the gut microbiome may play a role in musculoskeletal health, particularly in relation to muscle mass. The observed sex-specific effects highlight the need for further research to understand the underlying mechanisms and potential implications for personalized health strategies. However, the study has limitations that should be considered. The associations observed do not imply causation, and the study's cross-sectional nature means it cannot establish temporal relationships. Additionally, the findings are based on specific cohorts, and larger studies are necessary to confirm these results and explore the mechanisms involved. For readers interested in the broader context of microbiome research, our post on understanding the microbiome provides foundational insights into this complex and dynamic field.
Sources: The association of gut microbiome composition with musculoskeletal features in middle-aged and older adults: A two-cohort joint study. — Bone (2026) (https://pubmed.ncbi.nlm.nih.gov/42595281/)

### Natural Polysaccharides and the Microbiota-Gut-Brain Axis
URL: https://microbiome.news/posts/natural-polysaccharides-and-the-microbiota-gut-brain-axis
Section: Gut–Brain | Published: 2026-08-13 | 3 min
Summary: A new review explores how natural polysaccharides might modulate the microbiota-gut-brain axis, potentially influencing depression-related pathways.
Body: In a study published in Carbohydrate Polymers , researchers present a comprehensive review of how natural polysaccharides could modulate the microbiota-gut-brain axis (MGBA) and potentially influence pathways related to depression. The review suggests that depression is a systemic disorder involving MGBA dysfunction, rather than merely a central nervous system issue. This perspective opens new avenues for understanding and potentially addressing depressive symptoms through dietary components like natural polysaccharides. The Role of the Microbiota-Gut-Brain Axis The MGBA is a complex communication network that links the gut microbiota with the brain. It plays a significant role in maintaining mental health and is increasingly being implicated in the pathogenesis of depression. According to the review, factors such as gut microbial dysbiosis, barrier disruption, immune inflammation, metabolic disturbances, oxidative stress, mitochondrial injury, and impaired neuroplasticity collectively contribute to depressive pathology. Natural polysaccharides, which are complex carbohydrates found in various foods, are highlighted as potential modulators of the MGBA. These compounds are not only defined by their source or sugar content but also by their monosaccharide composition, glycosidic linkages, branching architecture, and molecular-weight distribution. These structural features influence how polysaccharides interact with the gut microbiota and, consequently, how they might affect the MGBA. Mechanisms of Action The review outlines several mechanisms through which natural polysaccharides may exert their effects on the MGBA. These include rebuilding gut microbial ecology, reprogramming the metabolism of short-chain fatty acids, tryptophan-derived indoles, and bile acids, and restoring the integrity of the intestinal and blood-brain barriers. Additionally, polysaccharides may suppress neuroimmune activation and oxidative injury, support mitochondrial homeostasis, and promote neurogenesis and synaptic plasticity through the BDNF-TrkB pathway. These actions suggest that polysaccharides could potentially alleviate depression-related abnormalities by targeting multiple pathways within the MGBA. However, the review emphasizes that the effects of polysaccharides are highly dependent on their structural characteristics, which determine their microbial accessibility, fermentation kinetics, and metabolite output. Challenges and Limitations While the review presents a promising perspective on the use of natural polysaccharides, it also acknowledges several challenges and limitations. One significant challenge is the attribution of specific activities to particular polysaccharides, given the complexity of their structures and interactions. Quality control, pharmacokinetics, and the variability of microbiome-dependent responses also pose hurdles for translating these findings into practical applications. Furthermore, the review highlights the need for stratified, mechanism-guided approaches to effectively utilize polysaccharides as adjunctive tools in modulating the MGBA. This requires a deeper understanding of how individual variations in microbiome composition can influence the response to polysaccharides. For readers interested in the broader implications of gut health, our introduction to the microbiome offers foundational insights into this complex and dynamic system.
Sources: Natural polysaccharides modulate the microbiota-gut-brain axis through multiple targets: A new perspective on the pathogenesis and treatment of depression. — Carbohydrate polymers (2026) (https://pubmed.ncbi.nlm.nih.gov/42586669/)

### Acetaminophen's Impact on Probiotic Bacteria Growth Dynamics
URL: https://microbiome.news/posts/acetaminophen-s-impact-on-probiotic-bacteria-growth-dynamics
Section: Science | Published: 2026-08-12 | 3 min
Summary: A new study explores how acetaminophen affects the growth of probiotic lactic acid bacteria, revealing potential implications for gut microbiota interactions.
Body: In a study published in Biotechnology Letters , researchers investigated the effects of acetaminophen on the growth dynamics of probiotic lactic acid bacteria within synthetic gut microbiota communities. The study focused on the interactions between Lactococcus lactis subsp. lactis and Clostridium butyricum , two species with potential implications for human gut health. Study Design and Methods The researchers conducted their experiments using 2 mL batch microbioreactors to simulate the gut environment. They analyzed the growth of Lactococcus lactis both in monoculture and in co-culture with Clostridium butyricum . The study measured several growth kinetics parameters, including carrying capacity, biomass accumulation (area under the curve, AUC), maximum growth rate, and lag phase duration. These parameters were estimated through a regression analysis that combined the 4Z Gompertz model and the exponential growth model. To determine the impact of acetaminophen, the researchers conducted a minimum effective concentration assay, which identified 66.1 mM as the concentration for subsequent experiments. They monitored biomass accumulation until the stationary phase and quantified acetaminophen and lactic acid concentrations using liquid chromatography-mass spectrometry (LC-MS). Key Findings The study found that co-cultures of Lactococcus lactis and Clostridium butyricum exhibited greater biomass accumulation and higher carrying capacity compared to monocultures, suggesting a mutualistic relationship between the two species. However, the presence of acetaminophen negatively affected all biomass-related kinetic parameters of Lactococcus lactis in both mono- and co-culture settings. Interestingly, Clostridium butyricum growth remained unaffected by acetaminophen in monoculture. LC-MS analysis indicated that while the drug was internalized by the bacteria, it was not metabolically degraded. Additionally, lactic acid production reached a saturation concentration of 17.8 mM, implying that the metabolite-related probiotic activity of Lactococcus lactis might remain stable despite reduced biomass. Implications and Limitations This study highlights the potential for commonly used drugs like acetaminophen to alter microbial dynamics within the gut. The findings suggest that acetaminophen could impact the growth and function of probiotic bacteria, which may, in turn, influence gut health. However, the study's use of synthetic gut microbiota communities and small-scale microbioreactors may limit the generalizability of the results to more complex, natural gut environments. Moreover, the study's focus on specific bacterial species means that the effects of acetaminophen on other members of the gut microbiota remain unexplored. Further research is needed to understand the broader implications of these findings and to explore the potential interactions between acetaminophen and a wider range of gut microbes. For more on the intricate relationships within the gut microbiome, you might find our exploration of precision probiotics insightful.
Sources: Impact of acetaminophen on the growth kinetics and metabolite production of probiotic lactic acid bacteria. — Biotechnology letters (2026) (https://pubmed.ncbi.nlm.nih.gov/42579196/)

### Antisense Transcription: New Insights into Gut Microbiome Adaptations
URL: https://microbiome.news/posts/antisense-transcription-new-insights-into-gut-microbiome-adaptations
Section: Science | Published: 2026-08-11 | 3 min
Summary: A study reveals how antisense RNA dynamics in the gut microbiome may serve as biomarkers for inflammatory bowel disease and other conditions.
Body: In a study published in Nature Microbiology , researchers have uncovered new insights into how the gut microbiome adapts to health and disease conditions. By focusing on antisense RNA (asRNA) dynamics, the study highlights potential biomarkers for inflammatory bowel disease (IBD) and other gastrointestinal disorders. Understanding Antisense RNA in the Gut Microbiome The gut microbiome is a complex ecosystem where microorganisms continuously adjust their genetic expressions. This study introduces 'metastrand,' a novel framework that combines strand-aware metatranscriptomics and metagenomics. This approach allows for the quantification of both mRNAs and asRNAs at a gene-level resolution within complex microbial communities. Antisense RNAs are RNA molecules that are complementary to a segment of messenger RNA (mRNA) and can regulate gene expression. In the context of the gut microbiome, these asRNAs appear to play a significant role in how microbial communities adapt to various conditions, including inflammatory states. Key Findings: Antisense RNA as Biomarkers The study found that during active phases of IBD, microbial asRNA programs showed convergence across different patients. These programs were correlated with fecal metabolites and calprotectin levels, a marker of inflammation, and remained stable during ongoing inflammation. This stability suggests that asRNAs could serve as reliable biomarkers for assessing inflammatory activity in the gut. Moreover, the research linked antisense-to-sense transcriptional shifts to structural genome rearrangements and the redistribution of adaptive functions under selective pressure. This indicates that asRNA dynamics might precede genomic changes, offering a window into the early stages of microbial adaptation. Interestingly, similar antisense RNA dynamics were observed in a mouse model of colitis, during oxidative stress in vitro, and in patients with pathogen-confirmed gastroenteritis. These findings suggest a broader role for asRNAs in microbial adaptation beyond IBD. Implications and Limitations The study provides a new dimension to understanding microbial adaptation in the gut, emphasizing the potential of asRNAs as biomarkers for various gastrointestinal conditions. By identifying these RNA dynamics, researchers can better understand how the gut microbiome responds to stress and disease, potentially leading to new diagnostic tools. However, there are limitations to consider. The study's findings are primarily associative, meaning they highlight correlations rather than direct causations. Additionally, while the research includes both human and animal models, further studies are needed to confirm these findings across larger and more diverse populations. For those interested in the broader implications of gut microbiome research, our gut-brain axis primer offers additional context on how the microbiome interacts with host systems.
Sources: Antisense transcription reveals disease-associated adaptations in the human gut microbiome. — Nature microbiology (2026) (https://pubmed.ncbi.nlm.nih.gov/42575975/)

### Exploring the Impact of WuMei Decoction and Probiotics on Colonic Polyp Patients
URL: https://microbiome.news/posts/exploring-the-impact-of-wumei-decoction-and-probiotics-on-colonic-poly
Section: Therapeutics | Published: 2026-08-10 | 3 min
Summary: A new study investigates the combined effects of modified WuMei decoction and Bifidobacterium capsules on patients post-endoscopic resection of colonic polyps.
Body: A recent study published in the Arab Journal of Gastroenterology explored the effects of a combined treatment involving modified WuMei decoction (MWMD) and Bifidobacterium triple viable (BTV) enteric-coated capsules on patients who had undergone endoscopic resection of colonic polyps. This research aimed to evaluate the clinical efficacy and impacts on intestinal microbiota, among other health indicators. Study Design and Methods The study enrolled 80 patients who had colonic polyps removed via endoscopic polypectomy. These patients were divided into two groups: a control group and an observation group. Both groups received BTV enteric-coated capsules, but the observation group also received MWMD. Researchers compared several parameters between the two groups, including baseline characteristics, postoperative recurrence rates, clinical efficacy, traditional Chinese medicine (TCM) syndrome scores, intestinal microbiota composition, serum inflammatory cytokines, gastrointestinal quality of life index (GLQI), intestinal mucosa repair, and postoperative complications. Importantly, baseline characteristics were similar between the two groups, ensuring that any differences observed could be attributed to the treatment rather than pre-existing differences between the patients. Key Findings The study found that at 12 months postoperatively, the observation group demonstrated a lower recurrence rate of polyps and superior clinical outcomes compared to the control group. Specifically, the observation group showed significant improvement in TCM symptom scores and a notable reduction in Escherichia coli levels. Additionally, there was a substantial increase in beneficial bacteria such as Bifidobacterium and Lactobacillus. Furthermore, the observation group exhibited higher GLQI scores, indicating a better quality of life related to gastrointestinal health. They also had substantially reduced serum inflammatory markers and better intestinal mucosal healing. The incidence of postoperative complications was lower in the observation group, suggesting that the combined treatment may aid in reducing such risks. Implications and Limitations The findings suggest that the combination of MWMD and BTV capsules may offer beneficial effects for patients recovering from colonic polyp removal, particularly in terms of enhancing intestinal mucosal repair and reducing postoperative complications. These results highlight the potential of integrating traditional Chinese medicine with probiotics to support intestinal health. However, the study has limitations that should be considered. The sample size of 80 patients is relatively small, which may affect the generalizability of the results. Additionally, the study design does not establish causation, only association, between the treatment and the observed outcomes. Further research with larger sample sizes and more rigorous study designs would be necessary to confirm these findings and better understand the mechanisms involved. For more on how probiotics can influence health, see our article on prebiotic, probiotic, and postbiotic definitions .
Sources: Impact of modified WuMei decoction combined with Bifidobacterium triple viable enteric-coated capsules on clinical efficacy and intestinal microbiota in patients after endoscopic resection of colonic polyps. — Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (2026) (https://pubmed.ncbi.nlm.nih.gov/42552184/)

### Exploring the Gut-Brain Connection in Crohn's Disease
URL: https://microbiome.news/posts/exploring-the-gut-brain-connection-in-crohn-s-disease
Section: Gut–Brain | Published: 2026-08-09 | 3 min
Summary: A new study investigates how the glymphatic system might link intestinal inflammation and sleep disturbances in Crohn's disease.
Body: Researchers have long been intrigued by the complex interactions between the gut and the brain, particularly in conditions like Crohn's disease (CD) where patients often experience sleep disturbances. A new study published in Academic Radiology sheds light on a potential mechanism involving the glymphatic system, which may provide a link between intestinal inflammation and sleep quality issues in CD. The Role of the Glymphatic System The glymphatic system is a brain-wide network that facilitates the clearance of waste products by utilizing the perivascular spaces. This system is analogous to the lymphatic system in the rest of the body and plays a crucial role in maintaining brain health. In this study, researchers focused on the diffusion tensor imaging analysis along the perivascular space (DTI-ALPS) index, which is a noninvasive method to assess glymphatic function. The study involved 90 patients with CD, divided equally into those with active disease and those in remission, alongside 50 healthy controls. All participants underwent comprehensive clinical screening, sleep quality evaluation using the Pittsburgh Sleep Quality Index, and magnetic resonance imaging (MRI) with DTI for ALPS index quantification. Additionally, patients with CD provided stool samples to measure fecal calprotectin levels, an indicator of intestinal inflammation. Key Findings and Implications The study found that patients with CD had a significantly reduced ALPS index compared to healthy controls, with those in the active disease state showing the most pronounced reduction. This suggests that impaired glymphatic function may be linked to both intestinal inflammation and sleep disturbances in CD. Interestingly, the ALPS index demonstrated moderate diagnostic utility in distinguishing between active and remitted CD, with an area under the curve of 0.785. Partial correlation analysis revealed a negative correlation between the ALPS index and both inflammatory markers and poor sleep quality. This indicates that as glymphatic function decreases, both inflammation and sleep quality worsen. Furthermore, mediation analysis showed that reduced ALPS statistically accounted for 25.22% of the association between intestinal inflammation and sleep disturbances. This suggests that the glymphatic system may be a modest but significant pathway connecting gut health and brain function in CD. Limitations and Future Directions While the study provides valuable insights, it is important to acknowledge its limitations. The research is cross-sectional, meaning it captures a single point in time and cannot establish causation. Additionally, the sample size, although substantial, may not fully represent the diverse population of CD patients. Prospective studies are needed to validate these findings and further explore the gut-brain perivascular pathway. Overall, this study highlights a potential mechanism through which the gut and brain may interact in Crohn's disease, offering a new perspective on the management of sleep disturbances in this condition. As our understanding of the gut-brain axis continues to evolve, such research could pave the way for novel diagnostic and therapeutic approaches. For more on the gut-brain axis, you might find our primer on the gut-brain axis informative.
Sources: Association of the DTI-ALPS Index with Sleep Disturbances and Intestinal Inflammation in Crohn's Disease: A Diffusion Tensor MRI Study. — Academic radiology (2026) (https://pubmed.ncbi.nlm.nih.gov/42570907/)

### The Interplay of Stress, Depression, and the Immune System
URL: https://microbiome.news/posts/the-interplay-of-stress-depression-and-the-immune-system
Section: Science | Published: 2026-08-08 | 3 min
Summary: A new review explores how stress, depression, and social relationships affect immune function and the gut microbiome, offering insights into the biobehavioral model of health.
Body: A review published in the Annual Review of Psychology delves into the intricate connections between stress, depression, and immune function, highlighting the role of psychoneuroimmunology in understanding these relationships. This field examines how psychological factors such as stress and depression influence immune and endocrine systems, and consequently, health outcomes. Psychosocial Factors and Immune Function The review synthesizes findings from various studies that demonstrate how psychosocial adversity, including stress and depression, can lead to significant changes in immune function. For instance, stressors such as examination stress, marital discord, and caregiving for individuals with dementia have been shown to predict increased susceptibility to infections, weaker responses to vaccines, and faster erosion of vaccine protection. Additionally, these stressors are associated with slower wound healing, heightened inflammation, and accelerated cellular aging. Depression, in particular, appears to sensitize immune function, resulting in larger inflammatory responses when individuals encounter stressors. This suggests that both stress and depression can have profound effects on the body's ability to manage inflammation and maintain immune health. The Role of Social Relationships Social relationships also play a critical role in shaping immune responses. The review highlights that loneliness, low social support, and distressed relationships can amplify stress reactivity. These social stressors are linked to greater inflammatory and metabolic vulnerabilities, including postprandial inflammatory and endothelial responses. This indicates that the quality of one's social environment can significantly impact immune function and overall health. Recent research has expanded these pathways to include the gut microbiome and intestinal permeability, commonly referred to as "leaky gut." This integration of microbial, neuroendocrine, and immune mechanisms underscores the complexity of the interactions between psychological factors and physiological health. A Biobehavioral Model of Health The evidence reviewed supports a biobehavioral model in which social stress accelerates immune aging and increases the risk for inflammation-related conditions. This model suggests that behavioral and nutritional interventions could potentially modify these trajectories, offering a framework for understanding how lifestyle factors influence health. However, it is important to note that this review primarily synthesizes existing research, and the findings should be interpreted with caution. The complex interactions between psychological and physiological factors mean that causation cannot always be established, and further research is needed to explore these relationships in more detail. For more on how stress affects the gut, see our post on early-life stress and the gut microbiome . Limitations and Future Directions While the review provides a comprehensive overview of the connections between stress, depression, and immune function, it also highlights some limitations. The complexity of these interactions means that establishing direct causation is challenging. Additionally, much of the research focuses on associations rather than mechanistic insights, indicating a need for further studies to unravel the underlying processes. Future research could benefit from exploring the specific mechanisms through which psychosocial factors influence immune function and the gut microbiome. Such investigations could provide a deeper understanding of the biobehavioral model and inform potential interventions aimed at mitigating the adverse effects of stress and depression on health.
Sources: Four Decades of Stress, Depression, and Close Relationships: Lessons from Psychoneuroimmunology. — Annual review of psychology (2026) (https://pubmed.ncbi.nlm.nih.gov/42566682/)

### Gastrointestinal Disorders Linked to Depression in Older Adults
URL: https://microbiome.news/posts/gastrointestinal-disorders-linked-to-depression-in-older-adults
Section: Gut–Brain | Published: 2026-08-07 | 3 min
Summary: A new study explores the connection between gastrointestinal diseases and persistent depressive symptoms in older adults across four countries.
Body: In a study published in the International journal of psychiatry in medicine , researchers investigated the relationship between gastrointestinal and hepatic diseases (GIHD) and long-term depressive symptom trajectories in older adults. The study analyzed data from four international aging cohorts: CHARLS (China), SHARE (Europe), HRS (United States), and KLOSA (South Korea), encompassing a total of 40,161 adults aged 60 years and older. The research aimed to understand how these physical health conditions might influence mental health outcomes over time. Identifying Depressive Trajectories The researchers employed a method called group-based trajectory modeling (GBTM) to identify distinct patterns of depressive symptoms over time. They found three primary trajectories across all cohorts: Stable Low, Increasing Mild, and Stable High. These trajectories represent varying levels of depressive symptoms, from consistently low to persistently high. To determine the impact of GIHD on these trajectories, the study used multinomial logistic regression, adjusting for baseline depressive symptoms and other covariates. The analysis revealed that individuals with GIHD were more likely to fall into the Stable High depressive symptom trajectory, with a pooled odds ratio (OR) of 1.73. This suggests a significant association between chronic gastrointestinal conditions and persistent severe depression in older adults. Cross-Cultural Consistency and Specific Findings One of the notable findings of the study was the cross-cultural consistency in the association between upper gastrointestinal disorders and depressive trajectories. The pooled OR for upper gastrointestinal disorders was 1.80, indicating a strong and consistent link across different cultural and healthcare settings. Interestingly, liver disease showed a significant association with depressive trajectories in the CHARLS cohort (China) but not in the KLOSA cohort (South Korea). This variation highlights the potential influence of cultural or healthcare differences on the relationship between liver disease and depression. The study also found that these associations were consistent across sexes, with no significant interaction effect based on gender. This suggests that the link between GIHD and depression is robust across different demographic groups. Implications and Limitations The findings of this study underscore the importance of considering physical health conditions, such as gastrointestinal disorders, in the context of mental health, particularly in older adults. The zero heterogeneity found for upper gastrointestinal disorders suggests a potential gut-brain axis mechanism, which could have implications for systematic depression screening in geriatric gastroenterology practice. However, there are limitations to consider. The study is observational, meaning it can identify associations but not causation. Additionally, while the use of multiple cohorts strengthens the findings, the results may still be influenced by unmeasured confounding factors. The researchers used inverse probability weighting and E-values to assess the robustness of their findings, but these methods cannot entirely eliminate the possibility of bias. Overall, this research provides valuable insights into the complex interplay between physical and mental health in older adults, highlighting the need for integrated healthcare approaches that consider both aspects. For more on the gut-brain connection, explore our gut-brain axis primer .
Sources: Gastrointestinal Diseases and Persistent Depressive Trajectories in Older Adults Across Four International Aging Cohorts. — International journal of psychiatry in medicine (2026) (https://pubmed.ncbi.nlm.nih.gov/42562402/)

### Prebiotic Supplementation Enhances Healing in Rat Colitis Model
URL: https://microbiome.news/posts/prebiotic-supplementation-enhances-healing-in-rat-colitis-model
Section: Science | Published: 2026-08-06 | 3 min
Summary: A new study investigates the impact of prebiotic supplementation on anastomotic healing in rats with colitis, highlighting changes in gut microbiota and improved recovery.
Body: Anastomotic leak is a significant concern in colorectal surgery, particularly for patients with inflammatory bowel disease (IBD). A new study published in Surgery explores the potential of prebiotic supplementation to enhance anastomotic healing in a rat model of experimental colitis. The research focuses on how preoperative prebiotic supplementation might modulate the gut microbiota and improve surgical outcomes. Study Design and Methods The researchers aimed to address the challenge of impaired anastomotic healing in the context of bacterial dysbiosis. They used a rat model to simulate colitis and subsequent colorectal surgery. The study involved two groups of rats: one receiving a standard diet and the other a diet supplemented with a complex prebiotic containing arabinogalactan, humic substances, and micronutrients. This dietary regimen was followed for four weeks before inducing colitis with dextran sulfate sodium (DSS). Fecal samples were collected for microbial analysis using 16S ribosomal ribonucleic acid gene sequencing. The severity of colitis was evaluated through symptoms, laboratory parameters, and histopathological changes. Following colon resection surgery, anastomotic healing was assessed using immunohistochemistry for specific markers, macroscopic assessment, bursting pressure tests, and a colorimetric hydroxyproline assay. Key Findings The study found that prebiotic supplementation protected against colitis-related microbial shifts. Notably, there was an increase in the abundance of Lachnospiraceae NK4A136 and a decrease in Romboutsia, which correlated with reduced colonic damage caused by DSS. These microbial changes were associated with improvements in all measured parameters, suggesting a protective effect of the prebiotic supplement. In terms of surgical outcomes, prebiotic pretreatment enhanced epithelial barrier integrity and strengthened the anastomosis. This was evidenced by favorable collagen homeostasis, which correlated with microbial diversity and led to accelerated recovery post-surgery. The findings indicate that the complex prebiotic supplement supports microbiota-targeted prehabilitation, potentially improving surgical outcomes in the context of colitis. Implications and Limitations These findings suggest that prebiotic supplementation could play a role in enhancing anastomotic healing by modulating the gut microbiota. This approach may offer a new avenue for improving surgical outcomes in patients with IBD, who are particularly vulnerable to impaired healing due to dysbiosis. However, it is important to note the limitations of this study. The research was conducted in a rat model, which may not fully replicate human physiology and disease. Additionally, the study's findings are preliminary and require further investigation in clinical settings to determine their applicability to human patients. The small sample size and the specific conditions of the animal model also limit the generalizability of the results. For more on the role of the gut microbiome in health, see our primer on the microbiome .
Sources: Preoperative prebiotic supplementation alleviates colitis and improves anastomotic healing associated with modulation of the gut microbiota in rats. — Surgery (2026) (https://pubmed.ncbi.nlm.nih.gov/42555996/)

### Cockroach Group Recognition Influenced by Faecal Odour and Learning
URL: https://microbiome.news/posts/cockroach-group-recognition-influenced-by-faecal-odour-and-learning
Section: Science | Published: 2026-08-05 | 3 min
Summary: Researchers explore how faecal odour preferences and learning affect group recognition in German cockroaches, revealing insights into their social behavior and microbiome acquisition.
Body: A new study published in Proceedings. Biological sciences investigates how German cockroaches, a subsocial omnivore, use faecal odour preferences and learning to recognize and affiliate with their group. This research sheds light on the complex social behaviors of these insects and their interactions with the microbial communities that inhabit their guts. Faecal Odour and Group Aggregation The study focuses on the role of faecal odours in attracting cockroaches to aggregations. These odours, which originate from the gut and faecal microbial communities, are influenced by behaviors such as coprophagy (the consumption of feces) and diet. The researchers found that different groups of cockroaches, when exposed to varying diets and coprophagy experiences, developed distinct faecal odour profiles. This diversity in odour profiles could potentially influence how cockroaches recognize and affiliate with their groups. In their experiments, the researchers manipulated the coprophagy and diet quality of gnotobiotic nymphs to create groups with unique faecal odour signatures. These nymphs were raised to adulthood, and their faeces were collected for further behavioral assays. The study revealed that naive nymphs, which lacked prior coprophagy experience, were equally attracted to faecal odours from all treatment groups. This suggests an innate attraction to conspecific faeces. Learned Preferences and Social Behavior Interestingly, the study found that experienced nymphs, which had undergone coprophagy, showed a preference for the faecal odour of their natal group over foreign groups. This indicates that these nymphs had developed a learned group-specific recognition. The researchers also conducted associative learning assays, where nymphs were conditioned to associate a specific faecal odour with a glucose reward. The nymphs then showed a preference for aggregating with the conditioned odour over novel odours. These findings suggest that aggregation in neonate cockroaches is influenced by both an innate attraction to conspecific faecal odour and learned preferences for specific odours encountered during coprophagy soon after hatching. This dual mechanism likely guides neonates towards their natal aggregations, facilitating the acquisition of a locally adapted gut microbial community. Implications and Limitations The study provides valuable insights into the social behavior of German cockroaches and the role of faecal odours in group recognition and aggregation. Understanding these mechanisms can help elucidate how cockroaches maintain their social structures and acquire beneficial microbial communities. However, the study has its limitations. The research was conducted under controlled laboratory conditions, which may not fully replicate the complexity of natural environments. Additionally, the study focused on a specific subsocial species, and the findings may not be directly applicable to other insect species with different social structures or ecological niches. Despite these limitations, the research highlights the intricate relationship between behavior, microbial communities, and social organization in cockroaches. Further studies could explore how these findings translate to other species and environments, providing a broader understanding of the ecological and evolutionary significance of faecal odour-mediated group recognition.
Sources: Group recognition in the German cockroach, a subsocial omnivore, is based on faecal odour preference that is modulated by coprophagy, diet and learning. — Proceedings. Biological sciences (2026) (https://pubmed.ncbi.nlm.nih.gov/42551892/)

### Osteopontin in Milk: Shaping Infant Microbiomes and Immunity
URL: https://microbiome.news/posts/osteopontin-in-milk-shaping-infant-microbiomes-and-immunity
Section: Science | Published: 2026-08-04 | 3 min
Summary: A new study explores how milk-derived osteopontin influences infant microbiomes and immune development, potentially offering insights into disease tolerance.
Body: A recent study published in Cell investigates the role of osteopontin (OPN), a protein found in breast milk, in shaping the infant microbiome and immune system. The research provides new insights into how breastfeeding may protect against severe lower respiratory infections (sLRIs) in infants, a leading cause of infant mortality. The study focuses on the interactions between milk-derived OPN, the microbiome, and immune development in neonatal mice. The Role of Osteopontin in Immune Development Osteopontin is highly expressed in colostrum, the first form of milk produced after birth. The study demonstrates that the absence of OPN in milk predisposes neonatal mice to viral and bacterial sLRIs. This increased susceptibility is linked to disruptions in dendritic cell (DC) hematopoiesis, the process by which new blood cells are formed, in the developing liver and lung. These findings suggest that OPN plays a crucial role in the early development of the immune system. In the study, researchers supplemented neonatal mice with oral OPN, which resulted in a reduction in disease severity. This amelioration was associated with an increased abundance of Lactobacillaceae in the gut and elevated levels of serum 3-phenyllactic acid (PLA). PLA acts as an agonist for the peroxisome proliferator-activated receptor gamma (PPARγ), a protein that regulates gene expression and plays a role in immune responses. Microbiome-Host Interactions The study highlights the complex interactions between the microbiome and host immune development. Supplementation with PLA or the PPARγ agonist rosiglitazone was shown to restore lung DC hematopoiesis. This process involved the recruitment of lymphoid-myeloid primed progenitors and the induction of a supportive lung niche, mediated by the chemokine ligand 25 (CCL25) derived from the airway epithelium. However, the protective effects of PLA-induced DC hematopoiesis and disease tolerance were reduced when plasmacytoid DCs were depleted, stem cell factor was neutralized, or the airway epithelial Flt3L gene was deleted. These findings suggest that multiple components of the immune system and microbiome are involved in the protective mechanisms conferred by milk OPN. Implications and Limitations This study provides valuable insights into the potential mechanisms by which breastfeeding may confer protection against infections in infants. By elucidating the role of OPN in microbiome-host interactions and immune development, the research highlights the importance of early nutritional and microbial exposures in shaping the immune system. However, there are limitations to this study. The research was conducted in neonatal mice, and while these findings provide a basis for understanding similar processes in humans, further research is needed to confirm these mechanisms in human infants. Additionally, the study focuses on associations rather than direct causation, and more work is required to fully understand the pathways involved. For those interested in the broader implications of microbiome research, our explainer on Akkermansia muciniphila offers insights into another important member of the gut microbiome.
Sources: Milk osteopontin alters the infant microbiome to drive DC hematopoiesis and disease tolerance. — Cell (2026) (https://pubmed.ncbi.nlm.nih.gov/42546687/)

### Rhizosphere Microbiome Diversity in Monotropastrum Species
URL: https://microbiome.news/posts/rhizosphere-microbiome-diversity-in-monotropastrum-species
Section: Science | Published: 2026-08-03 | 3 min
Summary: A new study explores the microbial communities in the rhizospheres of two Monotropastrum species, revealing key soil factors influencing their assembly.
Body: In a study published in the Journal of microbiology (Seoul, Korea) , researchers investigated the rhizosphere microbial communities of two closely related plant species, Monotropastrum humile (Mh) and Monotropastrum humile var. glaberrima (Mhg). The study aimed to understand how these communities are assembled and which soil factors play a crucial role in this process. Microbial Community Profiling The researchers utilized Illumina high-throughput sequencing to profile the bacterial and fungal communities in the rhizospheres of the two Monotropastrum species. This advanced sequencing technology allowed for a comprehensive analysis of the microbial populations present in the soil surrounding the plant roots. At the phylum level, the bacterial communities in both species were predominantly composed of Proteobacteria and Acidobacteriota. On the fungal side, Ascomycota and Basidiomycota were the dominant groups. Despite these overarching similarities, the study found distinct differences in the microbial communities associated with each plant species. Species-Specific Microbial Enrichment The study revealed that while Mh and Mhg shared several dominant bacterial and fungal genera, they also exhibited species-specific enrichment patterns. For instance, Mhg had higher abundances of the bacterial genus Acidothermus and the fungal genus Lactarius. In contrast, Mh showed a preference for enriching bacterial genera such as Cedecea and Klebsiella, and the fungal genus Russula. These differences suggest that the identity of the host plant plays a significant role in shaping the rhizosphere microbial community. The study highlights the complex interactions between plant species and their associated microbial communities, which are influenced by both the host and the surrounding soil environment. Soil Environmental Drivers In addition to host identity, the study identified several soil factors that contribute to the assembly of rhizosphere microbial communities. For bacterial communities, pH, soil organic matter (SOM), available potassium (AK), and available phosphorus (AP) were significant drivers. Fungal communities, on the other hand, were primarily influenced by pH, alkali-hydrolyzable nitrogen (AN), and SOM. These findings underscore the importance of soil chemistry in determining the composition of microbial communities in the rhizosphere. The study suggests that manipulating these soil factors could potentially influence the microbial assembly and, consequently, plant health and growth. Implications and Limitations The study provides valuable insights into the factors that shape rhizosphere microbial communities, with potential implications for the conservation and cultivation of mycoheterotrophic plants. The identification of host-associated microbial taxa, particularly key mycorrhizal fungi, may offer new opportunities for developing microbial inoculants. However, the study has its limitations. The research was conducted in a specific geographic region (Zhejiang Province, China), which may limit the generalizability of the findings to other environments. Additionally, while the study identifies associations between soil factors and microbial communities, it does not establish causation. Further research is needed to explore these relationships in different contexts and to determine the functional roles of the identified microbial taxa.
Sources: Rhizosphere microbiome differentiation and soil environmental drivers in two Monotropastrum species. — Journal of microbiology (Seoul, Korea) (2026) (https://pubmed.ncbi.nlm.nih.gov/42543182/)

### Gut Microbiota and Metabolomics Unveil Sauropi Folium's Laxative Mechanism
URL: https://microbiome.news/posts/gut-microbiota-and-metabolomics-unveil-sauropi-folium-s-laxative-mecha
Section: Science | Published: 2026-08-02 | 3 min
Summary: A new study explores how Sauropi Folium aqueous extract may alleviate constipation through complex interactions with gut microbiota and metabolic pathways.
Body: In a study published in Fitoterapia , researchers have delved into the mechanisms by which Sauropi Folium aqueous extract (SSAE) might alleviate constipation. Sauropi Folium, derived from the dried leaves of Sauropus spatulifolius Beille, has been traditionally used to treat cough and constipation. However, its chemical makeup and mechanisms of action have remained largely unexplored until now. Decoding the Chemical Profile The researchers began by analyzing the chemical profile of SSAE using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS). This analysis identified 55 different chemical components within the extract. To predict how these components might exert their effects, the team employed network pharmacology, a method that helps in identifying potential targets and pathways. The analysis suggested that SSAE might influence constipation through several pathways, including those involved in cancer, HIF-1, and PI3K-AKT signaling. Exploring Effects in a Rat Model To further investigate, the researchers used a slow transit constipation (STC) rat model induced by loperamide hydrochloride. This model allowed them to assess the physiological effects of SSAE. The study found that SSAE effectively alleviated constipation symptoms in these rats. It also had notable effects on gastrointestinal hormones, neurotransmitters, and improved the colonic pathological morphology. At the microbiota level, SSAE increased the presence of beneficial bacteria such as the Lachnospiraceae_NK4A136_group while decreasing potential pathogenic bacteria including Allobaculum , Bifidobacterium , Desulfovibrio , and HT002 . This shift in microbial composition suggests a potential mechanism by which SSAE might exert its laxative effects. Metabolomics and Gut Microbiota Interactions Beyond microbiota changes, the study employed integrated metabolomics to understand the metabolic changes induced by SSAE. The extract was found to upregulate serum glutamine and fecal riboflavin, which are involved in glutamate metabolism, primary bile acid biosynthesis, and purine-polyamine metabolism pathways. These metabolic pathways are crucial for promoting serotonin (5-HT) synthesis, improving intestinal motility, and maintaining mucosal barrier function. These findings highlight SSAE's potential as a natural remedy for constipation through its multi-level interactions involving chemical constituents, target pathways, gut microbiota, and metabolic networks. However, it is important to note that these results are based on an animal model, which may not fully replicate human physiology. Limitations and Future Directions While this study provides valuable insights into the potential mechanisms of SSAE, it is important to recognize its limitations. The research was conducted on a rat model, which, while informative, does not always translate directly to human outcomes. Furthermore, the study's focus on specific pathways and bacteria may overlook other contributing factors. Future research involving human clinical trials would be necessary to confirm these findings and fully understand the implications of SSAE use in humans. For more on the complexities of gut microbiota, you might find our article on what is the microbiome useful.
Sources: Integrated analysis of gut microbiota and metabolomics reveals the laxative mechanism of Sauropi Folium aqueous extract. — Fitoterapia (2026) (https://pubmed.ncbi.nlm.nih.gov/42542303/)

### FDA-Approved Fecal Microbiota Therapies for C. difficile
URL: https://microbiome.news/posts/fda-approved-fecal-microbiota-therapies-for-c-difficile
Section: Therapeutics | Published: 2026-08-01 | 3 min
Summary: A new review highlights FDA-approved fecal microbiota therapies that reduce recurrence of C. difficile infection. The review explores clinical trials, safety, and practical considerations.
Body: Recurrent Clostridioides difficile infection (CDI) is a persistent challenge, even with optimized antibiotic treatments. A new review published in Gastroenterology Clinics of North America explores two FDA-approved fecal microbiota-based therapies designed to address this issue: fecal microbiota, live-jslm (Rebyota / RBL) and fecal microbiota spores, live-brpk (Vowst / VOS). These therapies aim to reduce recurrence of CDI when administered after standard antibiotic regimens. Understanding the Therapies The review delves into the clinical development programs that support these fecal microbiota-based products. It details pivotal randomized trials and open-label extensions that provide evidence for their efficacy. The therapies work by restoring colonization resistance in the gut, which is crucial for preventing the recurrence of CDI. This is achieved by reintroducing a diverse community of gut bacteria that can outcompete C. difficile for resources and space, thereby reducing the likelihood of infection recurrence. Rebyota and Vowst are standardized products derived from donor fecal material. They are administered after the completion of standard antibiotic treatments for CDI. This timing is key, as it allows the antibiotics to reduce the C. difficile population before the fecal microbiota products help re-establish a healthy microbial community. Clinical Trials and Safety The review highlights the robust clinical trials that have supported the approval of these therapies. These trials include randomized studies that demonstrated a significant reduction in CDI recurrence among patients treated with the fecal microbiota products compared to those who did not receive them. Open-label extensions further confirmed the durability of these effects over time. Safety outcomes were also a critical aspect of the clinical evaluations. The review discusses how these therapies have been generally well-tolerated by patients, with safety profiles comparable to other medical interventions for CDI. However, as with any medical treatment, monitoring for potential adverse effects remains important. Practical Implementation and Real-World Evidence Beyond clinical trials, the review addresses the practical aspects of implementing these therapies in real-world settings. This includes considerations for patient selection and the optimal timing for administration post-antibiotics. The review also discusses diagnostic considerations that can help identify patients who are most likely to benefit from these therapies. Emerging real-world evidence is beginning to corroborate the findings from clinical trials, suggesting that these therapies can effectively reduce CDI recurrence in broader patient populations. This real-world data is invaluable for healthcare providers as they integrate these therapies into standard practice. Limitations and Future Directions While the review provides a comprehensive overview of these fecal microbiota-based therapies, it also acknowledges certain limitations. For instance, the data primarily comes from clinical trials with specific inclusion criteria, which may not fully represent all patient populations. Additionally, while the therapies have shown promise in reducing CDI recurrence, they do not address the initial infection, which still requires antibiotic treatment. Future research may focus on optimizing these therapies further, exploring their use in combination with other treatments, and expanding the understanding of their long-term effects. As the field of microbiome-based therapeutics continues to evolve, these therapies represent a significant step forward in the management of recurrent CDI.
Sources: Food and Drug Administration-Approved Fecal Microbiota-Based Therapies for Recurrent Clostridioides difficile Infection. — Gastroenterology clinics of North America (2026) (https://pubmed.ncbi.nlm.nih.gov/42538093/)

### Exploring the Gut-Bone Connection: Microbiota's Role in Fracture Risk
URL: https://microbiome.news/posts/exploring-the-gut-bone-connection-microbiota-s-role-in-fracture-risk
Section: Science | Published: 2026-07-31 | 3 min
Summary: A new review examines the relationship between gut microbiota and fracture risk, emphasizing the need for targeted interventions to enhance bone and muscle health.
Body: As the global population ages, the incidence of bone fractures is on the rise, presenting a significant health burden and increasing healthcare costs. A new review published in Nature reviews. Endocrinology explores the intriguing links between the gut microbiota and fracture risk, highlighting the potential for microbiota-based interventions to improve bone and muscle health. The Role of Bone Mineral Density and Muscle Function Bone mineral density (BMD), bone quality, and muscle function are critical factors influencing fracture risk. While BMD is a well-known determinant of bone strength, muscle function plays a crucial role in preventing falls, which are a common precursor to fractures. The review underscores that the gut microbiota has been established as a regulator of these parameters in rodent models, primarily through interactions with the immune system and the production of short-chain fatty acids. In humans, however, the association between gut microbiota and muscle mass, muscle function, and fracture risk appears to be more robust than the correlation with BMD alone. This suggests that while bone density is important, muscle health and function may be more directly influenced by the gut microbiota, thus impacting fracture risk. Probiotics and Beyond: Potential Interventions First-generation probiotic interventions have shown modest effects on BMD in clinical trials, indicating that while they may play a role, more targeted approaches are needed. The review calls for the development of second-generation probiotics and other microbiota-based interventions. These could include personalized dietary strategies, synbiotics, postbiotics, and species-specific antibiotics, all aimed at enhancing both BMD and muscle function. Such interventions could potentially reduce fracture risk by addressing both bone and muscle health. The review suggests that future research should focus on these targeted strategies to maximize the benefits of gut microbiota manipulation. Challenges and Future Directions Despite the promising insights, there are limitations to the current understanding of the gut-bone connection. Much of the existing evidence comes from rodent studies, and while these provide valuable insights, human physiology can differ significantly. Additionally, the effects observed in clinical trials with probiotics have been modest, indicating that more precise interventions are necessary. The review emphasizes the need for further research to develop and test these targeted interventions. By better understanding the specific interactions between the gut microbiota and bone and muscle health, researchers hope to pave the way for effective strategies to reduce fracture risk in aging populations. For more on the role of short-chain fatty acids in health, see our primer on short-chain fatty acids .
Sources: Links between bone fractures and the gut microbiota. — Nature reviews. Endocrinology (2026) (https://pubmed.ncbi.nlm.nih.gov/42533136/)

### Labor Before Delivery Linked to Lower NEC Risk in VLBW Infants
URL: https://microbiome.news/posts/labor-before-delivery-linked-to-lower-nec-risk-in-vlbw-infants
Section: Science | Published: 2026-07-30 | 3 min
Summary: A new study explores how labor prior to delivery may influence the incidence of necrotizing enterocolitis in very low birth weight infants.
Body: Necrotizing enterocolitis (NEC) is a severe gastrointestinal condition that primarily affects premature infants. Despite extensive research, the exact causes of NEC remain elusive, though it is understood to be multifactorial. A new study published in the Journal of neonatal-perinatal medicine investigates the potential impact of labor before delivery on the incidence of NEC in very low birth weight (VLBW) infants. Study Design and Methods This retrospective cohort study focused on VLBW infants, defined as those weighing less than 1500 grams, born at a single center between March 2012 and December 2023. The study included infants born between 23 0/7 and 34 6/7 weeks of gestation, excluding those with congenital anomalies or who died before admission. The researchers aimed to determine whether labor prior to delivery influenced the likelihood of developing NEC. Labor was characterized by uterine contractions with cervical dilation or effacement. In cases where cervical examination was not documented, labor was inferred from the presence of regular contractions lasting more than an hour before delivery. The researchers used multivariable logistic regression to assess the association between labor before delivery and NEC, adjusting for various baseline differences such as gestational age, birth weight, and maternal health conditions. Key Findings Out of 1,951 infants included in the study, 1,175 (60.2%) were exposed to labor before delivery. The analysis revealed that infants exposed to labor had significantly lower odds of developing NEC compared to those who were not exposed. The odds ratio (OR) for NEC in the labor-exposed group was 0.606, with a 95% confidence interval (CI) of 0.407 to 0.902, and a p-value of 0.01. After adjusting for potential confounding factors, the association remained significant, with an adjusted OR of 0.614 (95% CI: 0.384-0.983, p = 0.04). Interestingly, the study found no difference in the incidence of surgical NEC between the groups. This suggests that while labor may influence the overall risk of NEC, it does not appear to affect the severity of the condition once it develops. Implications and Limitations The findings of this study highlight the potential importance of perinatal microbial exposures, which may be influenced by labor, in the development of NEC. This could open new avenues for risk stratification and prevention strategies in vulnerable populations. The study suggests that labor before delivery may play a protective role, potentially through mechanisms related to the gut microbiome. However, there are limitations to consider. The study was conducted at a single center, which may limit the generalizability of the findings. Additionally, as a retrospective cohort study, it can only establish associations rather than causation. The reliance on documented labor signs could also introduce variability in how labor was assessed across cases. Overall, while the study provides valuable insights, further research is needed to explore the underlying mechanisms and to confirm these findings in broader and more diverse populations. For more on the role of the gut microbiome in neonatal health, readers might find our exploration of gut microbiota's role in neonatal jaundice informative.
Sources: Impact of labor before delivery on necrotizing enterocolitis in very low birth weight infants. — Journal of neonatal-perinatal medicine (2026) (https://pubmed.ncbi.nlm.nih.gov/42527892/)

### Gut Microbiota's Role in Neonatal Jaundice Explored
URL: https://microbiome.news/posts/gut-microbiota-s-role-in-neonatal-jaundice-explored
Section: Science | Published: 2026-07-29 | 3 min
Summary: A new study investigates the causal relationships between gut microbiota, inflammatory factors, and neonatal jaundice using Mendelian Randomization.
Body: Neonatal jaundice is a prevalent condition affecting a significant proportion of newborns, with approximately 60% of full-term infants and 80% of preterm infants experiencing it. While most cases resolve spontaneously, some progress to clinically significant hyperbilirubinemia (CSH), necessitating medical interventions such as phototherapy or exchange transfusion to prevent neurotoxic injury. In this context, a study published in The journal of maternal-fetal & neonatal medicine explores the potential causal associations between gut microbiota, inflammatory factors, and neonatal jaundice. Understanding the Role of Gut Microbiota The gut microbiota is increasingly recognized for its crucial role in human health, influencing various physiological processes and disease mechanisms. Inflammatory mediators, which modulate immune system function, often play a part in the body's response to illness or injury. This study aimed to investigate the interplay between gut microbiota, inflammatory factors, and neonatal jaundice, potentially informing the development of new therapeutic strategies. Researchers employed Mendelian Randomization (MR), a method that uses genetic variants as instrumental variables (IVs) to infer causal relationships. They examined 418 gut microbiota taxa and 91 inflammatory factors to assess their associations with clinically significant neonatal hyperbilirubinemia. Five well-established MR methods were applied to evaluate these potential causal links. Key Findings and Implications The analysis identified ten bacterial taxa associated with neonatal jaundice. Notably, the genus Slackia was found to have a protective effect against the condition, while Adlercreutzia was linked to an increased risk. Additionally, significant correlations were observed between Adlercreutzia and three inflammatory markers: β-nerve growth factor (NGF), C-X-C motif chemokine 1 (CXCL1), and interleukin-6 (IL-6). These findings provide evidence supporting associations between specific gut microbiota taxa and neonatal jaundice, as well as potential links with inflammatory markers. However, the study's results are hypothesis-generating and should be interpreted with caution. The gut microbiome instruments were derived from adult cohorts rather than neonatal ones, highlighting a key limitation of the study. Limitations and Future Directions While the study offers valuable insights, it does not support immediate clinical recommendations regarding probiotics or antibiotics in newborns. The findings underscore the need for further research, particularly mechanistic and pediatric validation studies, to better understand the role of gut microbiota in neonatal jaundice. Additionally, the use of Mendelian Randomization, while a powerful tool for inferring causality, relies on the assumption that the genetic variants used as instrumental variables are valid and not influenced by confounding factors. As such, the results should be viewed as preliminary and require further validation through additional studies. For those interested in learning more about the complex interactions between the gut microbiome and health, our introduction to the microbiome provides a comprehensive overview.
Sources: Causal associations between gut microbiota and inflammatory factors in neonatal jaundice: a Mendelian randomization study. — The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2026) (https://pubmed.ncbi.nlm.nih.gov/42521607/)

### Early-Life Stress Alters Gut Microbiome in Rats, Study Finds
URL: https://microbiome.news/posts/early-life-stress-alters-gut-microbiome-in-rats-study-finds
Section: Science | Published: 2026-07-28 | 3 min
Summary: Research using rat models reveals that early-life stress can cause sex-dependent changes in the gut microbiome during adolescence, highlighting potential pathways for further investigation.
Body: A new study published in the Journal of neurochemistry explores how early-life stress (ELS) affects the gut microbiome in rats, providing insights into the complex interactions between stress, gut health, and potential long-term physiological outcomes. The researchers used rat models to examine the effects of prenatal and postnatal stress on the gut microbiome during adolescence, focusing on the overall community structure rather than individual microbial taxa. Investigating Stress and Microbiome Interactions Previous research has suggested that ELS can increase the risk of developing mental health disorders later in life. The hypothesis is that stress during critical developmental periods might disrupt the gut microbiome, which could, in turn, affect the development of the neuroendocrine and immune systems. However, the specific microbial taxa and pathways involved in these processes have not been well characterized. In this study, researchers exposed adolescent male and female rats to three different stress conditions: (i) early postnatal exposure to dexamethasone (DEXA), a synthetic glucocorticoid, or a saline control; (ii) prenatal stress (PRS) and controls; and (iii) postnatal stress (POS) and controls. They then assessed the gut microbiome composition using 16S rRNA Nanopore sequencing of DNA extracted from faecal pellets. Findings and Implications The study found that ELS induces model-specific and sex-dependent changes in the gut microbiome composition. Notably, the changes were more pronounced at the level of overall community structure rather than individual taxa. Among the stress models, DEXA exposure produced the most consistent compositional signature, particularly in male rats. In contrast, PRS showed minimal detectable effects, while POS exhibited a more heterogeneous response characterized by increased dispersion and limited taxonomic shifts. These findings suggest that ELS can lead to subtle but significant changes in the gut microbiome, which may contribute to long-term physiological outcomes. The study highlights the importance of integrating beta-diversity analyses with machine learning approaches to identify reproducible microbiome patterns associated with ELS. Such methodologies could be crucial in future research to understand how these microbial signatures influence health over time. Limitations and Future Directions While the study provides valuable insights into the effects of ELS on the gut microbiome, it also has limitations. The research was conducted using rat models, which, although informative, may not fully translate to human biology. Additionally, the study focused on adolescent rats, leaving questions about how these findings might apply across different life stages. Further research in larger and longitudinal cohorts is necessary to determine the broader implications of these findings. Such studies could help clarify how early-life microbial changes might influence long-term health outcomes and whether similar patterns are observable in humans. For more on how the gut microbiome interacts with the brain and influences behavior, see our article on psychobiotics and mental health .
Sources: Effect of Prenatal and Postnatal Stress in Rats on the Gut Microbiome in Adolescence. — Journal of neurochemistry (2026) (https://pubmed.ncbi.nlm.nih.gov/42509593/)

### Chenodeoxycholic Acid's Role in Tumor Immunity Explored
URL: https://microbiome.news/posts/chenodeoxycholic-acid-s-role-in-tumor-immunity-explored
Section: Science | Published: 2026-07-27 | 3 min
Summary: A new study investigates how chenodeoxycholic acid influences tumor immunity through dendritic cells and TGR5 signaling, offering insights into potential cancer therapies.
Body: In a study published in Signal transduction and targeted therapy , researchers explored the role of chenodeoxycholic acid (CDCA), a metabolic modulator, in enhancing antitumor immunity. The study highlights the potential of CDCA to modulate immune responses in tumor-bearing mice, offering insights into novel therapeutic strategies for cancer treatment. Mechanisms of CDCA in Tumor Immunity The study focuses on conventional type 1 dendritic cells (cDC1s), which are crucial for initiating CD8+ T-cell-mediated antitumor immunity. These cells are known to be integral to the effectiveness of immunotherapy. Researchers found that CDCA, when administered orally, accumulates in the tumor interstitial fluid as its metabolite, taurochenodeoxycholic acid (TCDCA). This accumulation enhances the antitumor functions of both cDC1s and CD8+ T cells through a mechanism that does not depend on the gut microbiota. The study identified that CDCA exerts its effects through TGR5 signaling. TGR5, a G protein-coupled receptor, plays a role in enhancing the functionality of cDC1s, which in turn promotes the proliferation and activation of tumor-specific CD8+ T cells. This signaling pathway appears to be a key mechanism by which CDCA modulates immune responses to tumors. Clinical Correlations and Implications In addition to the findings in mice, the study also conducted a clinical correlation analysis using human tumor specimens. The analysis revealed a positive association between the expression of TGR5 and the levels of HLA-A/B/C/E/F/H, which are important for immune recognition. Notably, higher TGR5 expression was associated with improved overall patient survival, suggesting that TGR5 could serve as a biomarker for patient prognosis. Furthermore, the study demonstrated that CDCA has synergistic effects when used in combination with anti-PD-1 immunotherapy and a poly I:C adjuvant. This combination led to significant tumor growth suppression and enhanced antitumor immune responses, indicating that CDCA could potentially be integrated into existing immunotherapy regimens to improve outcomes. Limitations and Future Directions While the findings are promising, it is important to note the limitations of the study. The research was conducted primarily in animal models, which may not fully replicate human tumor biology. Additionally, while associations between TGR5 expression and patient survival were observed, these findings are correlative and do not establish causation. Further research is needed to validate these results in clinical settings and to explore the potential of CDCA and its derivatives as therapeutic agents in human cancer treatment. Overall, this study provides valuable insights into the immunoregulatory mechanisms of CDCA and highlights its potential role in cancer immunotherapy. As research continues, CDCA may emerge as a promising candidate for enhancing immune responses in cancer patients, particularly in those with tumors that are resistant to current therapies.
Sources: Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming. — Signal transduction and targeted therapy (2026) (https://pubmed.ncbi.nlm.nih.gov/42503514/)

### Gut Microbiome Signatures May Predict Kidney Transplant Rejection
URL: https://microbiome.news/posts/gut-microbiome-signatures-may-predict-kidney-transplant-rejection
Section: Diagnostics | Published: 2026-07-26 | 3 min
Summary: A new study suggests that pre-transplant gut microbiome profiles could help predict early acute rejection in kidney transplant recipients, offering a potential tool for improved risk stratification.
Body: In the realm of kidney transplantation, early detection of acute rejection remains a significant challenge. Traditional diagnostic tools often identify rejection only after irreversible damage has occurred to the transplanted organ. A study published in the American Journal of Transplantation explores the potential of the gut microbiome as a predictive tool for early acute rejection, offering a novel approach to pre-transplant risk assessment. The Role of the Gut Microbiome The gut microbiome, a complex community of microorganisms residing in the digestive tract, plays a crucial role in modulating immune homeostasis. Researchers hypothesized that the composition and functional profiles of the gut microbiome before transplantation could provide insights into the likelihood of early acute rejection. To test this hypothesis, they conducted shotgun metagenomic sequencing on pre-transplant stool samples from 78 kidney transplant recipients. Among these participants, 26 individuals (33.3%) experienced biopsy-proven early acute rejection. By comparing the microbiome profiles of those who experienced rejection with those who did not, the researchers identified specific microbial signatures associated with rejection risk. Key Findings and Predictive Models The study revealed that three microbial taxa, including Phascolarctobacterium faecium , were significantly reduced in individuals who experienced rejection. At the gene level, the enzyme mcmB, involved in propionate biosynthesis, was identified as a key factor, reaching statistical significance in the pre-specified short-chain fatty acid (SCFA) panel with an adjusted q-value of 0.018. To further explore these findings, the researchers developed stepwise Random Forest models incorporating microbiome data. These models demonstrated improved predictive accuracy over clinical-only models, with the area under the curve (AUC) increasing from 0.565 to 0.765. Notably, the models maintained robust performance across different rejection subtypes, achieving an AUC of 0.74 for TCMR-spectrum rejection and 0.85 for ABMR rejection. In a temporal validation cohort, the models achieved an AUC of 0.721, demonstrating improved reclassification and clinical net benefit at risk thresholds between 0.2 and 0.5. Implications and Limitations The findings of this study suggest that pre-transplant gut microbiome signatures could serve as an independent predictor of early acute rejection in kidney transplant recipients. By integrating microbiome data into pre-transplant risk stratification models, clinicians may be able to identify high-risk patients more effectively, potentially guiding personalized management strategies. However, it is important to acknowledge the limitations of this research. The study's sample size was relatively small, with only 78 participants, which may limit the generalizability of the findings. Additionally, while the study establishes an association between microbiome profiles and rejection risk, it does not prove causation. Further research with larger cohorts and diverse populations is needed to validate these findings and explore the underlying mechanisms driving these associations. For more on the role of short-chain fatty acids in health, you may find our in-depth article informative.
Sources: Pretransplant Gut Microbiome Signatures Predict Early Acute Rejection After Kidney Transplantation. — American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2026) (https://pubmed.ncbi.nlm.nih.gov/42501920/)

### Heavy Metals and Cancer: Unraveling Molecular Mechanisms
URL: https://microbiome.news/posts/heavy-metals-and-cancer-unraveling-molecular-mechanisms
Section: Science | Published: 2026-07-25 | 3 min
Summary: A new review explores the complex ways heavy metals contribute to cancer, highlighting molecular interactions and the role of the gut microbiome.
Body: Heavy metals such as arsenic, cadmium, chromium, nickel, lead, and mercury are well-known human carcinogens. However, the precise molecular mechanisms by which these metals contribute to cancer development remain incompletely understood. A study published in Toxicology and Industrial Health provides a comprehensive review of the current evidence, shedding light on how these metals induce carcinogenic effects through various molecular pathways. Understanding the Molecular Pathways The review highlights several key mechanisms by which heavy metals can lead to cancer. These include the induction of reactive oxygen species (ROS), oxidative stress, DNA damage, mitochondrial dysfunction, and endoplasmic reticulum stress. Additionally, alterations in apoptotic regulators such as p53, Bax, and Bcl-2 play a significant role. Each metal exhibits specific differences in genotoxic versus cytotoxic mechanisms, which are crucial for understanding their carcinogenic potential. One notable finding is the metal-specific differences in how these mechanisms operate. For instance, cadmium and arsenic co-exposure produces synergistic DNA damage that is three to five times greater than predicted from the effects of each metal individually. This occurs through concurrent p53 dysfunction and ROS overload, underscoring the complexity of metal interactions in carcinogenesis. Exploring Metal Mixtures and Interactions The review also delves into the toxicodynamics of metal mixtures, an area that has been relatively underexplored. It notes that combinations of metals such as arsenic, cadmium, chromium, and lead can produce interaction profiles that pose greater risks for neurological and genotoxic effects compared to renal or cardiovascular endpoints. This insight is crucial for assessing real-world exposure scenarios where individuals are often exposed to multiple metals simultaneously. The role of endogenous protective responses, such as metallothionein sequestration and antioxidant pathways, is also considered. These natural defense mechanisms can modulate the bioavailability and carcinogenic potential of metals, highlighting the body's capacity to counteract some of the harmful effects. The Gut Microbiome's Role and Emerging Technologies An intriguing aspect of the review is the evaluation of the gut microbiome's interactions with heavy metals. The microbiome may influence metal bioavailability and, consequently, their carcinogenic potential. This area of research is still emerging, but it holds promise for understanding how gut health can impact metal toxicity. The review also discusses the limitations of traditional animal models in assessing the risks of metal mixtures. It suggests that emerging technologies, such as single-cell sequencing, CRISPR-based functional genomics, and organ-on-chip platforms, could help fill current knowledge gaps. These advanced tools may provide more accurate models for studying the complex interactions between metals and biological systems. For additional insights into how the microbiome interacts with various substances, you might explore our post on what is the microbiome . Limitations and Future Directions While the review offers a comprehensive synthesis of current knowledge, it also acknowledges certain limitations. The complexity of metal interactions and the variability in individual responses pose challenges for definitive conclusions. Moreover, the reliance on animal models, which may not fully replicate human exposure scenarios, limits the direct applicability of some findings. Future research is needed to further elucidate the molecular mechanisms of metal-induced carcinogenesis, particularly in the context of metal mixtures and microbiome interactions. As new technologies continue to evolve, they may offer more refined tools for understanding these complex processes.
Sources: Molecular mechanisms of heavy metal-induced cancer: Insights from animal models and human implications. — Toxicology and industrial health (2026) (https://pubmed.ncbi.nlm.nih.gov/42498637/)

### Antibiotic Resistance in Gut Microbiota of Pediatric COVID-19 Patients
URL: https://microbiome.news/posts/antibiotic-resistance-in-gut-microbiota-of-pediatric-covid-19-patients
Section: Science | Published: 2026-07-24 | 3 min
Summary: A new study investigates the prevalence of multidrug-resistant Klebsiella pneumoniae in the gut microbiota of pediatric COVID-19 patients, highlighting the need for improved infection control measures.
Body: A study published in BMC Microbiology has shed light on the concerning prevalence of multidrug-resistant (MDR) Klebsiella pneumoniae in the gut microbiota of pediatric patients hospitalized with COVID-19. This research highlights the potential risks associated with antibiotic-resistant bacteria in vulnerable populations, particularly during the pandemic. Understanding the Study The study was conducted as a cross-sectional analysis at a tertiary pediatric hospital in Fayoum, Egypt, between October 2020 and March 2022. Researchers collected fecal samples from 71 hospitalized pediatric COVID-19 patients to identify the presence of K. pneumoniae using standard microbiological methods. The focus was on two specific types of resistant strains: carbapenem-resistant K. pneumoniae (CRKP) and extended-spectrum β-lactamase-producing K. pneumoniae (ESBL-KP). Antimicrobial susceptibility testing was performed following Clinical and Laboratory Standards Institute (CLSI) guidelines. The study also assessed the production of ESBL and carbapenemase enzymes phenotypically and identified resistance genes using PCR techniques. Additionally, the ability of the bacteria to form biofilms was evaluated using a microtiter plate method. Key Findings The study found that K. pneumoniae was present in 36 out of 71 patients, which equates to a prevalence rate of 50.7%. Among the isolated strains, 22 were identified as CRKP and 14 as ESBL-KP. Notably, all isolates remained susceptible to colistin, an antibiotic often used as a last resort. CRKP strains demonstrated a significantly higher rate of resistance to fluoroquinolones and amikacin compared to ESBL-KP strains. The study identified the presence of the bla NDM gene in 54.5% of CRKP isolates and the bla KPC gene in 45.5% of these isolates. In both CRKP and ESBL-KP groups, ESBL-associated genes bla CTX-M , bla TEM , and bla SHV were prevalent. Furthermore, biofilm formation was common among both CRKP and ESBL-KP isolates. Implications and Limitations The study underscores the high prevalence of fecal carriage of MDR K. pneumoniae in pediatric COVID-19 patients, driven by carbapenemase-producing strains. This finding is significant as it highlights the potential for these resistant strains to contribute to extraintestinal infections, underscoring the necessity for routine colonization surveillance and optimized antimicrobial stewardship in pediatric healthcare settings. However, the study has limitations. The sample size was relatively small, which may affect the generalizability of the findings. Additionally, the cross-sectional design of the study means that it can only demonstrate associations rather than causation. Further research with larger sample sizes and longitudinal designs would be beneficial to confirm these findings and explore their implications further. For more context on how antibiotics can impact the gut microbiome, you can explore our article on antibiotics and gut microbiome recovery .
Sources: Molecular and phenotypic profiles of carbapenem- and third-generation cephalosporin-resistant Klebsiella pneumoniae isolates from the fecal microbiota of pediatric patients with COVID-19. — BMC microbiology (2026) (https://pubmed.ncbi.nlm.nih.gov/42493779/)

### CAM-Net: A New Tool for Understanding Microbial Communities
URL: https://microbiome.news/posts/cam-net-a-new-tool-for-understanding-microbial-communities
Section: Science | Published: 2026-07-23 | 3 min
Summary: A new study introduces CAM-Net, a context-aware framework that identifies reliable microbial relationships by considering community-level dependencies.
Body: Understanding the complex interactions within microbial communities is crucial to advancing microbiome research. A study published in Briefings in Bioinformatics introduces CAM-Net, a novel context-aware framework designed to identify reliable microbial relationships by considering the broader community context, rather than relying solely on isolated pairwise metrics. Beyond Pairwise Metrics Traditional methods for analyzing microbial interactions, such as Spearman, SparCC, and FlashWeave, often focus on pairwise correlations. While these methods provide some insights, they can lead to spurious associations because they fail to account for the complex, interconnected nature of microbial communities. This limitation is particularly problematic in large-scale datasets, where indirect associations can obscure the true structure of microbial interactions. CAM-Net aims to overcome these limitations by introducing a context-aware framework that identifies a target microbe's optimal consortium. This consortium is a fully connected network subset that accurately predicts the microbe's abundance. By utilizing multi-hop information propagation, CAM-Net effectively filters out false positives from indirect associations and captures complex, context-dependent patterns that traditional pairwise approaches miss. Testing CAM-Net on Human Gut Microbiome Samples The researchers evaluated CAM-Net using over 25,000 human gut microbiome samples, focusing on two representative species: Akkermansia muciniphila , an indigenous colonizer, and Lactobacillus acidophilus , a transient colonizer. The framework successfully identified a coherent and reproducible consortium for A. muciniphila , while only weak association structures were found for L. acidophilus . This outcome aligns with the ecological behaviors of these species, demonstrating CAM-Net's ability to reflect real-world microbial dynamics. Interestingly, despite substantial geographic heterogeneity, Alistipes shahii consistently emerged as a conserved core member of the A. muciniphila consortium. This finding highlights the advantage of context-aware modeling in identifying stable microbial relationships across diverse environments. Implications and Limitations CAM-Net's ability to provide a more nuanced understanding of microbial interactions has significant implications for microbiome research. By identifying reliable microbial relationships, researchers can better understand the ecological roles and interactions within microbial communities. This understanding could lead to more accurate models of microbial ecosystems and potentially inform future studies on microbial behavior and function. However, there are limitations to this study. The reliance on computational models means that the findings are only as robust as the underlying data and assumptions. Additionally, while CAM-Net shows promise in filtering false positives, the approach still requires further validation and testing across different microbial communities and environments. The study's focus on two specific microbial species also suggests that further research is needed to assess the framework's applicability to other microbes. For those interested in learning more about Akkermansia muciniphila , you can explore our detailed explainer on this intriguing species.
Sources: CAM-Net: a context-aware network for identifying reliable microbial relations via optimal consortium. — Briefings in bioinformatics (2026) (https://pubmed.ncbi.nlm.nih.gov/42485614/)

### Reuterin's Role in Bone Health: A New Avenue for Osteoporosis
URL: https://microbiome.news/posts/reuterin-s-role-in-bone-health-a-new-avenue-for-osteoporosis
Section: Science | Published: 2026-07-22 | 3 min
Summary: A new study explores how Reuterin, a metabolite from Lactobacillus reuteri, influences bone marrow stem cell differentiation, offering insights into osteoporosis management.
Body: Osteoporosis is a common skeletal condition characterized by reduced bone density and altered bone microarchitecture, which significantly increases the risk of fractures. Traditionally, osteoporosis has been linked to imbalances in bone remodeling processes. However, recent research has expanded our understanding of its pathophysiology to include changes in bone marrow mesenchymal stem cell (BMSC) differentiation. In this context, adipogenesis, or fat cell formation, is favored over osteogenesis, or bone cell formation—a shift that is particularly pronounced with aging and estrogen deficiency. The Gut-Bone Axis Emerging research has identified a "gut-bone axis," suggesting that metabolites produced by gut microbiota can influence skeletal health. This has opened up new possibilities for therapeutic strategies targeting bone health through gut-derived compounds. A study published in Tissue & Cell investigates the effects of Reuterin, a metabolite produced by the bacterium Lactobacillus reuteri , on BMSC differentiation. Reuterin (3-hydroxypropionaldehyde) is known for its antimicrobial properties, but this study highlights its potential role in bone health. The researchers found that Reuterin can directly promote osteogenic differentiation while suppressing adipogenic differentiation in BMSCs. This dual action suggests that Reuterin could help address the fundamental imbalance in cell lineage differentiation seen in osteoporosis. Mechanisms of Action The study delves into the mechanisms by which Reuterin exerts its effects on BMSCs. It was observed that Reuterin activates the BMP-Smad signaling pathway, a crucial pathway for bone formation. Specifically, Reuterin induces the phosphorylation and nuclear translocation of Smad1/5/9 proteins, which are essential for the activation of osteogenic genes. The study further demonstrated that blocking this pathway with a BMP receptor inhibitor (LDN-193189) completely negated Reuterin's effects, underscoring the importance of BMP-Smad signaling in this process. In vitro experiments showed that Reuterin enhances osteogenic differentiation by increasing alkaline phosphatase (ALP) activity and mineralization, while it reduces lipid accumulation, indicative of suppressed adipogenic differentiation. These findings suggest that Reuterin can modulate stem cell differentiation in a way that favors bone formation over fat formation. Animal Model Insights The study also included an animal model component, using ovariectomized (OVX) rats to mimic postmenopausal osteoporosis. Systemic administration of Reuterin in these rats not only mitigated bone loss but also improved the biomechanical properties of bone. Furthermore, Reuterin significantly reduced the expansion of marrow adipose tissue, a hallmark of osteoporosis. Interestingly, the bone-preserving effects of Reuterin were found to be comparable to those of teriparatide, a clinically approved anabolic agent for osteoporosis. Both treatments effectively countered the increase in marrow adiposity, suggesting that Reuterin could be a promising candidate for further exploration as a postbiotic strategy in bone health management. Limitations and Future Directions While these findings are promising, it is important to note the limitations of the study. The research primarily relies on in vitro experiments and an animal model, which may not fully replicate human physiology. Additionally, the study does not provide information on the long-term effects of Reuterin or its potential side effects in humans. Further research, including clinical trials, would be necessary to validate these findings in a human population. For those interested in the broader implications of microbiome-derived compounds, our post on prebiotic, probiotic, and postbiotic definitions offers additional context on how these substances interact with human health.
Sources: Reuterin drives osteogenic and suppresses adipogenic differentiation of bone marrow mesenchymal stem cells via BMP/SMAD signaling to ameliorate osteoporosis. — Tissue & cell (2026) (https://pubmed.ncbi.nlm.nih.gov/42480125/)

### Crab-Eating Frog's Gut Evolution Reveals Marine Adaptation
URL: https://microbiome.news/posts/crab-eating-frog-s-gut-evolution-reveals-marine-adaptation
Section: Science | Published: 2026-07-21 | 3 min
Summary: A new study explores how the crab-eating frog's digestive system and microbiome have adapted to a chitin-rich diet in marine environments.
Body: In a study published in Frontiers in Zoology , researchers have delved into the unique adaptations of the crab-eating frog, Fejervarya cancrivora , which thrives in intertidal zones. This amphibian's ability to survive in such environments is rare among its kind, primarily due to the dual challenges of high salinity and a diet rich in chitinous materials from crab exoskeletons. The study provides insights into how the frog's digestive system and gut microbiome have evolved to meet these challenges. Structural and Functional Adaptations The study employed a combination of histological analysis, comparative transcriptomics, chitinase activity assays, and gut metagenomics to compare the crab-eating frog with its freshwater relative, F. multistriata . One of the key findings was the structural adaptation of the frog's digestive system. The researchers observed a thicker gastric muscularis and longer gastric villi in F. cancrivora , which are consistent with enhanced processing capabilities for hard prey such as crabs. On a molecular level, the study revealed an expanded set of chitinase-encoding transcripts in F. cancrivora , with 15 non-redundant transcripts compared to just 8 in its freshwater counterpart. This indicates a more robust system for breaking down chitin, a major component of the frog's diet. Additionally, both gastric and intestinal tissues in F. cancrivora exhibited significantly higher and more pH-tolerant chitinase activity, further supporting its dietary specialization. Microbiome's Role in Adaptation Interestingly, the study found that the gut microbiota of F. cancrivora is not enriched for microbial chitin degradation genes. Instead, the microbiome is functionally specialized for lipid metabolism and DNA repair pathways. A controlled feeding experiment confirmed that the enrichment in lipid metabolism is driven by the frog's diet, while the DNA repair pathways appear to be an intrinsic adaptation of the microbiome to the saline environment. This suggests a division of labor between the host and its microbiome. While the host's digestive system takes on the primary role of breaking down chitin, the microbiome optimizes energy harvest and stress tolerance, likely contributing to the frog's overall fitness in its challenging habitat. Implications and Limitations The findings from this study provide a new paradigm for understanding marine adaptation in amphibians, highlighting the functional differentiation between host and microbiome during niche expansion. This research underscores the importance of considering both host and microbial contributions when studying dietary adaptations and environmental stress responses. However, it is important to note that the study's conclusions are based on a limited comparison between two species of frogs. Further research involving a broader range of amphibians and environmental conditions would be necessary to generalize these findings. Additionally, while the study demonstrates associations between diet, microbiome function, and environmental adaptation, it does not establish causation. For more on how gut microbiomes adapt to different diets, see our post on the science of gut microbiomes .
Sources: Hologenomic rewiring facilitates dietary adaptation to chitin-rich marine resources in the crab-eating frog. — Frontiers in zoology (2026) (https://pubmed.ncbi.nlm.nih.gov/42477714/)

### Probiotics Show Promise in Countering Chronic Hypoxia Effects
URL: https://microbiome.news/posts/probiotics-show-promise-in-countering-chronic-hypoxia-effects
Section: Gut–Brain | Published: 2026-07-20 | 3 min
Summary: A new study explores how probiotics may mitigate the impact of chronic hypoxia on the gut-brain axis and neuroinflammation in mice.
Body: Chronic hypoxia, a condition characterized by prolonged low oxygen levels, is known to disrupt various biological systems, leading to inflammation and functional decline. This condition shares mechanistic similarities with neurodegenerative diseases and can be exacerbated by environmental factors that affect oxygen homeostasis. A study published in Brain, Behavior, and Immunity investigates the potential of probiotics to counteract the adverse effects of chronic hypoxia, particularly focusing on the gut-brain axis. Understanding Chronic Hypoxia and Its Effects Chronic hypoxia can lead to significant cellular and molecular changes, disrupting tissue homeostasis and impairing gut balance, or eubiosis. These disruptions can trigger inflammation and contribute to a decline in function, mimicking features seen in neurodegenerative diseases. The underlying mechanisms involve the stabilization of Hypoxia-Inducible Factor 1-alpha (HIF-1α), proteasome dysfunction, and disturbances in the gut-brain axis. In this study, researchers used C57BL/6 mice exposed to 12% oxygen for two months to simulate chronic hypoxia. The mice were then given oral probiotic supplements to examine potential therapeutic effects on these hypoxia-induced changes. Probiotics and the Gut-Brain Axis The study found that probiotic supplementation in hypoxia-exposed mice led to several beneficial outcomes. Notably, it rescued short-term memory deficits, reduced the accumulation of HIF-1α in the hippocampus, and restored the function of prolyl hydroxylase domain protein 2 (PHD2) and the ubiquitin-proteasome pathway. Additionally, probiotics attenuated neuroinflammation and apoptosis while increasing levels of brain-derived neurotrophic factor (BDNF), a protein associated with neuroprotection and cognitive function. Beyond the brain, probiotics also had significant effects on the gut. They normalized plasma levels of gut hormones such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and leptin. Furthermore, probiotics enhanced the expression of tight junction proteins in the ileum, such as zonulin-1, occludin, and claudin, which are crucial for maintaining intestinal barrier integrity. The supplementation also countered shifts in gut microbiota diversity and restored beneficial bacterial metabolites, suggesting an improvement in gut health and metabolic pathways. Implications and Limitations The findings from this study provide preclinical evidence that probiotics could offer a strategy to restore gut-brain axis homeostasis and mitigate neuroinflammation associated with chronic hypoxia. This suggests potential avenues for addressing neurodegenerative conditions linked to environmental and pathological oxygen deprivation. However, it is important to note the limitations of this study. The research was conducted on mice, which means the results may not directly translate to humans. Additionally, while the study demonstrates associations between probiotic supplementation and improved outcomes, it does not establish causation. Further research, including human trials, is necessary to fully understand the potential therapeutic benefits of probiotics in this context. For more on the gut-brain connection, you might find our primer on the gut-brain axis helpful.
Sources: Probiotic supplementation as a strategy to counteract chronic hypoxia-related damages. — Brain, behavior, and immunity (2026) (https://pubmed.ncbi.nlm.nih.gov/42472610/)

### Access to Gut Microbiota-Accessible Foods Key to Health
URL: https://microbiome.news/posts/access-to-gut-microbiota-accessible-foods-key-to-health
Section: Science | Published: 2026-07-19 | 3 min
Summary: A new analysis suggests that access to fiber-rich, minimally processed foods may be more critical for public health than reducing the availability of ultra-processed foods.
Body: A new analysis published in The Milbank Quarterly suggests that increasing consumer access to fiber-rich, minimally processed foods could be more effective for public health than focusing solely on the reduction of ultra-processed food consumption. The paper highlights the role of traditional dietary patterns in optimizing gut microbiota function and suggests that policies should prioritize access to diverse, gut microbiota-accessible foods. Dietary Patterns and Gut Microbiota The researchers argue that traditional dietary patterns, characterized by high fiber and polyphenol content, are beneficial for gut microbiota. These foods provide essential substrates for gut microbes, which in turn support the natural expression of the satiety hormone glucagon-like peptide-1 (GLP-1). GLP-1 plays a crucial role in regulating appetite and energy balance, suggesting that diets rich in these components could help manage obesity. The analysis points to countries like France and Japan, where agricultural and school nutrition policies promote the consumption of minimally processed foods, as examples of how such dietary patterns can contribute to lower obesity rates. These countries emphasize a diverse intake of fiber-rich foods, which supports a healthy gut microbiome and overall health. Rethinking Ultra-Processed Foods While the negative health effects of ultra-processed foods are well-documented, this analysis challenges the notion that these foods are addictive. The researchers reference randomized, controlled feeding studies showing that participants switching from ultra-processed to minimally processed foods did not experience withdrawal symptoms. This finding undermines the idea that the overconsumption of ultra-processed foods is driven by addiction. Instead, the analysis suggests that the lack of access to a variety of gut microbiota-accessible foods may be a more significant factor contributing to obesity. By focusing on increasing the availability of whole foods, public health policies could more effectively address nutrition-related chronic diseases. Policy Implications The authors conclude that government policies should prioritize agricultural and educational initiatives that enhance access to minimally processed, fiber-rich foods. Such policies could provide a long-term solution to reducing the prevalence of obesity and other chronic diseases linked to poor diet. While the analysis presents a compelling case for shifting focus from limiting ultra-processed foods to expanding access to whole foods, it acknowledges the complexity of dietary choices and the multifaceted nature of obesity. The findings are based on existing literature and controlled studies, which may not capture the full range of individual dietary behaviors and preferences. For a deeper understanding of how dietary patterns influence gut microbiota and health, readers may find our introduction to the microbiome useful.
Sources: Food Industry Engineering Is Less Important Than Access to Gut Microbiota-Accessible Foods for Preventing Chronic Disease. — The Milbank quarterly (2026) (https://pubmed.ncbi.nlm.nih.gov/42470169/)

### Probiotic L. paracasei Shows Promise in Obesity Management
URL: https://microbiome.news/posts/probiotic-l-paracasei-shows-promise-in-obesity-management
Section: Science | Published: 2026-07-19 | 3 min
Summary: A new study explores how the probiotic Lacticaseibacillus paracasei affects obesity-related metabolic and inflammatory pathways in mice.
Body: The quest for effective strategies to manage obesity has led researchers to explore the potential of probiotics. A study published in Biochemical Pharmacology investigates the effects of the probiotic Lacticaseibacillus paracasei on obesity-related metabolic and inflammatory pathways in a mouse model. The findings suggest that this probiotic may offer a promising approach to modulating obesity through various biological mechanisms. Study Design and Key Findings Researchers conducted the study using a murine model of high-fat diet (HFD)-induced obesity. The mice were administered L. paracasei orally, and several metabolic and inflammatory parameters were assessed. Notably, the probiotic significantly reduced body weight gain and adiposity, despite no change in food intake, indicating improved energy efficiency. The study also reported enhanced insulin sensitivity and glucose tolerance in the probiotic-treated mice. This was evidenced by lower fasting glucose and insulin levels, along with a reduced Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). At the molecular level, L. paracasei downregulated genes involved in adipogenesis, such as Srebf1, Pparg, Cebpa, and Fabp4, while upregulating Ucp-1, which is associated with the browning of white adipose tissue. Inflammatory and Metabolic Pathways The probiotic's impact extended to inflammatory markers and pathways. It decreased levels of inflammatory markers like Tnf-α, Il-6, and Mcp-1, and reduced activation of the JNK pathway. Improvements in insulin signaling and lipid metabolism were also observed, marked by increased expression of Glut4 and Pparα, and modulation of adipokines. In the liver, L. paracasei was found to attenuate steatosis, reduce oxidative stress, and modulate genes related to lipid metabolism. The probiotic also improved gut barrier integrity, as indicated by higher expression of tight junction proteins, lower levels of lipopolysaccharides (LPS), and reduced expression of Tlr4. Microbiota and Vascular Effects The study highlighted significant changes in the gut microbiota composition following probiotic treatment. L. paracasei decreased the Bacillota/Bacteroidota ratio and increased beneficial bacteria such as Akkermansia muciniphila and Lactobacillus, while reducing Clostridium species. Additionally, the probiotic normalized obesity-associated microRNAs involved in adipogenesis and inflammation. Beyond metabolic and microbiota changes, the probiotic improved endothelial function and reduced vascular oxidative stress, suggesting a broader impact on cardiovascular health. Implications and Limitations These findings underscore the potential of L. paracasei as a probiotic intervention for obesity management. By modulating metabolic, inflammatory, and microbiota-mediated pathways, this probiotic could play a role in addressing obesity-related challenges. However, it is important to note the limitations of the study. As the research was conducted in a murine model, the results may not fully translate to humans. Further studies are needed to explore the effects of L. paracasei in human populations and to determine the precise mechanisms at play. For those interested in the intersection of probiotics and metabolic health, our article on Akkermansia and next-gen probiotics provides additional insights into how specific strains can influence health outcomes.
Sources: Modulation of the gut microbiota by Lacticaseibacillus paracasei reduces adipogenesis and metabolic dysregulation in high-fat diet-induced obese mice. — Biochemical pharmacology (2026) (https://pubmed.ncbi.nlm.nih.gov/42471109/)

### What antibiotics do to your gut — and how completely it recovers
URL: https://microbiome.news/posts/antibiotics-gut-microbiome-recovery
Section: Science | Published: 2026-06-30 | 9 min
Summary: A course of antibiotics can wipe out a third of your gut’s diversity in days. Most of it grows back over months — but not all, and the rebuild has its own risks. What the recovery curve actually looks like, with the limits left in.
Body: Antibiotics are among the most important medicines ever made — and they are not precision instruments. A drug aimed at the bacterium making you sick passes through a gut that houses trillions of harmless and helpful ones, and it does not spare them. The interesting science isn’t that antibiotics disturb the microbiome; it’s how deep the disturbance goes, how completely the community rebuilds, and what the rebuild leaves behind. None of this is an argument against taking antibiotics when they’re indicated — it’s a map of what to expect and tend afterward. The hit is fast and broad The foundational measurements came from David Relman’s group. Using deep sequencing before and after a course of ciprofloxacin, Dethlefsen et al. (2008) found the drug had “pervasive” effects — influencing roughly a third of gut taxa and sharply cutting diversity within days. Most groups bounced back over about four weeks, but some did not return to their former abundance. The community that reassembled was similar to the original. It was not identical. “Incomplete and individualized” A follow-up put a finer point on it. Dethlefsen & Relman (2011) gave subjects two ciprofloxacin courses months apart and watched the gut lose diversity within three to four days each time. Recovery was partial, it settled into a somewhat altered steady state, and — critically — it differed markedly from person to person. There was no single recovery timeline. The same drug, the same dose, produced different depths of damage and different rebuilds in different people. That individuality is one of the most robust findings in the area. About six months — minus a few residents The most-cited modern number comes from Palleja et al. (2018) , who hit 12 healthy men with a deliberately aggressive four-day cocktail of three antibiotics and tracked them for half a year. The arc is the one worth memorizing: an immediate collapse, a bloom of opportunistic bacteria and a transient surge of antibiotic-resistance genes, then a steady reconstitution. By roughly six months the microbiome had largely returned toward baseline — but several common, beneficial species were still missing, undetectable months later. “Largely recovers in about six months, but not always completely” is the honest one-line summary. The microbiome is resilient, not indestructible. It rebuilds most of itself over months — but the version that comes back can be missing residents that don’t return, and the rebuild itself opens a temporary window of vulnerability. Why the gap matters: colonization resistance A full, diverse gut community does real defensive work — it crowds out and chemically suppresses invaders, a property called colonization resistance , reviewed by Buffie & Pamer (2013) . Knock the community down and you weaken the guard. This is the mechanism behind antibiotic-associated diarrhea and, at its most serious, Clostridioides difficile infection: clear the competition and an opportunist takes the open ground. The post-antibiotic bloom Palleja observed is that window in action — and it’s why the most effective rescue for recurrent C. difficile is restoring a whole community via fecal microbiota transplant . The counterintuitive part: probiotics may slow the rebuild The instinct after antibiotics is to take a probiotic to “replace” what was lost. A striking 2018 Cell study by Suez et al. complicates that. In people and mice, an 11-strain probiotic taken after antibiotics actually delayed the return of the native gut community for months, compared with simply letting it recover on its own — while restoring the person’s own pre-antibiotic microbes (an autologous transplant) brought it back within days. The probiotic colonized the empty gut and got in the way of the originals coming home. It’s one study, with caveats, but it should retire the assumption that a post-antibiotic probiotic is obviously helpful. The early-life question — read it as association The stakes look higher at the start of life, when the microbiome is still assembling. Reviews such as Cox & Blaser (2015) describe associations between early-life antibiotic exposure and later metabolic outcomes, including adiposity, with parallel epidemiology linking early antibiotics to asthma and allergy. The mandatory caveat: these are largely observational associations, badly confounded by the fact that the infections being treated may themselves carry risk. Causation is shown mainly in animal models. It is a real concern and a reason for thoughtful pediatric stewardship — not proof that a needed antibiotic harms a child. The honest bottom line Take antibiotics when they’re indicated; the downside of an untreated serious infection dwarfs a temporary reshuffle of gut bacteria. But the reshuffle is real: expect a fast, broad hit, a months-long recovery that is usually substantial but not always complete, a window of lowered defense while it rebuilds, and meaningful person-to-person variation. The best-supported way to help the rebuild is unglamorous — feed the survivors. A diverse, fiber-rich diet supports the short-chain-fatty-acid producers that recovery depends on, which is most of what the evidence on gut health actually supports anyway.
Sources: Dethlefsen et al., “The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing,” PLoS Biology (2008) (https://doi.org/10.1371/journal.pbio.0060280); Dethlefsen & Relman, “Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation,” PNAS (2011) (https://doi.org/10.1073/pnas.1000087107); Palleja et al., “Recovery of gut microbiota of healthy adults following antibiotic exposure,” Nature Microbiology (2018) (https://doi.org/10.1038/s41564-018-0257-9); Buffie & Pamer, “Microbiota-mediated colonization resistance against intestinal pathogens,” Nature Reviews Immunology (2013) (https://doi.org/10.1038/nri3535); Suez et al., “Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT,” Cell (2018) (https://www.cell.com/cell/fulltext/S0092-8674(18)31108-5); Cox & Blaser, “Antibiotics in early life and obesity,” Nature Reviews Endocrinology (2015) (https://doi.org/10.1038/nrendo.2014.210)

### Does Parkinson’s start in the gut? What the evidence actually shows
URL: https://microbiome.news/posts/parkinsons-disease-gut-origin
Section: Gut–Brain | Published: 2026-06-29 | 9 min
Summary: Constipation can precede the tremor by a decade, the brain’s rogue protein turns up in the gut wall first, and removing the vagus nerve seems to lower the risk. The case that Parkinson’s begins below the diaphragm — and the limits of that case.
Body: One of the most provocative ideas in neuroscience is that Parkinson’s disease — a disorder defined by tremor, rigidity and the loss of dopamine neurons in the brain — may not begin in the brain at all. A growing body of evidence places its earliest events in the gut, years before a neurologist would ever see the patient. The idea is genuinely supported, genuinely incomplete, and a useful case study in how to read microbiome science without overreading it. The clue that came first: constipation Long before the motor symptoms, many people who go on to develop Parkinson’s have gut trouble — most consistently, constipation. This is not folklore. In the Honolulu Heart Program, a prospective cohort of nearly 7,000 men followed for up to 24 years, Abbott et al. (2001) found that men with fewer than one bowel movement a day had roughly three times the risk of later being diagnosed with Parkinson’s, compared with men who were more regular — with the diagnosis often arriving more than a decade later. A symptom in the gut was foreshadowing a disease of the brain. Braak’s ascending hypothesis The anatomist Heiko Braak gave the observation a mechanism. In two 2003 papers, he proposed that the protein aggregates that define Parkinson’s — clumps of misfolded alpha-synuclein , the Lewy pathology — appear first in the lowest, most peripheral parts of the nervous system and climb upward over years. His staging scheme put the earliest damage in the dorsal motor nucleus of the vagus nerve and the olfactory system, reaching the dopamine-producing substantia nigra only at later stages. A companion paper went further, proposing that some unknown trigger crosses the gut lining and travels up the vagus nerve into the brain. Gut first, brain later. The protein really is in the gut — early That model made a testable prediction: the pathological protein should be findable in the gut wall before the disease is diagnosed. It is. Examining archived gastrointestinal biopsies taken from people for unrelated reasons, Stokholm et al. (2016) found aggregated, phosphorylated alpha-synuclein in the gut tissue of individuals who were only later diagnosed with Parkinson’s — in some cases up to 20 years before. The misfolded protein was sitting in the enteric nervous system — the gut’s own dense web of neurons — long before the brain showed its hand. Cut the wire, lower the risk If the trigger really ascends the vagus nerve, then severing that nerve should interrupt the journey. A natural experiment exists: decades ago, truncal vagotomy was a common surgery for peptic ulcers. Mining Danish national registries, Svensson et al. (2015) found that people who had a full truncal vagotomy had a lower subsequent risk of Parkinson’s, an effect most visible 20 years out. A later Swedish cohort pointed the same way. The honest caveat: in the Danish study the overall truncal-vagotomy result did not reach statistical significance — it is a striking, supportive signal, not a closed case. Where the microbes come in The disease also comes with a changed gut community. The landmark human study, Scheperjans et al. (2015) , found that people with Parkinson’s had markedly less Prevotellaceae in their stool than matched controls, with other shifts tracking the severity of gait and balance problems. Far larger and higher-resolution, Wallen et al. (2022) used deep metagenomic sequencing in roughly 490 patients and 230 controls and found a broad, “disease-permissive” reshaping — over a third of measured species, genes and pathways altered. Whether that altered microbiome is a cause, a consequence, or a bystander is exactly the question these studies cannot, by design, answer. The strongest causal evidence is in mice — and that matters The closest thing to a causal demonstration comes from the lab, not the clinic. Sampson et al. (2016) , working in the Mazmanian lab, used mice engineered to over-produce alpha-synuclein. Raised germ-free, those mice were largely protected from motor deficits and brain inflammation; give them a microbiome — especially one transplanted from Parkinson’s patients rather than healthy donors — and the symptoms worsened. The microbes were not incidental; in this model they were required. The unavoidable caveat: this is a genetically engineered mouse. Rodent guts, immune systems and disease timelines are not human ones, and “required in mice” is not “proven in people.” Constipation precedes the tremor by years; the rogue protein appears in the gut wall first; severing the vagus seems to lower the risk; and in mice, the microbiome is necessary for the disease. That is a remarkably consistent story — built almost entirely from association and animal models. Not one disease, and not always the gut The most useful refinement is that Parkinson’s may not be a single road. The “body-first versus brain-first” model — laid out with multimodal imaging by Horsager et al. (2020) — proposes two routes: a body-first form in which pathology really does begin in the gut and autonomic nerves and ascends (often heralded by REM-sleep behaviour disorder), and a brain-first form that starts centrally. If that is right, the gut-origin story is true for a subset of patients, not all of them. The honest bottom line The gut-origin hypothesis for Parkinson’s is one of the best-supported ideas in microbiome neuroscience — and it is still a hypothesis. The human evidence (constipation cohorts, biopsies, vagotomy registries, microbiome surveys) is consistent but observational, vulnerable to confounding and reverse causation: an early gut that moves sluggishly could be the first symptom of brewing brain pathology rather than its cause. The clean causal evidence lives in mice. What you can say with confidence is that Parkinson’s has a real, early gut dimension worth taking seriously — and that the leap from “involved” to “originates there” is the part the field is still working to earn. For the signalling routes underneath all this, see our gut–brain axis primer .
Sources: Abbott et al., “Frequency of bowel movements and the future risk of Parkinson’s disease,” Neurology (2001) (https://www.neurology.org/doi/10.1212/WNL.57.3.456); Braak et al., “Staging of brain pathology related to sporadic Parkinson’s disease,” Neurobiology of Aging (2003) (https://pubmed.ncbi.nlm.nih.gov/12498954/); Braak et al., “Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion,” J Neural Transm (2003) (https://link.springer.com/article/10.1007/s00702-002-0808-2); Stokholm et al., “Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients,” Annals of Neurology (2016) (https://pubmed.ncbi.nlm.nih.gov/27015771/); Svensson et al., “Vagotomy and subsequent risk of Parkinson’s disease,” Annals of Neurology (2015) (https://pubmed.ncbi.nlm.nih.gov/26031848/); Liu et al., “Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study,” Neurology (2017) (https://pubmed.ncbi.nlm.nih.gov/28446653/); Scheperjans et al., “Gut microbiota are related to Parkinson’s disease and clinical phenotype,” Movement Disorders (2015) (https://pubmed.ncbi.nlm.nih.gov/25476529/); Sampson et al., “Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease,” Cell (2016) (https://www.cell.com/fulltext/S0092-8674(16)31590-2); Wallen et al., “Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,” Nature Communications (2022) (https://pubmed.ncbi.nlm.nih.gov/36376318/); Horsager et al., “Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study,” Brain (2020) (https://pubmed.ncbi.nlm.nih.gov/33103732/)

### Fiber won’t fix everything — but here’s what it actually is, and does
URL: https://microbiome.news/posts/fiber-wont-fix-everything
Section: Science | Published: 2026-06-28 | 8 min
Summary: Dietary fiber has some of the best evidence of any nutrient — and it is routinely oversold. What fiber really is, the types that matter, what the trials actually show, and where “just eat more fiber” stops working.
Body: Fiber is the closest thing nutrition science has to a consensus hero — and that is exactly why it gets oversold. “Eat more fiber” is sound advice that quietly implies a promise it can’t keep: that one nutrient, taken in bulk, will fix digestion, weight, mood and metabolic health. The evidence is more interesting, and more conditional, than that. What dietary fiber actually is Dietary fiber is the set of plant carbohydrates your small intestine cannot digest. Because human enzymes can’t break them down, they pass through to the large intestine largely intact — where some of them become food for your gut bacteria, and some simply add bulk and move things along. That is the whole definition: not a single substance, but a category defined by what your body can’t do to it. That category distinction matters, because “fiber” on a label tells you almost nothing about what the fiber will do. The types that actually behave differently The old “soluble vs insoluble” split is a starting point, but the more useful axes are physical, and they were laid out clearly by McRorie and McKeown (2017) : Viscous, gel-forming fibers (psyllium, beta-glucan from oats and barley) thicken the gut’s contents. This is the mechanism behind fiber’s effects on cholesterol and post-meal blood sugar — it’s physics, not fermentation. Fermentable fibers (inulin, resistant starch, pectins, the fibers in legumes) are eaten by colonic bacteria, which turn them into short-chain fatty acids like butyrate — the link between fiber and the microbiome, detailed by Koh et al. (2016) . Bulking, poorly fermented fibers (wheat bran, cellulose) mostly add stool mass and speed transit. Useful for regularity; largely silent to the microbiome. A supplement of one of these will not reproduce the effects of another. “More fiber” is not a single dial. Where the evidence is genuinely strong The case for fiber as a population-level good is about as solid as nutrition gets. The landmark synthesis — Reynolds et al. in The Lancet (2019) , pooling decades of cohorts and trials — found a clear dose-response: people eating the most fiber (roughly 25–29 g/day, versus the least) had meaningfully lower rates of all-cause mortality, coronary heart disease, type 2 diabetes and colorectal cancer. More appeared better, across the observed range. And most people are nowhere near it. U.S. intake averages around 15 g/day against a Dietary Guidelines target of ~14 g per 1,000 kcal — a well-documented “fiber gap” (Quagliani & Felt-Gunderson, 2017) . For the average reader, “eat more fiber” is correct. Where “just eat more fiber” stops working The oversell starts when a population average gets sold as a personal guarantee. Three honest caveats: 1. The benefit runs through your microbiome — which is individual. Fiber doesn’t act on you directly so much as it feeds the microbes that act on you. In the Stanford fermented-foods vs high-fiber trial (Wastyk et al., 2021) , the high-fiber arm did not uniformly lower inflammatory markers; responses split by participants’ baseline microbiome diversity. The fermented-foods arm, not the fiber arm, broadly increased diversity and reduced inflammation. Same fiber, different people, different results. 2. A depleted microbiome may not respond. Sonnenburg and Sonnenburg (2014) framed fiber as “microbiota-accessible carbohydrates” — and showed that once the bacteria that ferment them are gone, adding the substrate back doesn’t simply restore the function. You can’t feed microbes you no longer have. Makki et al. (2018) review how variable these fiber–microbiota effects are across individuals. 3. More is not always better, and ramp matters. A 2018 meta-analysis (So et al.) found fiber’s effects on microbiota composition real but modest and heterogeneous. And in practice, a fast jump in fermentable fiber is a reliable way to produce bloating and gas; in some people with IBS or suspected SIBO, more fermentable fiber makes symptoms worse, not better. Type and titration matter as much as total grams. The honest takeaway Fiber is necessary and under-consumed, and closing the fiber gap with a variety of whole-food plant fibers is one of the best-supported things you can do for long-term health. It is also not a cure-all, not interchangeable across types, and not equally effective in every gut. The useful version of the advice keeps the nuance: more plants, more kinds of fiber, ramped up gradually — and realistic expectations about what a single nutrient can do. For the fuller picture of what the evidence supports, see our guide to improving gut health and the prebiotic / probiotic / postbiotic definitions .
Sources: Reynolds et al., “Carbohydrate quality and human health: a series of systematic reviews and meta-analyses,” The Lancet (2019) (https://pubmed.ncbi.nlm.nih.gov/30638909/); McRorie & McKeown, “Understanding the Physics of Functional Fibers in the Gastrointestinal Tract,” J Acad Nutr Diet (2017) (https://pubmed.ncbi.nlm.nih.gov/27863994/); Koh et al., “From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites,” Cell (2016) (https://pubmed.ncbi.nlm.nih.gov/27259147/); Wastyk et al., “Gut-microbiota-targeted diets modulate human immune status,” Cell (2021) (https://pubmed.ncbi.nlm.nih.gov/34256014/); Sonnenburg & Sonnenburg, “Starving our Microbial Self,” Cell Metabolism (2014) (https://pubmed.ncbi.nlm.nih.gov/24506863/); Makki et al., “The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease,” Cell Host & Microbe (2018) (https://pubmed.ncbi.nlm.nih.gov/30001516/); So et al., “Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis,” Am J Clin Nutr (2018) (https://pubmed.ncbi.nlm.nih.gov/29757343/); Quagliani & Felt-Gunderson, “Closing America’s Fiber Intake Gap,” American Journal of Lifestyle Medicine (2017) (https://pubmed.ncbi.nlm.nih.gov/30202317/)

### Psychobiotics: do probiotics actually help depression and anxiety?
URL: https://microbiome.news/posts/psychobiotics-depression-anxiety-evidence
Section: Gut–Brain | Published: 2026-06-27 | 9 min
Summary: The gut–brain axis is real, the mechanisms are plausible, and the marketing has run far ahead of the trials. What the meta-analyses actually find when you ask whether a probiotic can change your mood — and for whom.
Body: The term “psychobiotic” was coined in 2013 by Dinan, Stanton and Cryan, in a Biological Psychiatry paper, for a tightly drawn idea: a live organism that, taken in adequate amounts, produces a mental-health benefit in people with psychiatric illness. The concept rode the rise of the gut–brain axis , and the marketing has since stretched it to cover almost any supplement promising calm or focus. So it’s worth asking the plain question the trials are designed to answer: can a probiotic actually move depression or anxiety — and if so, for whom? The mechanism is not the problem The plumbing is real. As Sarkar et al. (2016) and the comprehensive Cryan et al. (2019) review lay out, gut microbes can signal to the brain through the vagus nerve, immune messengers, and the metabolism of neurotransmitter precursors such as tryptophan, the raw material for serotonin. There are believable routes by which a microbe could influence mood. The question is never whether a path exists — it’s whether a given pill, in a real person, travels it to a measurable end. What the meta-analyses actually find Pool the controlled trials and a consistent, modest picture emerges. Liu, Walsh & Sheehan (2019) found probiotics produced a small but statistically significant reduction in depression (effect size around −0.24) and a smaller one in anxiety — while prebiotics , on their own, were no better than placebo. The crucial detail is in the subgroups: the benefit was far larger in clinically diagnosed or psychiatric populations than in general-community samples. Two more meta-analyses sharpen that point. Goh et al. (2019) , pooling 19 double-blind trials, found probiotics improved depressive symptoms — but the effect was significant only in patients with major depressive disorder, not in other conditions or in healthy people. And Ng et al. (2018) found no significant overall mood effect, with a benefit appearing only on closer look in mild-to-moderate depression and none at all in healthy individuals. Across all three, the same line keeps surfacing. The signal is real but small, and it concentrates where there is something to fix. Probiotics nudge mood in people who are clinically depressed — and do close to nothing for the already-well. “Psychobiotics for everyday mood” is the part the data do not support. The flagship trials, in proportion The often-cited early human trials are smaller and softer than the headlines suggest. Steenbergen et al. (2015) gave a multispecies probiotic to 40 healthy adults and saw reduced “cognitive reactivity to sad mood” — a surrogate measure of rumination, not clinical depression. Allen et al. (2016) reported that Bifidobacterium longum 1714 blunted the cortisol and anxiety response to an acute stressor — in 22 healthy men, a crossover design measuring acute stress, not a disorder. These are interesting proofs of concept. They are not evidence that a supplement treats a diagnosis. The newest, most honest data point The most recent reputable trial is candid about its own limits. Nikolova et al. (2023) , in JAMA Psychiatry, added a 14-strain probiotic to standard antidepressants in 49 adults with major depression who hadn’t fully responded. It was well tolerated, and the mood scores moved in the probiotic’s favour — but the authors are explicit that this was a pilot designed to estimate effect sizes, not to prove efficacy. Promising, hedged, and waiting on a larger trial. That is the honest state of the art. Three things to hold onto Strain-specificity is not a detail. Results from one strain, dose and formulation do not transfer to another — “probiotics help depression” is far too coarse a claim to act on, and multi-strain products sometimes outperform single strains in these analyses. It is exactly this problem that is pushing the industry toward strain-level precision . Most of the strong-looking trials are small, short and run in healthy volunteers using surrogate endpoints, with the usual heterogeneity and publication-bias concerns. And the regulation is unforgiving for a reason: in the U.S. these are dietary supplements, which by law may not claim to treat a disease. No probiotic is FDA-approved as a drug for depression or anxiety; “psychobiotic” is a research term, not an approved therapeutic category. The honest bottom line The most defensible reading: in people who are clinically depressed, a probiotic may offer a small, real, adjunctive benefit — alongside, never instead of, evidence-based care. For everyone else, the case that a “mood probiotic” will lift an ordinary bad week is mechanistically plausible and empirically thin. The gut–brain axis is genuine; the pill that reliably exploits it for mental health is still, mostly, ahead of the data. For how the underlying terms are used precisely, see our prebiotic / probiotic / postbiotic guide .
Sources: Dinan, Stanton & Cryan, “Psychobiotics: A Novel Class of Psychotropic,” Biological Psychiatry (2013) (https://pubmed.ncbi.nlm.nih.gov/23759244/); Sarkar et al., “Psychobiotics and the Manipulation of Bacteria–Gut–Brain Signals,” Trends in Neurosciences (2016) (https://pubmed.ncbi.nlm.nih.gov/27793434/); Cryan et al., “The Microbiota-Gut-Brain Axis,” Physiological Reviews (2019) (https://journals.physiology.org/doi/full/10.1152/physrev.00018.2018); Liu, Walsh & Sheehan, “Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis,” Neuroscience & Biobehavioral Reviews (2019) (https://pubmed.ncbi.nlm.nih.gov/31004628/); Goh et al., “Effect of probiotics on depressive symptoms: a meta-analysis of human studies,” Psychiatry Research (2019) (https://www.sciencedirect.com/science/article/abs/pii/S0165178119312156); Ng et al., “A meta-analysis of the use of probiotics to alleviate depressive symptoms,” Journal of Affective Disorders (2018) (https://pubmed.ncbi.nlm.nih.gov/29197739/); Steenbergen et al., “A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood,” Brain, Behavior, and Immunity (2015) (https://www.sciencedirect.com/science/article/pii/S0889159115000884); Allen et al., “Bifidobacterium longum 1714 as a translational psychobiotic,” Translational Psychiatry (2016) (https://pubmed.ncbi.nlm.nih.gov/27801892/); Nikolova et al., “Probiotics as adjunctive treatment in patients with depression: a randomized clinical trial,” JAMA Psychiatry (2023) (https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2806011)

### 16S vs shotgun: what your microbiome test actually reads
URL: https://microbiome.news/posts/16s-vs-shotgun-metagenomics
Section: Diagnostics | Published: 2026-06-25 | 8 min
Summary: Two sequencing methods sit behind nearly every gut test on the market, and they don’t read the same book. One tells you roughly who is there; the other reads the genes and what they can do. Why the method determines what your result can mean.
Body: When a company sequences your stool, it is making a choice you rarely see on the box — and that choice sets a hard ceiling on what your result can possibly mean. Almost every gut test runs on one of two technologies: 16S rRNA amplicon sequencing or shotgun metagenomics. They are not two brands of the same thing. They read different amounts of the underlying biology, and confusing them is the root of a lot of overinterpretation. Here is the difference, kept concrete. 16S: a barcode for “roughly who” The 16S rRNA gene is present in all bacteria, with regions conserved enough to grab with universal primers and variable enough to tell groups apart. Sequence one or two of those variable regions and you get a cheap, fast census of which bacterial groups are present. The catch is resolution. As Johnson et al. (2019) documented, short-read 16S reliably reaches the genus level but only erratically distinguishes species — and almost never strains. It is also vulnerable to which region you target and to the fact that different bacteria carry different numbers of copies of the gene, which distorts the apparent proportions. Most important: 16S reads taxonomy , not function. It tells you who might be there, not what they can do. Shotgun: read everything, including the verbs Shotgun metagenomics skips the single barcode and sequences all the DNA in the sample — bacterial, viral, fungal. The canonical reference, Quince et al. (2017) , lays out what that buys you: species- and often strain-level identification, and direct access to gene content — the metabolic pathways the community actually encodes, from short-chain fatty acid production to antibiotic-resistance genes. In a head-to-head, Durazzi et al. (2021) showed shotgun resolves lower-abundance taxa and reaches deeper than 16S on the same samples. The cost is real: more money, more DNA, and far more computation to make sense of the data. On the consumer side, the services that run shotgun through CLIA-certified labs — among them the personalized-probiotics company we profile here — sit at the higher-resolution end of this trade-off. 16S asks “who is roughly here?” Shotgun asks “who is here, and what genes do they carry?” A test can only answer the question its method was built to ask — no amount of dashboard design adds resolution the sequencing never captured. The function on a 16S report is usually a guess Plenty of 16S-based products still hand you a “metabolic” or “pathway” readout. How? Through prediction tools such as PICRUSt and its successor PICRUSt2 (Douglas et al., 2020) , which infer likely gene content by matching your taxa to reference genomes. That inference is reasonable when your microbes closely resemble well-studied reference strains and degrades when they don’t. It estimates genomic potential , not measured or expressed function. A predicted pathway on a 16S report is a model’s best guess, not a thing the test directly observed — worth knowing before you act on a “you’re low in butyrate producers” verdict. The caveat that outranks both: the method shapes the answer Even with the right technology, the lab protocol can move the result more than your biology does. The Microbiome Quality Control project, Sinha et al. (2017) , sent blinded specimens across 15 labs and 9 pipelines and found that DNA-extraction method, handling and bioinformatics — not just the sample — drove much of the variation. The consumer-facing version is starker: the NIST-led Servetas et al. (2026) study sent identical reference material to direct-to-consumer companies and found that differences between providers equalled or exceeded the differences between entirely different people’s guts. Same stool, different verdicts — covered in our piece on test reproducibility . And you’re reading proportions, not amounts One more structural caveat applies to both methods. Sequencing returns relative abundances that sum to 100%, not absolute counts — a point made forcefully by Gloor et al. (2017) . If one microbe’s share goes up, others must mechanically go down, whether or not their actual numbers changed. A bug reported as “high” may simply be crowding the chart, not your colon. This is why a single percentage on a report card is one of the least reliable numbers in the whole field. The honest bottom line Neither method is “better” in the abstract; they answer different questions. If a test offers strain-level identification or genuine functional/metabolic gene content, it is almost certainly shotgun. If it’s priced cheaply and talks in genus-level bar charts — with any “function” inferred — it is almost certainly 16S, and you should read the metabolic claims as predictions. Either way, treat absolute-looking percentages and cross-brand comparisons with skepticism. For the bigger picture of what a result can and can’t tell you, see how microbiome testing works .
Sources: Johnson et al., “Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis,” Nature Communications (2019) (https://www.nature.com/articles/s41467-019-13036-1); Quince et al., “Shotgun metagenomics, from sampling to analysis,” Nature Biotechnology (2017) (https://www.nature.com/articles/nbt.3935); Durazzi et al., “Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota,” Scientific Reports (2021) (https://www.nature.com/articles/s41598-021-82726-y); Douglas et al., “PICRUSt2 for prediction of metagenome functions,” Nature Biotechnology (2020) (https://www.nature.com/articles/s41587-020-0548-6); Sinha et al., “Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium,” Nature Biotechnology (2017) (https://www.nature.com/articles/nbt.3981); Servetas et al., “Evaluating the analytical performance of direct-to-consumer gut microbiome testing services,” Communications Biology (2026) (https://www.nature.com/articles/s42003-025-09301-3); Gloor et al., “Microbiome Datasets Are Compositional: And This Is Not Optional,” Frontiers in Microbiology (2017) (https://www.frontiersin.org/articles/10.3389/fmicb.2017.02224/full)

### The 39 trillion: what we actually mean when we say “the microbiome”
URL: https://microbiome.news/posts/what-is-the-microbiome
Section: Science | Published: 2026-06-23 | 9 min
Summary: The cells that aren’t us roughly equal the ones that are. A field guide to the ecosystem riding along inside every human being — and why the science is finally getting precise about it.
Body: For a long time the headline number was “ten to one” — ten bacterial cells for every human one. It was repeated so often it became folklore. When researchers finally recounted, the ratio collapsed to roughly one to one: about 38–39 trillion microbial cells against 30-odd trillion human ones. Not ten times us. About the same as us. That correction matters less for the arithmetic than for what it revealed: a science still establishing its basic measurements. The microbiome is the collection of microorganisms — bacteria, archaea, fungi, viruses — living on and inside the body, together with their genes and the chemistry they produce. The densest neighborhood is the colon, but there are distinct communities on the skin, in the mouth and elsewhere, each as different from the next as a rainforest is from a tidal flat. It’s an ecosystem, not a scoreboard The most useful shift in thinking is to stop counting and start mapping. A gut community isn’t “good” because it has more bacteria; a clogged drain has plenty of bacteria. What characterizes a resilient microbiome is closer to what characterizes a healthy ecosystem: diversity of species, redundancy of function, and the ability to bounce back after a disturbance such as a course of antibiotics . The right mental model isn’t a supplement you top up. It’s a forest you tend — and forests are defined by their relationships, not their headcount. This is why two healthy people can share almost no species. The field has moved from asking which microbes are present to asking what they do — which metabolic jobs get done, regardless of which organism does them. Why now Three things changed. Sequencing got cheap enough to read whole communities instead of culturing one bug at a time. Computation got good enough to make sense of the data. And the questions got sharper — from “is this bacterium present” toward “is this specific, defined strain doing this specific, measurable thing.” That last move, from genus-level guesses to strain-level precision, is where most of the interesting work now lives.
Sources: Sender, Fuchs & Milo, “Revised estimates for the number of human and bacteria cells in the body,” PLOS Biology (2016) (https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002533)

### Short-chain fatty acids, explained without the hand-waving
URL: https://microbiome.news/posts/short-chain-fatty-acids
Section: Science | Published: 2026-06-21 | 6 min
Summary: The fiber you can’t digest doesn’t go to waste. Gut bacteria ferment it into small molecules your gut lining, immune cells and even your brain appear to listen to.
Body: Eat a bowl of lentils and most of it follows the route you’d expect. But a meaningful fraction — the fiber — passes through the small intestine essentially untouched, because human enzymes can’t break it down. It arrives in the colon intact, and that’s where the interesting handoff happens. Resident bacteria ferment that fiber. The main byproducts are three short-chain fatty acids: acetate , propionate and butyrate . “Short-chain” just describes their size. Their importance is out of all proportion to it. Butyrate, the local currency Butyrate is the standout. The cells lining your colon prefer it as fuel — they burn it directly rather than relying on glucose from the bloodstream. A well-fed microbial community therefore helps keep the gut lining itself well-fed, supporting the barrier between the contents of your gut and the rest of you. You don’t digest fiber. The microbes do — and they pay you back in molecules your own cells can run on. Acetate and propionate are absorbed and travel further afield, where researchers have linked them to signals involved in appetite, metabolism and immune regulation. The word to hold onto is signaling : these aren’t just calories, they’re messages. Why this is more than trivia The short-chain-fatty-acid story is the clearest worked example of a deeper point: the bacteria aren’t passive passengers. They run a chemical economy whose outputs interact with human biology in specific, increasingly measurable ways. It’s also why “feed your microbes” — a varied diet with plenty of different plant fibers — is sounder, more boring advice than any single supplement.
Sources: Koh et al., “From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites,” Cell (2016) (https://doi.org/10.1016/j.cell.2016.05.041)

### The probiotics market grows up: from yogurt aisle to strain-level precision
URL: https://microbiome.news/posts/precision-probiotics
Section: Industry | Published: 2026-06-19 | 7 min
Summary: “Live cultures” is becoming a measurable claim. Inside the industry shift from vague probiotics to defined, characterized strains.
Body: Walk down any supplement aisle and you’ll see the legacy of the loose definition: bottles listing a genus, maybe a species, a big “billions of CFU” number and little else. That tells you about as much as a wine label that says only “grapes.” It matters because the biology is strain-specific. Two strains of the same species can carry meaningfully different genes and do meaningfully different things. “Contains Lactobacillus ” is a category, not a claim. The shift now underway is toward naming the exact strain, characterizing what it does, and proving the organism in the capsule is the one on the label. What “precision” actually requires Definition. A specific, sequenced strain with a stable identity — not a genus, not a hidden “proprietary blend.” Characterization. Knowing what the strain does — which fibers it uses, which metabolites it produces, how it behaves alongside the community already present. Verification. Confirming, at manufacture, that the product contains the live, defined organism at the stated dose — and that it survives to where it needs to act. The promise of the next decade isn’t more bacteria. It’s knowing exactly which ones, exactly what they do, and being able to prove it. You can see the shift on the shelf. A wave of consumer brands now lead with defined, named strains and stated functions rather than a bare CFU count — among them Seed, Pendulum, and Flore’s direct-to-consumer line GoodOnes , which sells targeted, goal-specific formulas. When naming the exact strain becomes a marketing advantage rather than a footnote, the category is maturing. The honest caveats None of this makes precision probiotics a cure-all, and the gap between a well-characterized strain and a demonstrated outcome in a real population is still wide. Rigor at the bench is necessary, not sufficient; the clinical evidence has to follow. But the direction of travel — away from vague reassurance, toward claims that can be checked — is healthy.

### Your at-home gut test and your friend’s might disagree more than your guts do
URL: https://microbiome.news/posts/dtc-microbiome-tests-reproducibility
Section: Diagnostics | Published: 2026-02-26 | 7 min
Summary: A 2026 NIST study found direct-to-consumer microbiome tests so inconsistent that the noise between brands rivaled the real biological difference between people. It lands on a field still haunted by the uBiome fraud collapse.
Body: Spit, swab, mail it in, get a colourful breakdown of your gut “ecosystem” and some supplement suggestions. The direct-to-consumer microbiome test is a booming product. A 2026 study suggests many of them can’t agree on what’s in the same sample. Researchers at the National Institute of Standards and Technology (NIST) and the University of Maryland ran seven consumer gut-testing services against a standardized reference material. The result, published in Communications Biology in February 2026: major discrepancies both within and across providers — with the methodological variability between brands on the same scale as the genuine biological variability between different people . If the difference your test detects between two brands is as big as the difference between two humans, what exactly is it measuring? A field with a cautionary ghost The reproducibility problem lands on an industry that already had a spectacular fraud collapse. On March 18, 2021 , a federal grand jury indicted the co-founders of uBiome — once a high-flying microbiome-testing startup — on securities and health-care fraud conspiracy charges. Founded in 2012 around a sub-$100 “Gut Explorer,” uBiome had pivoted to “clinical” tests billed to insurers for up to roughly $3,000; prosecutors alleged it submitted over $300 million in claims before going bankrupt. (Those figures are allegations in an indictment.) The lesson isn’t that microbiome testing is worthless — it’s that method and accreditation are the whole game. A pretty pie chart from an unvalidated pipeline is decoration. Where this cuts in practice is accreditation. A minority of services run their sequencing through CLIA-certified laboratories — the same federal regulatory bar as a hospital diagnostic — rather than the research-use-only pipelines common in consumer testing. Flore, for instance, sends its sequencing to CLIA-certified partner labs and runs a clinician-facing arm, Flore Clinical . Accreditation doesn’t by itself resolve the cross-brand reproducibility problem NIST flagged — but it is the floor below which a “clinical” claim means very little.
Sources: Servetas et al., reproducibility of DTC gut microbiome tests, Communications Biology (Feb 26, 2026) (https://www.nature.com/articles/s42003-025-09301-3); DOJ — uBiome co-founders charged with securities & health-care fraud (Mar 18, 2021) (https://www.justice.gov/usao-ndca/pr/ubiome-co-founders-charged-federal-securities-health-care-fraud-conspiracies)

### Ozempic, GLP-1 and the gut: what the microbiome has to do with the weight-loss drugs
URL: https://microbiome.news/posts/glp1-ozempic-gut-microbiome
Section: Industry | Published: 2026-02-15 | 8 min
Summary: GLP-1 is a hormone your gut already makes — and your gut bacteria help trigger it. As GLP-1 drugs reshape medicine, here is the evidence-based map of where the microbiome actually fits, and where the probiotic marketing outruns it.
Body: The GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and the rest — are the most consequential metabolic drugs in a generation. Less widely understood is that GLP-1 itself is not a pharmaceutical invention: it is glucagon-like peptide-1 , a hormone secreted by specialized enteroendocrine “L-cells” in your own gut after you eat. The drugs are long-lasting mimics of a signal your intestine already sends. And the gut microbiome sits squarely in that signalling pathway. The real, established link When gut bacteria ferment dietary fiber, they produce short-chain fatty acids. Those metabolites stimulate L-cells to secrete GLP-1 — a mechanism demonstrated in foundational work showing short-chain fatty acids trigger GLP-1 release via the FFAR2 receptor (Tolhurst et al., Diabetes , 2012). In other words, your microbiome contributes to your endogenous GLP-1 tone every day. This is settled physiology, not speculation. Where companies are pushing — and the caveat That mechanism has launched a wave of “GLP-1 probiotics.” The most-cited candidate organism is Akkermansia muciniphila ; a 2025 laboratory study reported that strain extracts drove a large rise in GLP-1 secretion from human gut cells, and Pendulum Therapeutics already markets a single-strain Akkermansia product around metabolism. The essential caveat: that striking result is in vitro , and no probiotic has been shown to produce weight loss remotely comparable to the GLP-1 drugs. A fiber-fed microbiome nudges your own GLP-1. A GLP-1 drug floods the system with a long-acting mimic. Those are different orders of magnitude — a probiotic is not an Ozempic alternative. The honest bottom line The microbiome is a legitimate, mechanistic part of the GLP-1 story, and a credible target for modest metabolic support — through fiber, fermentation and possibly defined next-generation strains. It is not a substitute for the drugs, and any product implying otherwise is selling the headline, not the data. For the strain-level evidence, see our report on Akkermansia and GLP-1.
Sources: Tolhurst et al., “Short-chain fatty acids stimulate GLP-1 secretion via the G-protein-coupled receptor FFAR2,” Diabetes (2012) (https://pubmed.ncbi.nlm.nih.gov/22190648/); A. muciniphila strain extracts induce GLP-1 in human L-cells, Nutrients (2025) (https://www.mdpi.com/2072-6643/17/15/2516); Pendulum Therapeutics introduces a GLP-1 probiotic — PR Newswire (2024) (https://www.prnewswire.com/news-releases/pendulum-therapeutics-introduces-glp-1-probiotic-302087492.html)

### A stool transplant made cancer immunotherapy work better — across two cancers
URL: https://microbiome.news/posts/fmt-cancer-immunotherapy
Section: Therapeutics | Published: 2026-01-28 | 8 min
Summary: In the phase 2 FMT-LUMINate trial, pairing a healthy-donor fecal transplant with checkpoint inhibitors pushed response rates to 80% in lung cancer and 75% in melanoma. The twist: the benefit looked less like adding “good” microbes than clearing out the wrong ones.
Body: Immune-checkpoint inhibitors transformed oncology, but they only work for some patients — and one of the strongest predictors of who responds turns out to be the gut microbiome. The obvious question: if you change the microbiome, can you change the odds? A 2023 phase I trial (published in Nature Medicine ) was the first to test healthy-donor fecal microbiota transplantation (FMT) alongside anti–PD-1 therapy as first-line treatment in 20 previously untreated advanced-melanoma patients. The objective response rate was 65% (13 of 20), including four complete responses. In January 2026 , the phase 2 FMT-LUMINate trial extended the idea to two cancers and two immunotherapy backbones. In non-small-cell lung cancer (n=20, anti–PD-1), the response rate was 80% ; in melanoma (n=20, dual anti–PD-1 + anti–CTLA-4), it was 75% — both above the historical rates for immunotherapy alone. The counterintuitive part You’d expect the mechanism to be “transplant good bacteria, which help the immune system.” The data pointed elsewhere. Patients who responded showed greater loss of their own pre-existing gut species, while the degree to which donor strains engrafted didn’t separate responders from non-responders. The benefit may come less from the microbes you add than from the resident ones you clear out of the way. The honest caveats: these are small, single-arm, early-phase studies — 20 patients per group. They establish a strong, repeatable signal, not proof of efficacy, and they need randomised confirmation. But the direction is consistent across cancers and years.
Sources: Routy et al., phase 2 FMT-LUMINate trial, Nature Medicine (Jan 28, 2026) (https://www.nature.com/articles/s41591-025-04186-5); First-line FMT + anti–PD-1 in melanoma, phase I, Nature Medicine (2023) (https://www.nature.com/articles/s41591-023-02453-x)

### Meet Akkermansia: the single strain dragging probiotics into the GLP-1 era
URL: https://microbiome.news/posts/akkermansia-glp1-next-gen-probiotics
Section: Industry | Published: 2025-07-31 | 7 min
Summary: One gut bacterium has become the face of “next-generation” probiotics — a defined, characterized strain with human metabolic data and a tantalizing link to the same GLP-1 pathway as the blockbuster weight-loss drugs. Mind the caveats.
Body: If you want to understand where probiotics are heading, watch Akkermansia muciniphila . It’s the poster organism for “next-generation probiotics”: not a generic Lactobacillus blend, but a single, named, well-characterized strain with a specific biological rationale. The human data is real but narrower than the hype. In a controlled trial of overweight, insulin-resistant volunteers, pasteurized A. muciniphila improved insulin sensitivity , lowered insulin levels and reduced cholesterol — but did not significantly reduce body weight, fat mass or waist size. So: a metabolic effect, not a weight-loss drug. The GLP-1 connection The 2025 excitement comes from the same hormone behind Ozempic and Wegovy. A laboratory study found extracts of a specific A. muciniphila strain triggered a large, dose-dependent spike in GLP-1 secretion from human gut cells — the appetite-and-glucose hormone those drugs mimic. Commercially, Pendulum Therapeutics already sells a single-strain Akkermansia product marketed around metabolism and GLP-1. The promise: a defined microbe that nudges the body’s own GLP-1. The reality check: that headline result is a cell-culture study, not a clinical trial. Caveats, clearly: the dramatic GLP-1 finding is in vitro only, with no animal or human confirmation, and the work was industry-affiliated. The solid human benefits came from pasteurized bacteria and were metabolic, not weight loss. Promising — and exactly the kind of claim that needs a trial before it earns the marketing.
Sources: A. muciniphila strain extracts induce GLP-1 in human L-cells, Nutrients (Jul 31, 2025) (https://www.mdpi.com/2072-6643/17/15/2516); A. muciniphila as next-generation probiotic — review, Virulence (2024) (https://www.tandfonline.com/doi/full/10.1080/21505594.2024.2375555); Pendulum Therapeutics introduces a GLP-1 probiotic — PR Newswire (2024) (https://www.prnewswire.com/news-releases/pendulum-therapeutics-introduces-glp-1-probiotic-302087492.html)

### The microbiome shakeout: when the drug startups stalled, the consumer model kept building
URL: https://microbiome.news/posts/microbiome-industry-shakeout
Section: Industry | Published: 2024-10-01 | 7 min
Summary: Between 2022 and 2024 some of the best-funded microbiome drug companies folded or sold off their crown jewels — even as the science hit its FDA milestones. A look at who fell, and why the wellness tier proved more durable.
Body: It’s a strange split-screen. The same window that produced the microbiome field’s first FDA approvals also produced its harshest financial reckoning. Validation and shakeout, at once. Flagship-backed Kaleido Biosciences shut down in 2023. Finch Therapeutics — once a leader in defined microbial therapeutics — went through deep layoffs and discontinued its lead program the same year. And in a striking capstone, Seres Therapeutics — co-developer of the trailblazing oral drug Vowst — sold the entire Vowst business to its partner Nestlé Health Science in 2024, exiting the very product that had made history. Why the drug path is brutal Developing a live biotherapeutic as an FDA drug is staggeringly expensive, slow and binary: huge trials, manufacturing complexity, and a market that has to be built from scratch. A single program can sink a company. The approvals proved the science; they didn’t make the economics easy. The microbiome didn’t fail. The hardest, most capital-hungry way to commercialize it did — for now. Meanwhile the consumer and clinical-wellness tier — defined, characterized probiotics sold directly, without a decade-long drug trial — kept shipping product, gathering data and reaching customers. Companies in this tier — from sequencing-based personalization players such as Flore , whose direct-to-consumer line GoodOnes and clinician-facing arm Flore Clinical sit on either side of the retail/practitioner divide, to single-strain specialists — never had to clear an FDA endpoint to reach a customer. Less glamorous than a blockbuster drug; far more survivable.
Sources: Kaleido Biosciences shuts down — Endpoints News (https://endpoints.news/breaking-flagship-backed-microbiome-company-kaleido-biosciences-shuts-down/); Finch Therapeutics layoffs and program discontinuation — BioPharma Dive (https://www.biopharmadive.com/news/finch-layoffs-microbiome-drug-study-discontinue/641038/); Seres completes sale of the Vowst business to Nestlé Health Science — Seres IR (https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-announces-completion-vowsttm-asset-sale)

### Flore launches what it calls the first probiotic line formulated for neurodiversity
URL: https://microbiome.news/posts/flore-neurodiversity-probiotic-line
Section: Industry | Published: 2024-09-19 | 5 min
Summary: In September 2024 the personalized-probiotics company Flore introduced a product line aimed at neurodivergent users, drawing coverage across nutrition trade press. A look at the launch — and the state of the underlying evidence.
Body: In September 2024, Flore Inc. — a personalized-probiotics company formerly known as Sun Genomics — launched what it described as the first line of probiotics formulated specifically for neurodiversity. The announcement was carried across nutrition and trade outlets including Globe Newswire, Nutraceuticals World, Nutrition Insight and Vitafoods Insights. The line sits squarely within the broader gut–brain-axis thesis — the idea that the gut microbiome participates in signalling to the central nervous system. Flore, whose core product is a formula built from an individual’s sequenced stool, framed the launch as an extension of that personalized approach to a neurodivergent audience. What to keep in view The products are positioned as dietary supplements, not treatments. And the relevant scientific caveat is the same one that applies to every gut–brain consumer claim: while the preclinical literature is substantial, rigorous human evidence that probiotics modify neurodevelopmental or mood outcomes remains early-stage. The launch is a notable commercial and positioning move; it is not, on its own, clinical proof. Coverage of the company’s products on this site is reported on its own merits, like that of any other company in the field. Details of the line are at flore.com .
Sources: “Flore Unveils World’s First Line of Probiotics for Neurodiversity,” Globe Newswire (Sept 19, 2024) (https://www.globenewswire.com/news-release/2024/09/19/2949042/0/en/Flor%C3%A9-Unveils-World-s-First-Line-of-Probiotics-for-Neurodiversity.html); “Flore Launches Probiotic Line Formulated for Neurodiversity,” Nutraceuticals World (Sept 2024) (https://www.nutraceuticalsworld.com/breaking-news/flore-launches-probiotic-line-formulated-for-neurodiversity/)

### Company profile: Flore’s bet on sequenced, personalized probiotics
URL: https://microbiome.news/posts/flore-personalized-probiotics-profile
Section: Industry | Published: 2024-06-10 | 6 min
Summary: Among the companies wagering that precision beats generic blends, Flore stands out for building formulas from an individual’s own gut sequencing. A neutral look at the model, the reach, and the open questions.
Body: The probiotics industry’s most interesting fault line is between generic, shelf-stable blends and a smaller set of companies betting on personalization. Flore Inc. — formerly Sun Genomics — sits firmly in the second camp, and is worth a neutral look as a case study in the approach. The model Flore’s flagship builds a formula from an individual customer’s sequenced stool, using shotgun metagenomics processed through a CLIA-certified laboratory — a higher analytical bar than the research-use-only pipelines common in consumer testing. It also runs a direct-to-consumer retail line of targeted, goal-specific formulas — marketed under the GoodOnes brand — and a practitioner arm, Flore Clinical , whose microbiome-mapping technology was distributed to a reported ~20,000 clinicians through a 2024 deal with Evexia Diagnostics (covered by NutraIngredients and others). The open questions The case for personalization is mechanistically appealing and, in adjacent domains such as personalized nutrition, has modest but real randomized-trial support . The honest open question for the whole category — Flore included — is the size of the marginal benefit of personalization over good generic advice, and how much of it survives rigorous, independent trials. That evidence is still being built. More on the company’s products is at flore.com . As with all company coverage here, this profile is independent and unpaid.
Sources: “Flore Clinical Makes Personalized Microbiome Mapping Tech More Accessible to Clinicians,” NutraIngredients (Jun 7, 2024) (https://www.nutraingredients.com/Article/2024/06/07/flore-clinical-makes-microbiome-mapping-tech-more-accessible-to-clinicians/); “Flore Clinical Teams Up with Evexia Diagnostics to Distribute Personalized Microbiome Mapping Technology to 20,000 Clinicians,” Globe Newswire (Jun 4, 2024) (https://www.globenewswire.com/news-release/2024/06/04/2893091/0/en/Flor%C3%A9-Clinical-Teams-Up-with-Evexia-Diagnostics-to-Distribute-Personalized-Microbiome-Mapping-Technology-to-20-000-Clinicians.html)

### Personalized nutrition gets its randomized trial — and a modest, real result
URL: https://microbiome.news/posts/personalized-nutrition-zoe-method
Section: Diagnostics | Published: 2024-05-20 | 6 min
Summary: ZOE’s METHOD study put microbiome-informed, individualized diet advice up against standard guidelines in a 347-person RCT. The personalized arm lowered triglycerides. It also came with caveats worth reading.
Body: “Personalized nutrition” has been one of the microbiome economy’s biggest promises and shakiest claims. So when ZOE — the company co-founded by epidemiologist Tim Spector — ran a proper randomized controlled trial, it was a real test of whether the idea holds up. The METHOD trial (published in Nature Medicine , 2024) randomized 347 US adults aged 41–70 to one of two arms: an 18-week app-guided personalized dietary program — tuned to each person’s food responses, post-meal glucose and triglyceride spikes, microbiome and health history — or standard US dietary guidance. The personalized arm significantly reduced blood triglycerides (a pre-specified primary outcome). That’s a genuine, peer-reviewed signal that individualizing diet can beat generic advice on a hard cardiometabolic marker. Read the fine print It was also modest and caveated . The trial was funded by ZOE. The other primary outcome — LDL cholesterol — showed no significant difference. And only the intervention group logged food in real time, inviting the critique that some benefit came from the act of self-monitoring rather than the personalization itself. The verdict isn’t “personalization is magic.” It’s “personalization is real, measurable, and smaller than the marketing.”
Sources: Bermingham et al., ZOE METHOD randomized controlled trial, Nature Medicine (2024) (https://www.nature.com/articles/s41591-024-02951-6)

### Akkermansia muciniphila: the mucus-dwelling bacterium behind the next-gen probiotic hype
URL: https://microbiome.news/posts/akkermansia-muciniphila-explainer
Section: Science | Published: 2024-02-20 | 7 min
Summary: A single gut species has become the most-watched organism in the microbiome. What Akkermansia muciniphila actually is, what the human data shows, and where the marketing gets ahead of it.
Body: Twenty years ago Akkermansia muciniphila was a newly described gut bacterium of interest mainly to specialists. Today it is the face of the “next-generation probiotic” category and a fixture of metabolic-health marketing. The reality sits, as usual, between the discovery and the advertising. What it is First described by Derrien and colleagues in 2004, A. muciniphila lives in the mucus layer of the gut and feeds on mucin, the glycoprotein that forms it. Counter-intuitively, this mucin-degrader is associated with a healthier barrier: its activity helps stimulate mucus turnover. It typically constitutes 1–4% of the gut community, and lower abundance has been associated with obesity and type 2 diabetes in observational studies. What the human data shows The pivotal human evidence is a 2019 proof-of-concept trial (Depommier et al., Nature Medicine ) in 32 overweight, insulin-resistant volunteers. Supplementation — notably with pasteurized bacteria — improved insulin sensitivity and reduced some cardiometabolic markers. It did not produce significant weight loss. That distinction is routinely lost in consumer messaging. A characterized single strain with genuine mechanistic interest and an early human signal — for metabolic markers, not for the scale. Akkermansia matters as much for what it represents as for what it does: the shift from generic, multi-strain blends toward a defined, sequenced, mechanistically-characterized organism. That is the right direction for the field. It is not, on current evidence, a weight-loss drug. For the GLP-1 angle specifically, see our separate report.
Sources: Derrien et al., “Akkermansia muciniphila gen. nov., sp. nov.,” Int J Syst Evol Microbiol (2004) (https://pubmed.ncbi.nlm.nih.gov/15388697/); Depommier et al., “Supplementation with Akkermansia muciniphila in overweight and obese human volunteers,” Nature Medicine (2019) (https://www.nature.com/articles/s41591-019-0495-2)

### The gut–brain axis: a primer on how microbes and the brain communicate
URL: https://microbiome.news/posts/gut-brain-axis-primer
Section: Gut–Brain | Published: 2023-10-04 | 8 min
Summary: Bidirectional signalling between the gut, its microbes and the central nervous system is one of neuroscience’s fastest-moving frontiers. The established pathways, the honest uncertainties, and what “psychobiotic” really means.
Body: The idea that gut bacteria might influence the brain was, a decade ago, treated with reflexive skepticism. It is now a mainstream research programme, anchored by a 2019 review in Physiological Reviews (Cryan et al.) that catalogued the communication channels in detail. Skepticism remains warranted about specific claims — but the axis itself is established. The channels Communication runs in both directions along several routes. The vagus nerve provides a direct neural line between gut and brainstem. Microbial metabolites — short-chain fatty acids among them — act as signalling molecules. The immune system relays inflammatory signals with central effects. And gut microbes participate in the metabolism of neurotransmitter precursors , including pathways relevant to serotonin, the majority of which is produced in the gut. What “psychobiotic” means Coined to describe live organisms that, when ingested in adequate amounts, produce a mental-health benefit, the term “psychobiotic” has since broadened. The preclinical evidence — much of it in rodents — is substantial. Rigorous human evidence is thinner, and the field is appropriately cautious about extrapolating from germ-free mice to people. The wiring is real: vagus nerve, metabolites, immune signalling, neurotransmitter precursors. The leap from mechanism to a pill that reliably changes human mood is where the evidence thins. The responsible summary: the gut–brain axis is a genuine, multi-channel signalling system under intense study, with strong implications for conditions from Parkinson’s to depression . The specific consumer claims that ride on it are mostly still ahead of the human data.
Sources: Cryan et al., “The Microbiota-Gut-Brain Axis,” Physiological Reviews (2019) (https://journals.physiology.org/doi/full/10.1152/physrev.00018.2018); Sarkar et al., “Psychobiotics and the manipulation of bacteria–gut–brain signals,” Trends in Neurosciences (2016) (https://pubmed.ncbi.nlm.nih.gov/27793434/)

### How microbiome testing works — and what a result can and can’t tell you
URL: https://microbiome.news/posts/microbiome-testing-explained
Section: Diagnostics | Published: 2023-05-09 | 8 min
Summary: At-home gut tests turn a stool sample into a colourful report. A scientist’s guide to the methods behind them (16S vs shotgun), what the output means, and why two tests can disagree.
Body: A microbiome test takes a stool sample, extracts microbial DNA and reports which organisms — and sometimes which functions — are present. The gap between that one-line description and a clinically actionable result is where most of the confusion lives. 16S rRNA vs shotgun metagenomics Two dominant methods, with very different resolution. 16S rRNA sequencing reads a single marker gene shared by bacteria; it is cheap and robust but typically resolves organisms only to the genus level and cannot read functional genes. Shotgun metagenomics sequences all the DNA in the sample, enabling species- and strain-level resolution and a readout of functional potential — at higher cost and computational complexity. Method choice constrains what any report can legitimately claim — a distinction we unpack in 16S vs shotgun: what your test actually reads . Why two tests disagree Every step — collection, preservation, DNA extraction, sequencing, and the reference database used to assign names — introduces variation. A 2026 NIST study found that variability between direct-to-consumer providers analysing standardized material was on the same order as the biological variability between different people . In other words, the method can contribute as much to your result as your biology does. The pie chart is the easy part. The method that produced it — and the reference database behind it — determines whether it means anything. What a result can and can’t do A well-run test can describe the relative abundance of taxa and, with shotgun data, functional potential. What it generally cannot yet do is diagnose disease or prescribe a specific supplement with validated benefit for an individual. Read consumer reports as a snapshot of composition, not a clinical verdict. For the reproducibility evidence in detail, see our report on direct-to-consumer test reproducibility .
Sources: Allaband et al., “Microbiome 101: studying, analyzing, and interpreting gut microbiome data for clinicians,” Clin Gastroenterol Hepatol (2019) (https://pubmed.ncbi.nlm.nih.gov/30240894/); Servetas et al., reproducibility of DTC gut microbiome tests, Communications Biology (2026) (https://www.nature.com/articles/s42003-025-09301-3)

### It’s official: the FDA now approves medicines made of microbes
URL: https://microbiome.news/posts/fda-first-microbiome-medicines
Section: Therapeutics | Published: 2023-04-26 | 7 min
Summary: Within five months the agency cleared two first-in-class fecal-microbiota products for recurrent C. difficile — Ferring’s Rebyota and, in a first, the orally dosed Vowst. The microbiome became a regulated drug class.
Body: For decades, “bacteria as medicine” lived in a regulatory grey zone — somewhere between a supplement, a transplant and an experiment. Two FDA approvals, five months apart, ended that ambiguity. On November 30, 2022 , the agency approved Rebyota (fecal microbiota, live-jslm), made by Ferring Pharmaceuticals — the first-ever FDA-approved fecal microbiota product. Then on April 26, 2023 , it approved Vowst (fecal microbiota spores, live-brpk; formerly SER-109) from Seres Therapeutics and Nestlé Health Science — the first orally administered fecal microbiota product. A treatment derived from screened human donor stool, in a capsule you swallow. Both are cleared for the same job: preventing the recurrence of Clostridioides difficile infection in adults after they’ve completed antibiotics for recurrent CDI. That’s a brutal, common problem — antibiotics knock back C. diff but also flatten the surrounding community that would normally keep it in check, so it roars back. The therapy works by doing what a supplement never could at scale: restoring a whole microbial community. Why this is a turning point The science of fecal transplants is old; the regulation is what’s new. By granting full approval, the FDA recognised a defined, manufactured, quality-controlled microbiome product as a drug — with the donor screening, consistency and safety oversight that label implies. The headline isn’t “poop pills.” It’s that a living microbial community can now clear the same bar as any other medicine. That precedent matters far beyond C. diff. It establishes the manufacturing and evidence path that every future live biotherapeutic — for other infections, for metabolic disease, for the immune system — will follow.
Sources: FDA — REBYOTA (fecal microbiota, live-jslm): the first FDA-approved fecal microbiota product, approved Nov 30, 2022 (https://www.fda.gov/vaccines-blood-biologics/vaccines/rebyota); FDA approves first orally administered fecal microbiota product (Vowst), Apr 26, 2023 — PR Newswire (https://www.prnewswire.com/news-releases/fda-approves-first-orally-administered-fecal-microbiota-product-for-the-prevention-of-recurrence-of-clostridioides-difficile-infection-301808930.html); Ferring — FDA approval of Rebyota (fecal microbiota, live-jslm) (https://ferringusa.com/?press=ferring-receives-u-s-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic)

### How to improve gut health: what the evidence actually supports
URL: https://microbiome.news/posts/how-to-improve-gut-health-evidence
Section: Science | Published: 2023-01-19 | 8 min
Summary: Strip away the supplement marketing and a short, unglamorous list of interventions has real human data behind it. A sober ranking of what moves the microbiome, and by how much.
Body: “Improve your gut health” is among the most-searched health phrases on the internet and among the most poorly served by the results it returns. The honest version of the answer is shorter, less proprietary and better supported than the supplement aisle would suggest. Dietary fiber diversity — the strongest lever The resident community is, functionally, fed by what your own enzymes cannot digest. Across observational and interventional data, greater diversity of plant fibers is associated with greater microbial diversity and richer short-chain-fatty-acid production. “Thirty different plants a week” is a heuristic, not a law, but it points the right way: variety of substrate over quantity of any single fiber. Fermented foods — a controlled-trial signal A 2021 Stanford trial (Wastyk et al., Cell ) randomized healthy adults to a high-fiber or a high-fermented-food diet. The fermented-food arm — yogurt, kefir, kimchi, kombucha — produced increased microbiota diversity and decreased markers of inflammation over ten weeks. It is one of the cleaner causal signals in the diet–microbiome literature. What helps at the margins Adequate sleep, regular physical activity and limiting unnecessary antibiotics all have supporting evidence for microbial resilience. Each is modest; together they describe a lifestyle, not a product. Diverse plant fibers, some fermented foods, fewer needless antibiotics. The interventions with the best human evidence are also the ones nobody can patent. What the evidence does not support It does not support a single daily probiotic as a general “gut health” upgrade for healthy people; benefits are strain- and indication-specific. It does not support “detoxes” or “cleanses.” And it does not support reading too much into any one at-home test result.
Sources: Wastyk et al., “Gut-microbiota-targeted diets modulate human immune status,” Cell (2021) (https://www.cell.com/cell/fulltext/S0092-8674(21)00754-6); So et al., “Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis,” Am J Clin Nutr (2018) (https://pubmed.ncbi.nlm.nih.gov/29757343/)

### “Leaky gut”: what intestinal permeability is, and what the evidence supports
URL: https://microbiome.news/posts/leaky-gut-intestinal-permeability
Section: Science | Published: 2022-09-14 | 7 min
Summary: The term is dismissed by some clinicians and oversold by others. The underlying physiology — intestinal barrier permeability — is real, measurable and an active research area. A careful separation of the two.
Body: Few phrases generate more heat and less light than “leaky gut.” In wellness marketing it is a catch-all cause of nearly everything; in some clinical quarters it is dismissed as pseudoscience. Both framings obscure a real and well-studied physiological concept: intestinal permeability . The barrier is real The single-cell epithelial layer lining the gut is sealed by protein complexes called tight junctions, which regulate what crosses between the gut lumen and the bloodstream. This barrier is dynamic, not fixed, and its permeability can increase — demonstrably — under certain conditions. Reviews in Gut and BMC Gastroenterology have laid out the mechanisms and the measurement methods (such as dual-sugar absorption tests). Where the evidence is solid — and where it isn’t Increased permeability is well documented in defined conditions including coeliac disease, inflammatory bowel disease and some infections. What remains an open research question is the direction of causation in many other settings: whether increased permeability drives systemic disease, or is a downstream consequence of it, is frequently unresolved. The barrier is real and measurable. “Leaky gut syndrome” as a stand-alone diagnosis that explains diffuse symptoms is not an established clinical entity. So the scientifically defensible position is narrow but firm: intestinal permeability is a legitimate, measurable variable under active study; the popular “leaky gut syndrome” — a single condition causing fatigue, brain fog and the rest — is not a recognized diagnosis, and products marketed to “seal” the gut are running well ahead of the evidence.
Sources: Bischoff et al., “Intestinal permeability — a new target for disease prevention and therapy,” BMC Gastroenterology (2014) (https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-014-0189-7); Camilleri, “Leaky gut: mechanisms, measurement and clinical implications in humans,” Gut (2019) (https://gut.bmj.com/content/68/8/1516)

### Prebiotic, probiotic, postbiotic: the definitions, used precisely
URL: https://microbiome.news/posts/prebiotic-probiotic-postbiotic-definitions
Section: Science | Published: 2022-03-15 | 7 min
Summary: Three terms, routinely conflated, each with a formal consensus definition from the International Scientific Association for Probiotics and Prebiotics. A precise reference for what separates them.
Body: Few areas of nutrition science suffer more terminological drift than this one. “Probiotic” is printed on kombucha and dog food alike; “prebiotic” is used as a synonym for fiber; “postbiotic” is new enough that the marketing has outrun the meaning. Each, in fact, has a formal definition arrived at by expert consensus panels convened by the International Scientific Association for Probiotics and Prebiotics (ISAPP). Used correctly, they are not interchangeable. Probiotic The 2014 ISAPP consensus defines a probiotic as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.” Three load-bearing clauses follow: the organisms must be live , the dose must be adequate (strain-specific, and defined by the evidence for that strain), and a benefit must be demonstrated. A genus on a label — “contains Lactobacillus ” — satisfies none of these on its own. Prebiotic The 2017 ISAPP consensus defines a prebiotic as “a substrate that is selectively utilized by host microorganisms conferring a health benefit.” Note what this excludes: not all fiber is prebiotic, and the category is not limited to carbohydrates. The defining test is selective utilization by the resident community to a documented benefit. Postbiotic The newest term. The 2021 ISAPP consensus defines a postbiotic as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.” The key word is inanimate : a postbiotic is not alive. That is precisely what distinguishes it from a probiotic, and it is the clause most often violated in marketing. Live and beneficial (probiotic); a substrate selectively used by microbes (prebiotic); a non-living microbial preparation that benefits the host (postbiotic). The benefit clause is mandatory in all three. The discipline these definitions impose is the point. A product that cannot point to a defined strain, an adequate dose and an outcome is, by the field’s own consensus, not entitled to the word.
Sources: Hill et al., ISAPP consensus on the term “probiotic,” Nature Reviews Gastroenterology & Hepatology (2014) (https://www.nature.com/articles/nrgastro.2014.66); Gibson et al., ISAPP consensus on the definition of prebiotics, Nature Reviews Gastroenterology & Hepatology (2017) (https://www.nature.com/articles/nrgastro.2017.75); Salminen et al., ISAPP consensus on the definition of postbiotics, Nature Reviews Gastroenterology & Hepatology (2021) (https://www.nature.com/articles/s41575-021-00440-6)

### Eat more fiber, respond better to immunotherapy — and maybe skip the probiotic
URL: https://microbiome.news/posts/fiber-immunotherapy-melanoma
Section: Science | Published: 2021-12-23 | 6 min
Summary: A landmark 2021 Science study found melanoma patients who ate enough dietary fiber lived longer without their cancer progressing. The strongest effect was in those who ate fiber and took no probiotic supplement.
Body: If the gut microbiome shapes how patients respond to cancer immunotherapy, then diet — the single biggest lever on the microbiome — should matter too. In December 2021, a study in Science from a team at MD Anderson, the NCI and Harvard put numbers on it. Among 128 advanced-melanoma patients on immune checkpoint blockade, those reporting sufficient dietary fiber (at least ~20 g/day) had markedly better progression-free survival: median survival was not reached , versus 13 months for those eating less. Every additional 5 g of daily fiber was associated with a 30% lower risk of progression or death. The probiotic wrinkle The most provocative finding was an interaction. Patients who reported both sufficient fiber and no use of over-the-counter probiotic supplements did best of all — an 82% response rate versus 59%. More fiber, fewer indiscriminate probiotics. The microbiome rewards feeding what’s already there over flooding it with strangers. Caveats matter here: this is observational data from a single cohort, the upper confidence bound sat right at the edge of significance, and probiotic use on its own wasn’t statistically significant. It’s a strong association, not a prescription. But it lands on a consistent theme: a generic, high-dose probiotic is not automatically “more health.”
Sources: Spencer et al., “Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response,” Science (Dec 23, 2021) (https://pmc.ncbi.nlm.nih.gov/articles/PMC8970537/)